<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004217.pub2" GROUP_ID="NEONATAL" ID="943102071420320399" MERGED_FROM="" MODIFIED="2008-10-30 16:33:50 +0100" MODIFIED_BY="Diane Haughton" NOTES="&lt;p&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;emailed to JS amd DH August 15th 2004&lt;br&gt;received from NW August 13th &lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;sent to JS July 12, 2004&lt;br&gt;edited July 5, 2002 - sent to NW for review&lt;br&gt;final draft June 21, 2004&lt;br&gt;Exported from Review Manager 4.2.5&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2&lt;/p&gt;&lt;p&gt;CL 4/04 (review)&lt;/p&gt;&lt;p&gt;sent to BBF Aug 23 for edit to figure&lt;/p&gt;&lt;p&gt;CL 4/05 (minor update)&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-10-30 11:28:21 -0400" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2008-10-30 16:33:50 +0100" MODIFIED_BY="Diane Haughton">
<TITLE>Pain relief for neonatal circumcision</TITLE>
<CONTACT MODIFIED="2008-10-30 16:33:50 +0100" MODIFIED_BY="Diane Haughton"><PERSON ID="15180" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Barbara</FIRST_NAME><LAST_NAME>Brady-Fryer</LAST_NAME><SUFFIX>RN, PhD (c)</SUFFIX><POSITION>Director</POSITION><EMAIL_1>barbbradyfryer@cha.ab.ca</EMAIL_1><ADDRESS><DEPARTMENT>Child Health - Critical Care</DEPARTMENT><ORGANISATION>Capital Health</ORGANISATION><ADDRESS_1>Royal Alexandra Hospital</ADDRESS_1><ADDRESS_2>10240 Kingsway, Room 5027-10 DTC</ADDRESS_2><CITY>Edmonton</CITY><ZIP>T5H 3V9</ZIP><REGION>Alberta</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>780-491-5537</PHONE_1><FAX_1>780-477-4072</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-10-30 16:33:50 +0100" MODIFIED_BY="Diane Haughton"><PERSON ID="15180" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Barbara</FIRST_NAME><LAST_NAME>Brady-Fryer</LAST_NAME><SUFFIX>RN, PhD (c)</SUFFIX><POSITION>Director</POSITION><EMAIL_1>barbbradyfryer@cha.ab.ca</EMAIL_1><ADDRESS><DEPARTMENT>Child Health - Critical Care</DEPARTMENT><ORGANISATION>Capital Health</ORGANISATION><ADDRESS_1>Royal Alexandra Hospital</ADDRESS_1><ADDRESS_2>10240 Kingsway, Room 5027-10 DTC</ADDRESS_2><CITY>Edmonton</CITY><ZIP>T5H 3V9</ZIP><REGION>Alberta</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>780-491-5537</PHONE_1><FAX_1>780-477-4072</FAX_1></ADDRESS></PERSON><PERSON ID="12360" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Natasha</FIRST_NAME><LAST_NAME>Wiebe</LAST_NAME><POSITION>Research Associate</POSITION><EMAIL_1>nwiebe@ualberta.ca</EMAIL_1><ADDRESS><DEPARTMENT>Medicine</DEPARTMENT><ORGANISATION>University of Alberta</ORGANISATION><ADDRESS_1>4048 RTF</ADDRESS_1><ADDRESS_2>8308-114 Street</ADDRESS_2><CITY>Edmonton</CITY><ZIP>T6G 2E1</ZIP><REGION>Alberta</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 780 407 1532</PHONE_1><FAX_1>+1 780 407 1921</FAX_1></ADDRESS></PERSON><PERSON ID="15262" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Janice</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Lander</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>jlander@ualberta.ca</EMAIL_1><ADDRESS><DEPARTMENT>Nursing</DEPARTMENT><ORGANISATION>University of Alberta</ORGANISATION><ADDRESS_1>5-120A Clinical Sciences Building</ADDRESS_1><CITY>Edmonton</CITY><ZIP>T6G 2G3</ZIP><REGION>Alberta</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 780 492 6317</PHONE_1><FAX_1>+1 780 492 9954</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-10-28 15:37:52 -0400" MODIFIED_BY="Diane Haughton" NOTES="&lt;p&gt;Minor update: 8/3/05&lt;/p&gt;&lt;p&gt;New studies sought but none found: 8/3/05&lt;/p&gt;" NOTES_MODIFIED="2008-10-28 15:37:52 -0400" NOTES_MODIFIED_BY="Diane Haughton">
<UP_TO_DATE>
<DATE DAY="3" MONTH="8" YEAR="2005"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="3" MONTH="8" YEAR="2005"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2004"/>
</DATES>
<WHATS_NEW MODIFIED="2008-10-30 11:28:21 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;This review updates the existing review &amp;quot;Pain relief for neonatal circumcision&amp;quot; which was published in The Cochrane Library Issue 3, 2004 (Brady-Fryer 2004). &lt;br&gt;&lt;br&gt;The review has been updated to correct the numbers reported for total patients randomized for the included trials. Results of meta-analyses were not effected except in one case, comparison 03.02 where the effect size changed from [WMD = 15.8%, 95% CI -20.8 to -6.8] to [WMD = 15.22%; 95% CI 21.08 to 9.36]. &lt;br&gt;&lt;br&gt;Abstract was changed to note that data from three (not four) trials of DPNB versus EMLA including 133 patients were subjected to meta-analysis.&lt;br&gt;&lt;br&gt;No new trials were identified as a result of the most recent search.&lt;/p&gt;" NOTES_MODIFIED="2008-10-30 11:28:21 -0400" NOTES_MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="28" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-10-30 11:28:21 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-10-30 11:28:21 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="3" MONTH="8" YEAR="2005"/>
<DESCRIPTION>
<P>This review updates the existing review "Pain relief for neonatal circumcision" which was published in The Cochrane Library Issue 3, 2004 (Brady-Fryer 2004).<BR/>
<BR/>The review has been updated to correct the numbers reported for total patients randomized for the included trials. Results of meta-analyses were not effected except in one case, comparison 03.02 where the effect size changed from [WMD = 15.8%, 95% CI -20.8 to -6.8] to [WMD = 15.22%; 95% CI 21.08 to 9.36].<BR/>
<BR/>Abstract was changed to note that data from three (not four) trials of DPNB versus EMLA including 133 patients were subjected to meta-analysis.<BR/>
<BR/>No new trials were identified as a result of the most recent search.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="1" MONTH="5" YEAR="2004"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Capital Health</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Faculty of Nursing, University of Alberta</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Alberta Association of Registered Nurses</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Canadian Nurses Association</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Canadian Health Services Research Foundation</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-10-30 11:23:39 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-10-30 11:23:39 -0400" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-10-30 11:23:39 -0400" MODIFIED_BY="[Empty name]">Pain relief for neonatal circumcision</TITLE>
<SUMMARY_BODY>
<P>Circumcision is a painful procedure frequently performed on newborn baby boys without using pain relief. Available treatments include dorsal penile nerve block (DPNB), which involves injecting anesthetic at the base of the penis. Ring block is another form of penile block. Locally applied anesthetic creams include EMLA, a water-based cream including lidocaine and prilocaine. Based on 35 clinical trials involving 1,997 newborns, it can be concluded that DPNB and EMLA do not eliminate circumcision pain, but are both more effective than placebo or no treatment in diminishing it. Compared head to head, DPNB is substantially more effective than EMLA cream. Ring block and lidocaine creams other than EMLA also reduced pain but did not eliminate it. Trials of oral acetaminophen, sugar solutions, pacifiers, music, and other environmental modifications to reduce circumcision pain did not prove them effective. DPNB can cause minor bruising, bleeding, or swelling at the injection site. EMLA and other lidocaine creams can cause skin color changes or local skin irritation. There is a rare risk with lidocaine creams of causing methaemoglobinaemia (blue-baby syndrome, where the baby's blood lacks sufficient oxygen). However, two trials of EMLA for circumcision pain relief measured methaemoglobin levels and found them normal. The circumcision procedure itself, especially without pain relief, can cause short term effects such as choking, gagging, and vomiting. Long term effects of circumcision without pain relief are not well understood. Strict comparability between trials was rare. Trials used a variety of indicators to measure baby's pain. Crying time, facial expression, and sweating palms can indicate infant pain, as can increased heart rate, breathing rate, and blood pressure. Levels of chemical indicators that can be part of a pain or stress response and are present in the blood or saliva are another gauge of pain levels. Also, procedures were not generally performed in just the same way in different trials. Type of clamp used (8sing a Mogen clamp can shorten the duration of the procedure), length of wait time after injection or application of anesthetic and procedure techniques varied.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Circumcision is a painful procedure that many newborn males undergo in the first few days after birth. Interventions are available to reduce pain at circumcision; however, many newborns are circumcised without pain management. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>The objective of this review was to assess the effectiveness and safety of interventions for reducing pain at neonatal circumcision.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 2, 2004), MEDLINE (1966 - April 2004), EMBASE (1988 - 2004 week 19), CINAHL (1982 - May week 1 2004), Dissertation Abstracts (1986 - May 2004), Proceedings of the World Congress on Pain (1993 - 1999), and reference lists of articles. Language restrictions were not imposed.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised controlled trials comparing pain interventions with placebo or no treatment or comparing two active pain interventions in male term or preterm infants undergoing circumcision. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two independent reviewers assessed trial quality and extracted data. Ten authors were contacted for additional information. Adverse effects information was obtained from the trial reports. For meta-analysis, data on a continuous scale were reported as weighted mean difference (WMD) or, when the units were not compatible, as standardized mean difference.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Thirty-five trials involving 1,997 newborns were included. Thirty-three trials enrolled healthy, full term neonates, and two enrolled infants born preterm.<BR/> <BR/>Fourteen trials involving 592 newborns compared dorsal penile nerve block (DPNB) with placebo or no treatment. Compared to placebo/no treatment, DPNB demonstrated significantly lower heart rate [WMD -35 bpm, 95% CI -41 to -30], decreased time crying [WMD -54 %, 95% CI -64 to -44], and increased oxygen saturation [WMD 3.7 %, 95% CI 2.7 to 3.7]. Six trials involving 200 newborns compared eutectic mixture of analgesics (EMLA) with placebo. EMLA demonstrated significantly lower facial action scores [WMD -46.5, 95% CI -80.4 to -12.6], decreased time crying [WMD - 15.2 %, 95% CI -21 to -9.3] and lower heart rate [WMD -15 bpm, 95% CI -19 to -10]. DPNB, compared with EMLA in three trials involving 139 newborns (133 of whom were included in the analysis), demonstrated significantly lower heart rate [WMD -17 bpm, 95% CI -23 to -11] and pain scores. When compared with sucrose in two trials involving 127 newborns, DPNB demonstrated less time crying [MD -166 s, 95% CI -211 to -121], and lower heart rate [WMD -27 bpm, 95% CI -33 to -20]. Results obtained for trials comparing oral sucrose and oral analgesics to placebo, and trials of environmental modification were either inconsistent or were not significantly different. </P>
<P>Adverse effects included gagging, choking, and emesis in placebo/untreated groups. Minor bleeding, swelling and hematoma were reported with DPNB. Erythema and mild skin pallor were observed with the use of EMLA. Methaemoglobin levels were evaluated in two trials of EMLA, and results were within normal limits. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>DPNB was the most frequently studied intervention and was the most effective for circumcision pain. Compared to placebo, EMLA was also effective, but was not as effective as DPNB. Both interventions appear to be safe for use in newborns. None of the studied interventions completely eliminated the pain response to circumcision.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>Neither the American Academy of Pediatrics nor the Canadian Paediatric Society recommends routine or elective circumcision of the male newborn. Nevertheless, elective circumcision of male newborns is commonly performed in the first few days after birth. Approximately 1.2 million newborn males are circumcised in the United States annually at a cost of 150 to 270 million dollars (<LINK REF="REF-AAP-1999" TYPE="REFERENCE">AAP 1999</LINK>). Precise Canadian data are not available because the procedure has been delisted in many provinces, but it is estimated that 48% of male neonates born in Canada are circumcised (<LINK REF="REF-CPS-1996" TYPE="REFERENCE">CPS 1996</LINK>). The practice of male neonatal circumcision is not limited to North America; it is performed worldwide for religious and cultural reasons. </P>
<P>As an invasive, painful procedure, unanaesthetized circumcision elicits systemic stress responses in the vulnerable newborn which negatively affect major body systems. Documented physiological and behavioral responses include increased output of adrenal corticoids (<LINK REF="REF-Gunnar-1981" TYPE="REFERENCE">Gunnar 1981</LINK>; <LINK REF="REF-Talbert-1976" TYPE="REFERENCE">Talbert 1976</LINK>), increased heart rate and respiratory rate, decreased arterial oxygen (<LINK REF="REF-Rawlings-1980" TYPE="REFERENCE">Rawlings 1980</LINK>), skin flushing, vomiting and cyanosis (<LINK REF="REF-Poma-1980" TYPE="REFERENCE">Poma 1980</LINK>), changes in sleep/wake state, increased crying (<LINK REF="REF-Anders-1974" TYPE="REFERENCE">Anders 1974</LINK>; <LINK REF="REF-Gunnar-1981" TYPE="REFERENCE">Gunnar 1981</LINK>), and diminished responsiveness to parents (<LINK REF="STD-Dixon-1984" TYPE="STUDY">Dixon 1984</LINK>). Unanaesthetized circumcision has also been linked with complications such as apnea and choking (<LINK REF="STD-Lander-1997" TYPE="STUDY">Lander 1997</LINK>), gastric rupture (<LINK REF="REF-Connelly-1992" TYPE="REFERENCE">Connelly 1992</LINK>), and recurrence of pneumothorax (<LINK REF="REF-Auerbach-1978" TYPE="REFERENCE">Auerbach 1978</LINK>). Infants circumcised without anaesthesia exhibit stronger pain responses to routine immunizations during the first six months of life than infants who were not circumcised (<LINK REF="REF-Taddio-1997b" TYPE="REFERENCE">Taddio 1997b</LINK>), suggesting that circumcision pain may exert long term effects on infant behavior. </P>
<P>INTERVENTIONS FOR CIRCUMCISION PAIN</P>
<P>Numerous interventions to prevent or reduce circumcision pain have been examined. These include penile blocks, topical anaesthetics, oral analgesia and sucrose administration, non-nutritive sucking, music and other environmental interventions. </P>
<P>The technique of dorsal penile nerve block (DPNB) for newborn circumcision was first described in 1978 (<LINK REF="REF-Kirya-1978" TYPE="REFERENCE">Kirya 1978</LINK>), and it has since been extensively evaluated. More recently, subpubic (<LINK REF="REF-Dalens-1989" TYPE="REFERENCE">Dalens 1989</LINK>) and penile ring block techniques (<LINK REF="STD-Hardwick-Smith-1998" TYPE="STUDY">Hardwick Smith 1998</LINK>; <LINK REF="STD-Lander-1997" TYPE="STUDY">Lander 1997</LINK>) have been examined. Adverse effects of penile blocks appear to be limited to bruising and slight bleeding at the injection site (<LINK REF="REF-Snellman-1995" TYPE="REFERENCE">Snellman 1995</LINK>). Of note, the rapidity of onset of the anaesthetic used for penile blocks (generally 1% lidocaine without epinephrine) is intermediate and a "wait time" of 5 minutes is recommended to achieve anaesthesia (<LINK REF="REF-Taddio-2001" TYPE="REFERENCE">Taddio 2001</LINK>). Wait time is a concern for clinicians because it increases the total time required for the circumcision surgery; however, inadequate "wait time" influences anaesthetic effect (<LINK REF="REF-Kharasch-2003" TYPE="REFERENCE">Kharasch 2003</LINK>). </P>
<P>Several types of topical anaesthetics have been used for neonatal circumcision, including eutectic mixture of local anaesthetics (EMLA) and 4 to 30% lidocaine creams. EMLA is a water-based cream that contains 2.5% lidocaine and 2.5% prilocaine. Compared with placebo, EMLA attenuates the pain responses of increased heart rate, facial activity and crying, and decreased oxygen saturation (<LINK REF="STD-Lander-1997" TYPE="STUDY">Lander 1997</LINK>; <LINK REF="STD-Taddio-1997" TYPE="STUDY">Taddio 1997</LINK>). A meta-analysis of three studies examining this intervention indicated that the use of EMLA results in a significantly lower increase in heart rate (from baseline) and less crying during the various phases of circumcision surgery compared to placebo. In two of the included studies, lower facial action scores suggested less pain in the EMLA treated groups compared to placebo (<LINK REF="REF-Taddio-2002" TYPE="REFERENCE">Taddio 2002</LINK>). </P>
<P>Potential difficulties with drug administration and the presurgical wait time may limit the feasibility of topical anaesthesia as a pain intervention for circumcision in many settings (<LINK REF="STD-Lander-1997" TYPE="STUDY">Lander 1997</LINK>). Considerable technical skill is required to apply the drug, and to secure the occlusive dressing needed to keep it in place. For adequate absorption, EMLA must be applied for at least 60 minutes prior to surgery (<LINK REF="REF-Taddio-1998" TYPE="REFERENCE">Taddio 1998</LINK>), and must be reapplied if the infant voids during the wait time. </P>
<P>Methaemoglobinaemia (MetHb), caused by oxidation of haemoglobin by the metabolites of prilocaine, is a serious but relatively rare risk associated with EMLA use in infants less than 12 months of age. A recent systematic review of the use of EMLA for acute pain in infants demonstrated that the risk of significant MetHb is low with single dose applications of 0.5 to 2g applied for 10 - 180 minutes for full term neonates, and 0.5 to 1.25g applied for 3 to 180 minutes for preterm neonates (<LINK REF="REF-Taddio-1998" TYPE="REFERENCE">Taddio 1998</LINK>). Local skin reactions, such as blanching, erythema, and edema of the skin have been reported with the use of EMLA , but these are usually transient and not considered serious. </P>
<P>Sucrose or other sugar solutions alone or in combination with non-nutritive sucking have recently been recommended as interventions for procedural pain management (<LINK REF="REF-Mitchell-2000" TYPE="REFERENCE">Mitchell 2000</LINK>). Oral sucrose is thought to activate central endogenous pathways, and may stimulate release of endorphins from the hypothalamus. Non nutritive sucking (NNS) is also thought to have an analgesic-like effect through stimulation of orotactile and mechanoreceptor mechanisms (<LINK REF="REF-Gibbons-2001" TYPE="REFERENCE">Gibbons 2001</LINK>; <LINK REF="REF-Mitchell-2003" TYPE="REFERENCE">Mitchell 2003</LINK>). The sensations created by NNS may deflect attention away from pain and facilitate self regulation because the infant is in control of the sucking. Sucrose and NNS appear to operate synergistically when offered in combination, and may provide more effective pain relief (<LINK REF="REF-Carbajal-1999" TYPE="REFERENCE">Carbajal 1999</LINK>; <LINK REF="REF-Gibbons-2001" TYPE="REFERENCE">Gibbons 2001</LINK>; <LINK REF="REF-Gibbons-2002" TYPE="REFERENCE">Gibbons 2002</LINK>). The analgesic effect of sucrose is activated within two minutes, and lasts for three to five minutes (<LINK REF="REF-Haouari-1999" TYPE="REFERENCE">Haouari 1999</LINK>; <LINK REF="REF-Mitchell-2003" TYPE="REFERENCE">Mitchell 2003</LINK>). Although sucrose in a wide variety of dosages (concentrations from 12 to 24%, and volumes from 0.05 to 2.0 ml) has generally been found to decrease acute, procedural pain responses in neonates (<LINK REF="REF-Mitchell-2000" TYPE="REFERENCE">Mitchell 2000</LINK>; <LINK REF="REF-Stevens-1997" TYPE="REFERENCE">Stevens 1997</LINK>), the optimal dose has not yet been identified. Meta-analyses results indicate that a 0.24g dose is effective to reduce pain responses in term infants, and higher doses do not appear to increase effectiveness (<LINK REF="REF-Stevens-1997" TYPE="REFERENCE">Stevens 1997</LINK>). In comparison, relatively small doses (0.01 to 0.02g) appear to be effective for preterm infants (<LINK REF="REF-Johnston-1997" TYPE="REFERENCE">Johnston 1997</LINK>). Interest in sucrose or other sugar solutions as a single or adjunctive intervention for circumcision pain is reflected in the design of recent research (e.g. <LINK REF="STD-Kass-2001" TYPE="STUDY">Kass 2001</LINK>; <LINK REF="STD-Kaufman-2002" TYPE="STUDY">Kaufman 2002</LINK>). </P>
<P>Acetaminophen is the most frequently prescribed non-opioid oral analgesic used to treat mild to moderate pain in pediatric populations (<LINK REF="REF-Berde-2002" TYPE="REFERENCE">Berde 2002</LINK>; <LINK REF="REF-McGrath-1990" TYPE="REFERENCE">McGrath 1990</LINK>). Acetaminophen is safe and effective for neonates and can be administered orally or rectally (<LINK REF="REF-Stevens-1999" TYPE="REFERENCE">Stevens 1999</LINK>). Acetaminophen has been used as an intervention for circumcision pain (<LINK REF="STD-Howard-1994" TYPE="STUDY">Howard 1994</LINK>). <BR/> <BR/>A variety of non-pharmacological interventions have been evaluated for treatment of acute procedural pain in neonates. In theory, these interventions provide nonpainful stimuli that compete with painful stimuli for the neonate's attention, and thus may blunt the perception of pain (<LINK REF="REF-Bellieni-2002" TYPE="REFERENCE">Bellieni 2002</LINK>). Interventions such as rocking, massage, facilitated tucking, and cuddling reduce pain responses during invasive procedures (<LINK REF="REF-Campos-1994" TYPE="REFERENCE">Campos 1994</LINK>; <LINK REF="REF-Corff-1995" TYPE="REFERENCE">Corff 1995</LINK>; <LINK REF="REF-Gray-2000" TYPE="REFERENCE">Gray 2000</LINK>). Music and other sounds (intrauterine, heartbeat) provide an auditory stimulus which may modulate pain perception and these have been evaluated as interventions for circumcision pain (<LINK REF="STD-Marchette-1989" TYPE="STUDY">Marchette 1989</LINK>; <LINK REF="STD-Marchette-1991" TYPE="STUDY">Marchette 1991</LINK>).</P>
<P>NEONATAL PAIN RESPONSES </P>
<P>It is difficult to evaluate the effectiveness of interventions for circumcision pain because newborns are non-verbal and display stereotypic responses to a variety of painful and non-painful stimuli. To maximize the validity of pain assessment in newborn populations three classes of pain indicators or outcomes, biochemical, physiological, and behavioural, are generally employed for research. Salivary and serum cortisol, the most frequently measured biochemical indicators, serve as markers of the stress response to pain because hormones of the hypothalamic-pituitary-adrenal axis are assayed. Physiological indicators include heart rate, respiratory rate, blood pressure, transcutaneous oxygen saturation (Tc pO2), transcutaneous carbon dioxide (Tc pCO2), oxygen saturation (SaO2), palmar sweat, intracranial pressure (ICP) and vagal tone. In newborn populations, heart rate is the most frequently studied physiological indicator (<LINK REF="REF-Sweet-1998" TYPE="REFERENCE">Sweet 1998</LINK>). Behavioral indicators include facial expression, cry, gross motor movement, and changes in behavioral state. Facial expression (<LINK REF="REF-Grunau-1987" TYPE="REFERENCE">Grunau 1987</LINK>) is the most comprehensively studied behavioral indicator for neonatal pain. </P>
<P>Multidimensional measurement tools that employ more than one parameter usually contain physiological and behavioral indicators, and occasionally add contextual information to obtain an overall pain score. The Neonatal Infant Pain Scale (NIPS) (<LINK REF="REF-Lawrence-1993" TYPE="REFERENCE">Lawrence 1993</LINK>) and the Premature Infant Pain Profile (PIPP) (<LINK REF="REF-Stevens-1996" TYPE="REFERENCE">Stevens 1996</LINK>) are multidimensional tools frequently utilized as outcome measures for investigation of acute procedural pain in term and preterm neonates. Although a number of pain measures are available for use with neonatal populations, no single measure has proven to be the best for all situations. Accordingly, all outcomes evaluated in the included studies as measures of neonatal pain were included in this review.</P>
<P>SUMMARY</P>
<P>The substantial amount of research conducted to date suggests a willingness to address the problem of circumcision pain. However, the majority of neonates are circumcised without interventions for pain (<LINK REF="REF-Myron-1991" TYPE="REFERENCE">Myron 1991</LINK>; <LINK REF="REF-Ryan-1994" TYPE="REFERENCE">Ryan 1994</LINK>; <LINK REF="REF-Snellman-1995" TYPE="REFERENCE">Snellman 1995</LINK>; <LINK REF="REF-Wellington-1993" TYPE="REFERENCE">Wellington 1993</LINK>). This situation persists despite growing awareness that newborns may perceive pain more intensely than older children or adults (<LINK REF="REF-Anand-2001" TYPE="REFERENCE">Anand 2001</LINK>; <LINK REF="REF-Fitzgerald-1993" TYPE="REFERENCE">Fitzgerald 1993</LINK>) and can be significantly compromised by it. </P>
<P>It has been suggested that training to manage circumcision pain is inadequate to promote consistent use of available interventions (<LINK REF="REF-Howard--1998" TYPE="REFERENCE">Howard 1998</LINK>). Recent surveys indicate that significant numbers of obstetricians (75%), family practitioners (44%), and pediatricians (29%) do not use analgesia/anaesthesia for circumcision because of concerns about adverse drug effects or because they believe that the procedure does not require pain management (<LINK REF="REF-Maxwell-1999" TYPE="REFERENCE">Maxwell 1999</LINK>; <LINK REF="REF-Stang-1991" TYPE="REFERENCE">Stang 1991</LINK>; <LINK REF="REF-Stang-1998" TYPE="REFERENCE">Stang 1998</LINK>). </P>
<P>Although a wide variety of interventions for circumcision pain have been examined, the individual and relative effectiveness of each has not been systematically assessed. Thus, the apparent reluctance of practitioners to adopt the regular use of pain interventions for circumcision may reflect beliefs that the findings of research conducted to date are collectively un-interpretable. At the same time, negative perceptions of the technical and practical difficulties associated with pain interventions may diminish clinician motivation to implement their regular use.</P>
<P>A systematic review of the research in this area was needed to summarize and identify implications arising from the existing evidence, and to provide an informed basis for practice and to identify gaps in knowledge which require further investigation. This review adds to knowledge gained from a previous systematic review which examined the efficacy of a single intervention for circumcision pain (<LINK REF="REF-Taddio-2002" TYPE="REFERENCE">Taddio 2002</LINK>) by evaluating the efficacy and safety of all interventions for reducing pain at neonatal circumcision.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To determine the safety and effectiveness of interventions to relieve pain associated with neonatal circumcision. Subgroup analyses were prespecified according to wait time (after anaesthetic administration and prior to start of surgery) for penile blocks, and for dose delivered for sucrose interventions.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Randomised controlled trials (RCTs). Studies reported only as abstracts were included if relevant. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Male term or preterm neonates undergoing circumcision during the neonatal period (with postnatal age maximum of 28 days after reaching 40 weeks corrected gestational age). </P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Any intervention intended to relieve pain during the circumcision procedure, for example, penile blocks, topical anaesthetics, oral sucrose administration, oral analgesics, surgical devices or techniques, or environmental manipulation such as music therapy or special restraints. This review included trials of interventions for circumcision pain in which any intervention was compared with placebo, no treatment, or with another active intervention.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>The primary outcome was pain as assessed by: </P>
<P>1. Physiological variables, such as heart rate (HR), respiratory rate (RR), oxygen saturation, or blood pressure (whether reported as change in, mean or absolute values) <BR/>2. Biochemical variables, such as salivary or serum cortisol levels (whether reported as pre- and post- measures or as change from baseline values)<BR/>3. Cry variables, for example, latency and duration of first cry, total cry duration, and/or percentage of time crying during the circumcision procedure<BR/>4. Validated pain measures, for example:<BR/>- Neonatal Infant Pain Score (<LINK REF="REF-Lawrence-1993" TYPE="REFERENCE">Lawrence 1993</LINK>); <BR/>- Neonatal Facial Action Coding System (<LINK REF="REF-Grunau-1987" TYPE="REFERENCE">Grunau 1987</LINK>); <BR/>- Premature Infant Pain Profile (<LINK REF="REF-Stevens-1996" TYPE="REFERENCE">Stevens 1996</LINK>);<BR/>- Other pain measures.</P>
<P>Secondary outcomes:</P>
<P>Complications of pain interventions were assessed as secondary outcomes. The outcomes included but were not limited to:<BR/>1) occurrence/incidence of methaemoglobinaemia (topical anaesthesia)<BR/>2) blanching and local skin irritations (topical anaesthesia)<BR/>3) bleeding, bruising and hematoma formation (penile blocks)<BR/>4) behavioral responses such a choking, spitting up, etc. during circumcision (all interventions)</P>
<P>Difficulties encountered in implementation of pain interventions, as reported by researchers, were noted.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>Standard methods as per the guidelines of the Cochrane Neonatal Review Group (CNRG) were utilized. <BR/>1. CIRCUMCISION/exp<BR/>2. circumcision surgery.mp<BR/>3. newborn circumcision.mp<BR/>4. 1 OR 2 OR 3<BR/>5. local anaesthes*<BR/>6. penile block.mp/exp<BR/>7. dorsal penile nerve block.mp/exp<BR/>8. ring block.mp/exp<BR/>9. 5 OR 6 OR 7 OR 8<BR/>10. eutectic mixture of local anaesthetics.mp/exp<BR/>11. EMLA.mp/exp<BR/>12. LIDOCAINE.mp/exp<BR/>13. 10 OR 11 OR 12<BR/>14. acetaminophen.mp/ OR paracetamol.mp/exp<BR/>15. sucrose.mp<BR/>16. pacifiers.mp<BR/>17. music therapy.mp<BR/>18. Gomco clamp.mp<BR/>19. Mogen clamp.mp<BR/>20. 9 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 <BR/>21. 4 AND 20<BR/>22. HUMAN<BR/>23. MALE<BR/>24. 22 and 23<BR/>25. infant, newborn<BR/>26. neonat*<BR/>27. 25 OR 26<BR/>28. 24 AND 27<BR/>29. 21 AND 28<BR/>30. clinical trial<BR/>31. 29 AND 30</P>
<P>Databases searched included: Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 2, 2004; MEDLINE 1966 - April 2004; EMBASE 1988 - 2004 week 19; CINAHL 1982 - May week 1 2004; PubMed 1966 - May 2004; Web of Science 1975 - May 2004; Dissertation Abstracts 1986 - May 2004. Keywords and (MeSH) terms included infant/newborn, male, circumcision, penile blocks, sucrose, lidocaine, EMLA, acetaminophen. Abstracts of the World Congress on Pain were searched for the years 1993 - 1999 inclusive. Reference lists of all articles were screened to identify any additional studies. Language restrictions were not imposed.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>Study Selection</P>
<P>The titles and abstracts of all reports identified through the electronic and other searches were scanned independently by two reviewers and full study reports were obtained for those that appeared to meet the inclusion criteria. Study reports were then evaluated independently by two reviewers for possible inclusion in the review. Disagreements were resolved by consensus. Studies rejected at this stage were included in the Table of Excluded Studies.<BR/> <BR/>Quality Assessment</P>
<P>Assessment of the quality of all included studies was undertaken independently by two reviewers as a component of the data extraction process. Standard methods of the CNRG were used to assess: 1) the randomisation procedure, 2) concealment of allocation/blinding of randomisation, 3) blinding of intervention, 4) subject attrition and follow-up, and 5) blinding of outcome measurement. As per the CNRG guidelines, an overall quality score was not assigned. Reviewers were not blind to trial authors or institutions during the study selection or quality assessment processes.</P>
<P>Data Extraction</P>
<P>Data were extracted from included studies by two independent reviewers using a data extraction form designed specifically for this review. The data extraction form was developed in a draft format and piloted on several studies and modified as required before use. The reviewers abstracted data independently, compared results and resolved differences.</P>
<P>Sixteen trials included in this review either did not report outcome data, or did not report data in a format that could be analysed in this review (<LINK REF="STD-Arnett-1990" TYPE="STUDY">Arnett 1990</LINK>; <LINK REF="STD-Benini-1993" TYPE="STUDY">Benini 1993</LINK>; <LINK REF="STD-Blass-1991-A" TYPE="STUDY">Blass 1991 A</LINK>; <LINK REF="STD-Holliday-1999" TYPE="STUDY">Holliday 1999</LINK>; <LINK REF="STD-Holve-1983" TYPE="STUDY">Holve 1983</LINK>, <LINK REF="STD-Joyce-2001" TYPE="STUDY">Joyce 2001</LINK>; <LINK REF="STD-Kass-2001" TYPE="STUDY">Kass 2001</LINK>; <LINK REF="STD-Marchette-1989" TYPE="STUDY">Marchette 1989</LINK>; <LINK REF="STD-Marchette-1991" TYPE="STUDY">Marchette 1991</LINK>; <LINK REF="STD-Maxwell-1987" TYPE="STUDY">Maxwell 1987</LINK>; <LINK REF="STD-Mohan-1998" TYPE="STUDY">Mohan 1998</LINK>; <LINK REF="STD-Mudge-1989" TYPE="STUDY">Mudge 1989</LINK>; <LINK REF="STD-Spencer-1992" TYPE="STUDY">Spencer 1992</LINK>; <LINK REF="STD-Williamson-1997" TYPE="STUDY">Williamson 1997</LINK>; <LINK REF="STD-Zahorodny-1998" TYPE="STUDY">Zahorodny 1998</LINK>; <LINK REF="STD-Zahorodny-1999" TYPE="STUDY">Zahorodny 1999</LINK>). Additional information was sought from ten authors and means and standard deviations were subsequently obtained for three trials (<LINK REF="STD-Benini-1993" TYPE="STUDY">Benini 1993</LINK>; <LINK REF="STD-Joyce-2001" TYPE="STUDY">Joyce 2001</LINK>; <LINK REF="STD-Kass-2001" TYPE="STUDY">Kass 2001</LINK>). Where means and standard deviations were not available, data were imputed or derived from graphs contained in the reports (<LINK REF="STD-Arnett-1990" TYPE="STUDY">Arnett 1990</LINK>; <LINK REF="STD-Benini-1993" TYPE="STUDY">Benini 1993</LINK>; <LINK REF="STD-Blass-1991-A" TYPE="STUDY">Blass 1991 A</LINK>; <LINK REF="STD-Holliday-1999" TYPE="STUDY">Holliday 1999</LINK>; <LINK REF="STD-Maxwell-1987" TYPE="STUDY">Maxwell 1987</LINK>; <LINK REF="STD-Mohan-1998" TYPE="STUDY">Mohan 1998</LINK>; <LINK REF="STD-Mudge-1989" TYPE="STUDY">Mudge 1989</LINK>; <LINK REF="STD-Taddio-1997" TYPE="STUDY">Taddio 1997</LINK>). Missing standard deviations were either calculated from other summary statistics or imputed using singular or mean standard deviations from similar trials. </P>
<P>Several authors reported total sample size only and information about the number of subjects per group was obtained from the authors (<LINK REF="STD-Benini-1993" TYPE="STUDY">Benini 1993</LINK>; <LINK REF="STD-Joyce-2001" TYPE="STUDY">Joyce 2001</LINK>). When additional information about sample size could not be obtained from the authors, we assumed equal distribution to study groups in our data analyses (<LINK REF="STD-Blass-1991-A" TYPE="STUDY">Blass 1991 A</LINK>; <LINK REF="STD-Zahorodny-1998" TYPE="STUDY">Zahorodny 1998</LINK>; <LINK REF="STD-Zahorodny-1999" TYPE="STUDY">Zahorodny 1999</LINK>). </P>
<P>Data Analysis</P>
<P>The outcomes presented in this review were reported as results obtained during the whole circumcision procedure. Usually, the circumcision surgery was described as commencing with application of forceps to the dorsal foreskin of the penis (referred to as dorsal or lateral clamping) and ending with removal of the surgical clamp (the Gomco, Mogen, or Plastibell surgical device, also referred to as a clamp). Some authors reported a single numerical outcome result for the entire circumcision procedure (e.g. <LINK REF="STD-Butler-O_x0027_Hara-1998" TYPE="STUDY">Butler O'Hara 1998</LINK>; <LINK REF="STD-Howard-1999" TYPE="STUDY">Howard 1999</LINK>; <LINK REF="STD-Maxwell-1987" TYPE="STUDY">Maxwell 1987</LINK>; <LINK REF="STD-Taddio-1997" TYPE="STUDY">Taddio 1997</LINK>). Others reported numerical results by procedure phase or step (e.g. dorsal foreskin grasped with forceps, adhesion lysis, dorsal incision, surgical clamp application, foreskin amputation, surgical clamp removal) (<LINK REF="STD-Benini-1993" TYPE="STUDY">Benini 1993</LINK>; <LINK REF="STD-Lander-1997" TYPE="STUDY">Lander 1997</LINK>; <LINK REF="STD-Woodman-1999" TYPE="STUDY">Woodman 1999</LINK>). For the latter studies, depending on the outcome, we calculated either the arithmetic mean (e.g. heart rate) or total (e.g. time crying) across the phases or steps of the circumcision (as defined by the authors), and did not include the baseline or recovery phase data. Variance formulae for these arithmetic means and these totals were derived according to the general formula for linear combinations of variance (i.e. Var (X+Y) = Var(x) + Var(Y) + 2Cov(X,Y)). We assumed a correlation of 0.5 as proposed by <LINK REF="REF-Follmann-1992" TYPE="REFERENCE">Follmann 1992</LINK>. Additional Tables 1 - 7 (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>; <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>; <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>; <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>; <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>; <LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>; <LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK>) provide specific details on summary estimate extractions from the included studies.</P>
<P>Data were analysed using the statistical package (RevMan 4.2) provided by the Cochrane Collaboration. When two or more studies were identified that examined the same comparison and clinically similar outcomes, data were pooled using fixed effects. Random effects accounting for inter-study heterogeneity were considered in sensitivity analyses. Studies that compared an active intervention with placebo were analysed separately from those that compared the same active intervention with no treatment. </P>
<P>Continuous data summaries are reported as weighted mean differences (WMD) when the units provided were compatible. When the units were not compatible, the standardized mean difference (SMD) is reported. The SMD describes the difference between the treatments in terms of units of standard deviations (SDs). To improve interpretability, we also report estimates of WMDs derived from the estimated SMDs. To derive the WMDs from the SMDs, we selected either the unit used in the majority of the trials or the most clinically relevant unit under a particular comparison and pooled the available SDs from the trials that used that unit. We then multiplied this pooled SD by the SMD to obtain an estimate of the WMD. The WMDs thus derived are reported along side the SMDs in the results. An example of how a SMD was converted to a WMD is provided in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>. </P>
<P>Individual study outcomes were reported as both final values (FVs) and change from baseline values (CVs). It is appropriate to combine FVs and CVs when combining mean differences to calculate a WMD. However, it is not appropriate, generally, to combine FVs and CVs when combining SMD to calculate an overall SMD. CVs often have smaller standard errors (SEs) than FVs since some of the intra-patient variation is removed from their SEs. Thus the individual study CV SMD tend to be in smaller SD units than the individual study FV SMD. However, in this systematic review, many of the SEs for CVs were either within the range of the FV SEs or they were larger, which is counterintuitive to the argument presented here. Hence, some of the SMD calculated in this review do combine CVs and FVs (Metagraphs 01.03; 01.08; 01.09; 03.02). Additional Tables 1 - 7 (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>; <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>; <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>; <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>; <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>; <LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>; <LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK>) provide specific details on summary estimate extractions from the included studies.</P>
<P>Heterogeneity was assessed quantitatively with the I-squared statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). The I-squared statistic indicates the percent variability due to between study (or inter-study) variability as opposed to within study (or intra-study) variability. An I-squared greater than 50% may be considered large. Only non-null heterogeneity statistics are presented here. Too few studies under a single comparison did not allow for any assessment of publication bias nor extensive sub-group or sensitivity analyses. However, post-hoc, we selected heart rate (the most frequently reported outcome) for between-study subgroup analyses using a chi-square method proposed by <LINK REF="REF-Deeks-2001" TYPE="REFERENCE">Deeks 2001</LINK>. We selected the following subgroup analyses a priori: for penile block interventions, "wait time" from anaesthesia administration to start of the circumcision procedure were considered by the following three categories: no wait time reported, wait time &lt;/= 5 minutes, wait time &gt;/= 5 minutes; for sucrose administration interventions, dose of sucrose administered was to be considered but could not be due to the lack of information provided in the reports. Surgical clamp type, use of pacifiers as a co-intervention, and choice of control group were selected for consideration post-hoc.<U>
<BR/>
</U>
</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>210 unique references were identified through search of the electronic databases. The full text of forty-two potentially relevant articles were obtained and reviewed for possible inclusion in this review. Six studies were excluded (see Table - Characteristics of Excluded Studies). In two excluded studies, subjects were not randomised and the intervention was chosen by the attending physician (<LINK REF="STD-Malnory-2003" TYPE="STUDY">Malnory 2003</LINK>; <LINK REF="STD-Olson-1998" TYPE="STUDY">Olson 1998</LINK>). Two of the excluded studies had no comparison group (<LINK REF="STD-Mintz-1989" TYPE="STUDY">Mintz 1989</LINK>, <LINK REF="STD-Russell-1996" TYPE="STUDY">Russell 1996</LINK>). One study was a cohort design and the outcome data for the control group was obtained from a previously conducted trial (<LINK REF="STD-Taddio-2000" TYPE="STUDY">Taddio 2000</LINK>), and one (<LINK REF="STD-Taeusch-2002" TYPE="STUDY">Taeusch 2002</LINK>) was a head to head comparison of surgical clamps used for the circumcision procedure rather than a direct comparison of interventions for pain relief. </P>
<P>Thirty-five studies (thirty-six reports) were included in this systematic review. Details of each are given in the Table - Characteristics of Included Studies. Two reports outlined different outcome data from the same trial (<LINK REF="STD-Dixon-1984" TYPE="STUDY">Dixon 1984</LINK>, <LINK REF="STD-Holve-1983" TYPE="STUDY">Holve 1983</LINK>). Two trials were reported as abstracts only (<LINK REF="STD-Zahorodny-1998" TYPE="STUDY">Zahorodny 1998</LINK>, <LINK REF="STD-Zahorodny-1999" TYPE="STUDY">Zahorodny 1999</LINK>) and we were unable to obtain additional information from the authors. One unpublished report of Master's thesis research was included (<LINK REF="STD-Zolnoski-1993" TYPE="STUDY">Zolnoski 1993</LINK>).</P>
<P>Thirty-three of the thirty-five included studies enrolled healthy, full term neonates. One trial included infants born preterm (and less than 28 days age after reaching 40 weeks corrected gestational age) who were ready for discharge from the neonatal intensive care unit (NICU) at the time of circumcision (<LINK REF="STD-Butler-O_x0027_Hara-1998" TYPE="STUDY">Butler O'Hara 1998</LINK>), and one trial enrolled infants born preterm and weighing 1600 - 2500g at the time of circumcision (<LINK REF="STD-Holliday-1999" TYPE="STUDY">Holliday 1999</LINK>).</P>
<P>Nineteen trials examined the effectiveness of penile blocks (<LINK REF="STD-Arnett-1990" TYPE="STUDY">Arnett 1990</LINK>; <LINK REF="STD-Butler-O_x0027_Hara-1998" TYPE="STUDY">Butler O'Hara 1998</LINK>; <LINK REF="STD-Hardwick-Smith-1998" TYPE="STUDY">Hardwick Smith 1998</LINK>; <LINK REF="STD-Herschel-1998" TYPE="STUDY">Herschel 1998</LINK>; <LINK REF="STD-Holliday-1999" TYPE="STUDY">Holliday 1999</LINK>; <LINK REF="STD-Holve-1983" TYPE="STUDY">Holve 1983</LINK>; <LINK REF="STD-Howard-1999" TYPE="STUDY">Howard 1999</LINK>; <LINK REF="STD-Kass-2001" TYPE="STUDY">Kass 2001</LINK>; <LINK REF="STD-Kurtis-1999-A" TYPE="STUDY">Kurtis 1999 A</LINK>; <LINK REF="STD-Lander-1997" TYPE="STUDY">Lander 1997</LINK>; <LINK REF="STD-Masciello-1990" TYPE="STUDY">Masciello 1990</LINK>; <LINK REF="STD-Maxwell-1987" TYPE="STUDY">Maxwell 1987</LINK>; <LINK REF="STD-Newton-1999" TYPE="STUDY">Newton 1999</LINK>; <LINK REF="STD-Spencer-1992" TYPE="STUDY">Spencer 1992</LINK>; <LINK REF="STD-Stang-1988-A" TYPE="STUDY">Stang 1988 A</LINK>; <LINK REF="STD-Stang-1997" TYPE="STUDY">Stang 1997</LINK>; <LINK REF="STD-Williamson-1983" TYPE="STUDY">Williamson 1983</LINK>; <LINK REF="STD-Williamson-1986" TYPE="STUDY">Williamson 1986</LINK>; <LINK REF="STD-Williamson-1997" TYPE="STUDY">Williamson 1997</LINK>). Twelve trials assessed topical anaesthetics (EMLA, lidocaine creams) (<LINK REF="STD-Benini-1993" TYPE="STUDY">Benini 1993</LINK>; <LINK REF="STD-Butler-O_x0027_Hara-1998" TYPE="STUDY">Butler O'Hara 1998</LINK>; <LINK REF="STD-Holliday-1999" TYPE="STUDY">Holliday 1999</LINK>; <LINK REF="STD-Howard-1999" TYPE="STUDY">Howard 1999</LINK>; <LINK REF="STD-Joyce-2001" TYPE="STUDY">Joyce 2001</LINK>; <LINK REF="STD-Lander-1997" TYPE="STUDY">Lander 1997</LINK>; <LINK REF="STD-Mohan-1998" TYPE="STUDY">Mohan 1998</LINK>; <LINK REF="STD-Mudge-1989" TYPE="STUDY">Mudge 1989</LINK>; <LINK REF="STD-Taddio-1997" TYPE="STUDY">Taddio 1997</LINK>; <LINK REF="STD-Weatherstone-1993" TYPE="STUDY">Weatherstone 1993</LINK>; <LINK REF="STD-Woodman-1999" TYPE="STUDY">Woodman 1999</LINK>; <LINK REF="STD-Zahorodny-1998" TYPE="STUDY">Zahorodny 1998</LINK>), and nine evaluated oral sucrose in a variety of concentrations and doses (<LINK REF="STD-Blass-1991-A" TYPE="STUDY">Blass 1991 A</LINK>; <LINK REF="STD-Herschel-1998" TYPE="STUDY">Herschel 1998</LINK>; <LINK REF="STD-Kass-2001" TYPE="STUDY">Kass 2001</LINK>; <LINK REF="STD-Kaufman-2002" TYPE="STUDY">Kaufman 2002</LINK>; <LINK REF="STD-Mohan-1998" TYPE="STUDY">Mohan 1998</LINK>; <LINK REF="STD-Stang-1997" TYPE="STUDY">Stang 1997</LINK>; <LINK REF="STD-Zahorodny-1998" TYPE="STUDY">Zahorodny 1998</LINK>; <LINK REF="STD-Zahorodny-1999" TYPE="STUDY">Zahorodny 1999</LINK>; <LINK REF="STD-Zolnoski-1993" TYPE="STUDY">Zolnoski 1993</LINK>). In two trials, subjects received an oral analgesic (acetaminophen) (<LINK REF="STD-Howard-1994" TYPE="STUDY">Howard 1994</LINK>; <LINK REF="STD-Macke-2001" TYPE="STUDY">Macke 2001</LINK>). Three trials evaluated forms of environmental manipulation (e.g. music, intrauterine sounds) (<LINK REF="STD-Joyce-2001" TYPE="STUDY">Joyce 2001</LINK>; <LINK REF="STD-Marchette-1989" TYPE="STUDY">Marchette 1989</LINK>; <LINK REF="STD-Marchette-1991" TYPE="STUDY">Marchette 1991</LINK>). For trial details see Table - Characteristics of Included Studies.</P>
<P>In the trials, the interventions were compared with placebo/sham treatments (e.g. saline penile block or inactive topical cream), no treatment, or with other active interventions. In several trials, all subjects received an active baseline intervention (e.g. EMLA cream or DPNB) prior to administration of the study intervention (<LINK REF="STD-Butler-O_x0027_Hara-1998" TYPE="STUDY">Butler O'Hara 1998</LINK>; <LINK REF="STD-Kaufman-2002" TYPE="STUDY">Kaufman 2002</LINK>; <LINK REF="STD-Stang-1997" TYPE="STUDY">Stang 1997</LINK>). </P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>All of the studies included in this systematic review were described as RCTs. However, fifteen of the study reports provided insufficient information or described inadequate procedures for assurance of blinding of randomisation (see Table - Characteristics of Included Studies). Nine were double-blind for delivery of all interventions (<LINK REF="STD-Howard-1994" TYPE="STUDY">Howard 1994</LINK>; <LINK REF="STD-Howard-1999" TYPE="STUDY">Howard 1999</LINK>; <LINK REF="STD-Joyce-2001" TYPE="STUDY">Joyce 2001</LINK>; <LINK REF="STD-Macke-2001" TYPE="STUDY">Macke 2001</LINK>; <LINK REF="STD-Mudge-1989" TYPE="STUDY">Mudge 1989</LINK>; <LINK REF="STD-Taddio-1997" TYPE="STUDY">Taddio 1997</LINK>; <LINK REF="STD-Weatherstone-1993" TYPE="STUDY">Weatherstone 1993</LINK>; <LINK REF="STD-Woodman-1999" TYPE="STUDY">Woodman 1999</LINK>; <LINK REF="STD-Zolnoski-1993" TYPE="STUDY">Zolnoski 1993</LINK>). Some studies compared interventions which could not be masked, for example, block techniques (<LINK REF="STD-Masciello-1990" TYPE="STUDY">Masciello 1990</LINK>; <LINK REF="STD-Newton-1999" TYPE="STUDY">Newton 1999</LINK>; <LINK REF="STD-Spencer-1992" TYPE="STUDY">Spencer 1992</LINK>). Partial blinding was achieved in several trials through inclusion of a sham or placebo group (<LINK REF="STD-Arnett-1990" TYPE="STUDY">Arnett 1990</LINK>; <LINK REF="STD-Blass-1991-A" TYPE="STUDY">Blass 1991 A</LINK>; <LINK REF="STD-Holve-1983" TYPE="STUDY">Holve 1983</LINK>; <LINK REF="STD-Kass-2001" TYPE="STUDY">Kass 2001</LINK>; <LINK REF="STD-Kaufman-2002" TYPE="STUDY">Kaufman 2002</LINK>; <LINK REF="STD-Lander-1997" TYPE="STUDY">Lander 1997</LINK>; <LINK REF="STD-Stang-1988-A" TYPE="STUDY">Stang 1988 A</LINK>; <LINK REF="STD-Stang-1997" TYPE="STUDY">Stang 1997</LINK>). Blinding was occasionally achieved on a temporary basis during baseline assessments (<LINK REF="STD-Butler-O_x0027_Hara-1998" TYPE="STUDY">Butler O'Hara 1998</LINK>; <LINK REF="STD-Holliday-1999" TYPE="STUDY">Holliday 1999</LINK>). <BR/> <BR/>There was considerable methodologic diversity between the included studies. For example, there was variation between all of the trials as to what constituted the circumcision "procedure". In one trial (<LINK REF="STD-Williamson-1983" TYPE="STUDY">Williamson 1983</LINK>), outcome data were reported for an undefined three minute "dissection period". In other trials, data were reported for each of multiple steps of a standardized procedure (<LINK REF="STD-Benini-1993" TYPE="STUDY">Benini 1993</LINK>; <LINK REF="STD-Hardwick-Smith-1998" TYPE="STUDY">Hardwick Smith 1998</LINK>; <LINK REF="STD-Herschel-1998" TYPE="STUDY">Herschel 1998</LINK>; <LINK REF="STD-Lander-1997" TYPE="STUDY">Lander 1997</LINK>; <LINK REF="STD-Woodman-1999" TYPE="STUDY">Woodman 1999</LINK>), or reported as a single summary statistic for the entire procedure (<LINK REF="STD-Taddio-1997" TYPE="STUDY">Taddio 1997</LINK>). Other authors did not describe any details of the circumcision procedure followed for the trial (<LINK REF="STD-Blass-1991-A" TYPE="STUDY">Blass 1991 A</LINK>; <LINK REF="STD-Holliday-1999" TYPE="STUDY">Holliday 1999</LINK>; <LINK REF="STD-Maxwell-1987" TYPE="STUDY">Maxwell 1987</LINK>; <LINK REF="STD-Stang-1988-A" TYPE="STUDY">Stang 1988 A</LINK>; <LINK REF="STD-Weatherstone-1993" TYPE="STUDY">Weatherstone 1993</LINK>). In general, not enough information was provided by authors to be certain that outcome results were directly comparable across studies, as the events that constituted the procedure may not have been equivalent.</P>
<P>There were differences within the group of trials of DPNB (the most frequently studied intervention) in length of time fasting prior to surgery, anaesthetic dose, wait time after anaesthetic administration, and in type of surgical clamp used. In some cases, a single operator performed all circumcisions (<LINK REF="STD-Butler-O_x0027_Hara-1998" TYPE="STUDY">Butler O'Hara 1998</LINK>; <LINK REF="STD-Hardwick-Smith-1998" TYPE="STUDY">Hardwick Smith 1998</LINK>; <LINK REF="STD-Howard-1994" TYPE="STUDY">Howard 1994</LINK>), in others, the circumcisions were performed by a number of different operators (<LINK REF="STD-Howard-1999" TYPE="STUDY">Howard 1999</LINK>; <LINK REF="STD-Macke-2001" TYPE="STUDY">Macke 2001</LINK>; <LINK REF="STD-Stang-1997" TYPE="STUDY">Stang 1997</LINK>). Differences in operator technique or in the circumcision procedure could have effected outcome results. For most of the trials, subjects were required to fast prior to the surgery, however, the fasting period varied between trials from 30 - 90 minutes (<LINK REF="STD-Arnett-1990" TYPE="STUDY">Arnett 1990</LINK>; <LINK REF="STD-Blass-1991-A" TYPE="STUDY">Blass 1991 A</LINK>; <LINK REF="STD-Herschel-1998" TYPE="STUDY">Herschel 1998</LINK>; <LINK REF="STD-Kurtis-1999-A" TYPE="STUDY">Kurtis 1999 A</LINK>; <LINK REF="STD-Maxwell-1987" TYPE="STUDY">Maxwell 1987</LINK>) to 2 - 4 hours (<LINK REF="STD-Butler-O_x0027_Hara-1998" TYPE="STUDY">Butler O'Hara 1998</LINK>; <LINK REF="STD-Howard-1994" TYPE="STUDY">Howard 1994</LINK>; <LINK REF="STD-Kaufman-2002" TYPE="STUDY">Kaufman 2002</LINK>; <LINK REF="STD-Masciello-1990" TYPE="STUDY">Masciello 1990</LINK>). Hunger could have influenced outcomes such as duration of infant crying or other behavioral responses. In a number of studies, subjects were offered pacifiers (<LINK REF="STD-Holliday-1999" TYPE="STUDY">Holliday 1999</LINK>; <LINK REF="STD-Howard-1994" TYPE="STUDY">Howard 1994</LINK>; <LINK REF="STD-Howard-1999" TYPE="STUDY">Howard 1999</LINK>; <LINK REF="STD-Kurtis-1999-A" TYPE="STUDY">Kurtis 1999 A</LINK>; <LINK REF="STD-Mohan-1998" TYPE="STUDY">Mohan 1998</LINK>; <LINK REF="STD-Spencer-1992" TYPE="STUDY">Spencer 1992</LINK>; <LINK REF="STD-Stang-1997" TYPE="STUDY">Stang 1997</LINK>) although pacifiers were not the study intervention. In one trial, all subjects were offered sugar pacifiers (<LINK REF="STD-Butler-O_x0027_Hara-1998" TYPE="STUDY">Butler O'Hara 1998</LINK>). The potential effect of NNS on the outcomes measured in the trials providing pacifiers was not addressed in the reports. <BR/> </P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>ACTIVE VERSUS PLACEBO OR NO TREATMENT COMPARISONS<U>
<BR/>
</U>
<BR/>
</P>
<UL>
<LI>Penile block interventions</LI>
</UL>
<P>
<BR/> <I>Dorsal penile nerve block</I>
</P>
<P>Fourteen trials compared dorsal penile nerve block (DPNB) to no treatment or placebo (sham injection). A total of 592 infants were included. Three trials employed pain scores (Metagraph 01.01) as an outcome measure (<LINK REF="STD-Arnett-1990" TYPE="STUDY">Arnett 1990</LINK>; <LINK REF="STD-Holliday-1999" TYPE="STUDY">Holliday 1999</LINK>; <LINK REF="STD-Kass-2001" TYPE="STUDY">Kass 2001</LINK>). These trials were not combined for meta-analysis of effect on pain because the scores used are not similar in conceptual development or measurement technique. However, outcomes significantly favoured DPNB using all four scores reported: infant irritability score [MD -1.8, 95% CI -2.4 to -1.2], modified behavioral pain scale (MBPS) [MD -3.2 , 95% CI -4.5 to -1.9], Holliday's behaviour score [MD -8.8, 95% CI -11.1 to -6.5], and the crying component of the same behavioral score [MD -9.8, 95% CI -13 to -6.6]. Another behavioral measure, time crying, also significantly favoured the DPNB group [WMD -54 %, 95% CI -64 to -44; SMD -1.74, 95% CI -2.1 to -1.4; Metagraph 01.02; SMD displayed, WMD derived from SMD; data not shown].</P>
<P>Among the physiological measures, heart rate significantly favoured DPNB [WMD - 35 bpm, 95% CI -41 to -30; SMD -1.6, 95% CI -1.8 to -1.3; I<SUP>2</SUP> = 73%; Metagraph 01.03; ; SMD displayed, WMD derived from SMD; data not shown]. Oxygen saturation results also significantly favoured DPNB [WMD 3.2 %, 95% CI 2.7 to 3.7; I<SUP>2</SUP> = 97%; Metagraph 01.06]. Results were heterogeneous, and one author reported the loss of large amounts of data (<LINK REF="STD-Herschel-1998" TYPE="STUDY">Herschel 1998</LINK>). A single trial (<LINK REF="STD-Williamson-1983" TYPE="STUDY">Williamson 1983</LINK>) reported results for transcutaneous oxygen saturation that also significantly favoured DPNB [MD 9.3 torr, 95% CI 1.8 to 16.9; Metagraph 01.07]. </P>
<P>Respiratory rate (Metagraph 01.08) and serum B-endorphin (Metagraph 01.12) were not significantly different. Systolic blood pressure was reported in two studies. The combined result was significant and favoured DPNB [WMD -9 mmHg, 95% CI -16 to - 2; SMD -0.66, 95% CI -1.18 to -0.13; I<SUP>2</SUP>=92%; Metagraph 01.09; SMD displayed, WMD derived from SMD; data not shown] but the effect was not significant in the random effects model or when <LINK REF="STD-Maxwell-1987" TYPE="STUDY">Maxwell 1987</LINK> was removed. The populations for these two trials were different. <LINK REF="STD-Maxwell-1987" TYPE="STUDY">Maxwell 1987</LINK> recruited healthy newborns in the first few days of life, while <LINK REF="STD-Holliday-1999" TYPE="STUDY">Holliday 1999</LINK> enrolled low birthweight preterm infants. The preterm infants were cared for NICU and experience with other invasive procedures prior to circumcision may have affected their pain responses.</P>
<P>Serum cortisol (Metagraph 01.10) outcomes were reported in mg/dL, ug/dL and nmol/dL. Results were converted to nmol/dL using standard conversion factors and the outcomes expressed in these units were combined but were not significantly different. A single study (<LINK REF="STD-Kurtis-1999-A" TYPE="STUDY">Kurtis 1999 A</LINK>) reported salivary cortisol results and these were not significantly different. </P>
<P>In two studies (comparing DPNB to no treatment), authors did not report means and SDs. <LINK REF="STD-Williamson-1997" TYPE="STUDY">Williamson 1997</LINK> found significantly lower oxygen saturation and higher heart rates in the no treatment group during adhesion lysis and application of the surgical clamp (p&lt; 0.001). There was a significant difference in duration of crying between the groups (p &lt;0.001) with the DPNB group crying less. The second study found that the mean increase in heart rate and percent of time crying during circumcision was 50% less for infants in the DPNB group (p&lt; 0.01) (<LINK REF="STD-Holve-1983" TYPE="STUDY">Holve 1983</LINK>). The DPNB group infants were more attentive to stimuli following circumcision, and were better able to quiet themselves when disturbed (<LINK REF="STD-Dixon-1984" TYPE="STUDY">Dixon 1984</LINK>).</P>
<P>
<I>Ring block<BR/>
</I>
<BR/>Two trials compared ring block to no treatment and included 65 subjects (<LINK REF="STD-Hardwick-Smith-1998" TYPE="STUDY">Hardwick Smith 1998</LINK>; <LINK REF="STD-Lander-1997" TYPE="STUDY">Lander 1997</LINK>). Percent time crying was significantly reduced in the ring block group [WMD -26.3%, 95% CI -38 to -15, SMD -1.25, 95% CI -1.82 to -0.69; I<SUP>2</SUP> = 68%; Metagraph 02.01; SMD displayed, WMD derived from SMD; data not shown]. Only single studies reported other measures. In one (<LINK REF="STD-Lander-1997" TYPE="STUDY">Lander 1997</LINK>) heart rate significantly favoured the ring block group [MD -29 bpm, 95% CI -52 to - 7; Metagraph 02.02]. Oxygen saturation (Metagraph 02.03) and respiratory rate (Metagraph 02.04) were reported by <LINK REF="STD-Hardwick-Smith-1998" TYPE="STUDY">Hardwick Smith 1998</LINK> and were not significantly different. </P>
<UL>
<LI>Topical anaesthetics</LI>
</UL>
<P>
<BR/> <I>EMLA</I>
</P>
<P>Six studies compared EMLA to placebo for a total 200 patients (<LINK REF="STD-Benini-1993" TYPE="STUDY">Benini 1993</LINK>; <LINK REF="STD-Joyce-2001" TYPE="STUDY">Joyce 2001</LINK>; <LINK REF="STD-Lander-1997" TYPE="STUDY">Lander 1997</LINK>; <LINK REF="STD-Taddio-1997" TYPE="STUDY">Taddio 1997</LINK>; <LINK REF="STD-Woodman-1999" TYPE="STUDY">Woodman 1999</LINK>; <LINK REF="STD-Zahorodny-1998" TYPE="STUDY">Zahorodny 1998</LINK>). Two studies measured infant behavioral responses using the same pain score, the Neonatal Facial Coding System (<LINK REF="REF-Grunau-1987" TYPE="REFERENCE">Grunau 1987</LINK>). The trials used the same measure, but the researchers scored a different set of facial actions (see Additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>), and calculated the summary pain score differently. In both summation techniques, a lower score indicated less facial action and less pain. When combined, the results significantly favoured EMLA [WMD -46.5, 95% CI -80.4 to -12.6; SMD -0.6, 95% CI -1.0 to -0.2; Metagraph 03.01; SMD displayed, WMD derived from SMD; data not shown].</P>
<P>Cry time was also significantly decreased with EMLA treatment [WMD - 15.2 %, 95% CI -21 to - 9.3; SMD -0.78, 95% CI -1.08 to - 0.48; Metagraph 03.02; SMD displayed, WMD derived from SMD; data not shown]. One study (<LINK REF="STD-Joyce-2001" TYPE="STUDY">Joyce 2001</LINK>) did not favour the EMLA treatment, but for this study cry time was measured from the start of circumcision until crying stopped or until 30 minutes elapsed. The other studies measured cry time by phases of the procedure or gave a summary value for the procedure and thus only time spent crying during circumcision surgery could be calculated. </P>
<P>Heart rate was significantly decreased for infants treated with EMLA [WMD -15 bpm, 95% CI -19 to -10; Metagraph 03.03]. The effect on oxygen saturation was not significant [WMD 0.9%, 95% CI -0.2 to 2.0; Metagraph 03.04], and heterogeneity was large (I<SUP>2</SUP>= 86%). Respiratory rate, systolic and diastolic blood pressure (Metagraphs 03.05, 03.06, 03.07) were not significantly different. </P>
<P>
<I>Lidocaine cream</I>
</P>
<P>Three trials compared topical lidocaine to placebo and included 115 patients (<LINK REF="STD-Mudge-1989" TYPE="STUDY">Mudge 1989</LINK>; <LINK REF="STD-Weatherstone-1993" TYPE="STUDY">Weatherstone 1993</LINK>; <LINK REF="STD-Woodman-1999" TYPE="STUDY">Woodman 1999</LINK>). One study measured percentage of time spent in Brazelton behavioral state 6 (full cry) as a proxy for pain (<LINK REF="STD-Weatherstone-1993" TYPE="STUDY">Weatherstone 1993</LINK>) and the results were insignificant [MD -8, 95% CI -23 to 7; Metagraph 04.01]. Cry time was significantly reduced [WMD -60 s, 95% CI -99 to -20; Metagraph 04.02] and favoured lidocaine. Heart rate was also significantly reduced [WMD -9 bpm, 95% CI -14 to - 4; I<SUP>2</SUP>=12%; Metagraph 04.03]. A single study examined <I>B</I>-endorphin levels, and these were significantly reduced for the group treated with lidocaine [MD -49 pg/mL, 95% CI -89 to -9; Metagraph 04.06]. One study (<LINK REF="STD-Mudge-1989" TYPE="STUDY">Mudge 1989</LINK>) did not report standard deviations for oxygen saturation (Metagraph 04.04) and respiratory rate (Metagraph 04.05) and these could not be calculated from the information available. However, the direction of results favoured treatment with lidocaine. Oxygen saturation results for another study (<LINK REF="STD-Woodman-1999" TYPE="STUDY">Woodman 1999</LINK>) were not significantly different.</P>
<UL>
<LI>Oral sucrose/dextrose</LI>
</UL>
<P>
<BR/>Eight trials compared sugar solutions to water and/or no treatment and included 360 subjects (<LINK REF="STD-Blass-1991-A" TYPE="STUDY">Blass 1991 A</LINK>; <LINK REF="STD-Herschel-1998" TYPE="STUDY">Herschel 1998</LINK>; <LINK REF="STD-Kass-2001" TYPE="STUDY">Kass 2001</LINK>; <LINK REF="STD-Kaufman-2002" TYPE="STUDY">Kaufman 2002</LINK>; <LINK REF="STD-Stang-1997" TYPE="STUDY">Stang 1997</LINK>; <LINK REF="STD-Zahorodny-1998" TYPE="STUDY">Zahorodny 1998</LINK>; <LINK REF="STD-Zahorodny-1999" TYPE="STUDY">Zahorodny 1999</LINK>; <LINK REF="STD-Zolnoski-1993" TYPE="STUDY">Zolnoski 1993</LINK>). A variety of concentrations (24 to 50%) and volumes (1.5 to 10 ml) of sucrose or dextrose were tested. Two studies measured pain scores (<LINK REF="STD-Kass-2001" TYPE="STUDY">Kass 2001</LINK>; <LINK REF="STD-Stang-1997" TYPE="STUDY">Stang 1997</LINK>). The results were not combined because the measures are not similar in conceptual development or measurement technique. For example, distress scores (<LINK REF="STD-Stang-1997" TYPE="STUDY">Stang 1997</LINK>) ranging from 0 to 3 indicated no crying to sustained cry respectively. The modified behavioral pain scale (MBPS) scores (<LINK REF="STD-Kass-2001" TYPE="STUDY">Kass 2001</LINK>) ranged from 0 to 10 and incorporated ratings for facial expression, crying and body movements. Results using the behavioral distress score significantly favoured sucrose [MD -0.7 units, 95% CI -1.1 to -0.3], while the MBPS results were not significantly different (Metagraph 05.01). </P>
<P>Cry time results were not significantly different overall [WMD - 1.3 %, 95% CI -5.8 to -8.3; SMD 0.07, 95% CI -0.31 to 0.44; I<SUP>2</SUP> = 78%; Metagraph 05.02; SMD displayed, WMD derived from SMD; data not shown]. Individual results from five trials were inconsistent in direction. <LINK REF="STD-Zahorodny-1998" TYPE="STUDY">Zahorodny 1998</LINK> reported means only and SDs were substituted from another study using the same intervention and same outcome measure. One study (<LINK REF="STD-Kaufman-2002" TYPE="STUDY">Kaufman 2002</LINK>) reported a different measure of cry time. They averaged time spent crying in 10 second intervals, then took the cumulative average of that for each group. In this study, cry time was statistically significant and favoured the sucrose group (56 vs 86 s; P=0.0001). <LINK REF="STD-Zahorodny-1999" TYPE="STUDY">Zahorodny 1999</LINK> did not report means or standard deviations, but did report that both the sucrose and the water group cried much less than the no treatment group (p&lt;0.001), and that subjects receiving the sucrose pacifier cried the least (p&lt;.03). The sucrose and water groups in this trial also had smaller increases in heart rate compared to those receiving no intervention (p&lt;.017). These authors did not comment on any differences between the sucrose group and the water group. </P>
<P>The effect on heart rate was not significant [WMD -4 bpm, 95% CI -9 to 2; Metagraph 05.03] overall in three trials. Heterogeneity was large (I<SUP>2</SUP>=55%) with two trials favouring the water treatment and one trial favouring the sucrose treatment. In two trials (<LINK REF="STD-Herschel-1998" TYPE="STUDY">Herschel 1998</LINK>; <LINK REF="STD-Kass-2001" TYPE="STUDY">Kass 2001</LINK>) oxygen saturation was significantly greater in the sucrose group [WMD 1.8%, 95% CI 0.5 to 3.1; Metagraph 05.04] although heterogeneity was again large (I<SUP>2</SUP>=88%) and the random effects estimate was not significant [WMD 1.3%, 95% CI -2.7 to 5.2]. Serum cortisol (Metagraph 05.05) was measured in a single study (<LINK REF="STD-Stang-1997" TYPE="STUDY">Stang 1997</LINK>) and results were not significant. </P>
<P>The inconsistent results in these trials may be related to the volume and concentration of sucrose provided and to the sucrose delivery method. For example, in two studies the treatment group received a dose of 10 ml of 50% sucrose as the treatment intervention (<LINK REF="STD-Herschel-1998" TYPE="STUDY">Herschel 1998</LINK>; <LINK REF="STD-Zahorodny-1999" TYPE="STUDY">Zahorodny 1999</LINK>), while in two other studies, the treatment group received 2 ml of 50% sucrose (<LINK REF="STD-Kass-2001" TYPE="STUDY">Kass 2001</LINK>; <LINK REF="STD-Zahorodny-1998" TYPE="STUDY">Zahorodny 1998</LINK>). The treatment groups in the other trials received 1.5 ml (<LINK REF="STD-Blass-1991-A" TYPE="STUDY">Blass 1991 A</LINK>), 2.3 ml (<LINK REF="STD-Zolnoski-1993" TYPE="STUDY">Zolnoski 1993</LINK>) or an unspecified volume of 24% sucrose (<LINK REF="STD-Kaufman-2002" TYPE="STUDY">Kaufman 2002</LINK>; <LINK REF="STD-Stang-1997" TYPE="STUDY">Stang 1997</LINK>) respectively. The delivery method for the sugar solution also varied between studies. Five administered the sugar/water solution via a nipple/pacifier (<LINK REF="STD-Blass-1991-A" TYPE="STUDY">Blass 1991 A</LINK>; <LINK REF="STD-Herschel-1998" TYPE="STUDY">Herschel 1998</LINK>; <LINK REF="STD-Kaufman-2002" TYPE="STUDY">Kaufman 2002</LINK>; <LINK REF="STD-Stang-1997" TYPE="STUDY">Stang 1997</LINK>; <LINK REF="STD-Zahorodny-1999" TYPE="STUDY">Zahorodny 1999</LINK>) thus providing the opportunity for non-nutritive sucking. In one trial (<LINK REF="STD-Herschel-1998" TYPE="STUDY">Herschel 1998</LINK>), the sucrose group had a nipple (and the opportunity for non-nutritive sucking throughout the circumcision procedure), while the no treatment control group did not receive a pacifier at all. In two studies, the sugar solution was delivered using oral syringes (<LINK REF="STD-Kass-2001" TYPE="STUDY">Kass 2001</LINK>; <LINK REF="STD-Zolnoski-1993" TYPE="STUDY">Zolnoski 1993</LINK>). In one trial, the method of delivery was not specified (<LINK REF="STD-Zahorodny-1998" TYPE="STUDY">Zahorodny 1998</LINK>).</P>
<UL>
<LI>Oral analgesics</LI>
</UL>
<P>
<BR/> <I>Acetaminophen</I>
</P>
<P>Two trials compared acetaminophen to placebo with a total of 104 patients (<LINK REF="STD-Howard-1994" TYPE="STUDY">Howard 1994</LINK>; <LINK REF="STD-Macke-2001" TYPE="STUDY">Macke 2001</LINK>). The studies employed two different pain scales, and the results were not combined because the measures are not similar in conceptual development or measurement technique. <LINK REF="STD-Howard-1994" TYPE="STUDY">Howard 1994</LINK> used a comfort score that measures 10 behaviours (sleep, facial expression, motor activity, tone, etc.) to arrive at a composite score of 0 to 20. The lower the score, the more uncomfortable the infant. <LINK REF="STD-Macke-2001" TYPE="STUDY">Macke 2001</LINK> used the Nursing Child Assessment Feeding Scale (NCAFS) which measures mother-infant feeding interactions using 76 behavioral items based on the concepts of synchronism and adaptation. Lower scores on the NCAFS indicate less positive responses on the part of the infant. Results using the post-operative comfort score were not significant, but the total infant scores on the NCAFS were significant and favoured acetaminophen [MD 4.0, 95% CI 1.0 to 7.1; Metagraph 06.01]. All other outcomes (cry time, heart rate, respiratory rate Metagraphs 06.02, 06.03, 06.04) were not statistically significant. </P>
<P>ACTIVE VERSUS ACTIVE TREATMENT COMPARISONS</P>
<UL>
<LI>DPNB versus EMLA</LI>
</UL>
<P>
<BR/>Three studies compared DPNB to EMLA for a total of 139 patients (<LINK REF="STD-Butler-O_x0027_Hara-1998" TYPE="STUDY">Butler O'Hara 1998</LINK>; <LINK REF="STD-Howard-1999" TYPE="STUDY">Howard 1999</LINK>; <LINK REF="STD-Lander-1997" TYPE="STUDY">Lander 1997</LINK>). Two studies measured different pain scores (Metagraph 07.01). The results were not combined because of conceptual and measurement differences between the scales. The Neonatal Infant Pain Scale (NIPS) consists of 6 behavioral components with a composite score of 0 to 6 based on facial expression, crying, breathing pattern, body movement and arousal. The behavioral distress score measures crying on a scale of 0 (no crying) to 3 (sustained crying). Lower scores indicate less pain for both measures. Results using both scales were statistically significant and favoured DPNB; NIPS [MD -2.5, 95% CI -3.3 to -1.7]; behavioral distress score [MD -0.3, 95% CI -0.5 to -0.03]. </P>
<P>Cry time was measured in a single study and was not significantly different [MD -10%, 95% CI -30 to 10; Metagraph 07.02]. Heart rate was significantly reduced for the DPNB group [WMD -17 bpm, 95% CI -23 to -11; Metagraph 07.03] but heterogeneity was large (I<SUP>2</SUP>=93%). The random effects estimate was not statistically significant. <LINK REF="STD-Butler-O_x0027_Hara-1998" TYPE="STUDY">Butler O'Hara 1998</LINK> had a large mean difference [MD -40 bpm, 95% CI -51 to -29 ]; when this study was removed, heterogeneity was absent and the overall fixed effects WMD was no longer significant [WMD -7 bpm, 95% CI -14 to 0.5]. The large heterogeneity may be related to differences in the characteristics of the study subjects. Infants enrolled in the <LINK REF="STD-Butler-O_x0027_Hara-1998" TYPE="STUDY">Butler O'Hara 1998</LINK> trial were born prematurely and hospitalised in the neonatal intensive care unit (NICU). Postnatal age was 3 - 105 days by the time of circumcision (but less than 28 days after reaching 40 weeks corrected gestational age). Exposure to invasive treatments during their NICU stay may have caused the infants to become sensitized and thus respond differently than infants in the other two trials who were healthy newborns in the first few days of life. Respiratory rate (Metagraph 07.05), measured by a single study, was not significantly different.</P>
<UL>
<LI>DPNB versus sucrose</LI>
</UL>
<P>
<BR/>Two trials compared DPNB to sucrose for 127 patients. In one trial, pain was measured using the modified behavioral pain scale (MPBS) (<LINK REF="STD-Kass-2001" TYPE="STUDY">Kass 2001</LINK>) and the results significantly favoured DPNB [MD -3.2, 95% CI -4.7 to -1.8; Metagraph 08.01]. Cry time was measured in one trial and significantly favoured the DPNB group [MD -166 s, 95% CI -211 to -121; Metagraph 08.02]. Heart rate also significantly favoured DPNB [WMD -27 bpm, 95% CI -33 to -20; Metagraph 08.03]. Heterogeneity was large (I<SUP>2</SUP>=94%) however, both trials measuring heart rate favoured the DPNB group. The effect on oxygen saturation (Metagraph 08.04) was not significant, heterogeneity was large (I<SUP>2</SUP>=96%), and the individual trial estimates were not consistent in direction of effect. The authors of one study (<LINK REF="STD-Herschel-1998" TYPE="STUDY">Herschel 1998</LINK>) reported that a significant amount of oxygen saturation data (measured using pulse oximetry) was lost due to excessive motion. Also of note, the dose and delivery method of the sugar solution differed between the two studies. In one study (<LINK REF="STD-Kass-2001" TYPE="STUDY">Kass 2001</LINK>) subjects received 2 ml of 50% dextrose by oral syringe. In the other (<LINK REF="STD-Herschel-1998" TYPE="STUDY">Herschel 1998</LINK>), subjects received up to 10 ml of 50% sucrose by nipple and had a pacifier throughout the procedure. </P>
<UL>
<LI>DPNB versus ring block</LI>
</UL>
<P>
<BR/>One trial compared DPNB to ring block (<LINK REF="STD-Lander-1997" TYPE="STUDY">Lander 1997</LINK>) and included 27 patients. Results for cry time and heart rate were not significantly different between the groups (Metagraphs 09.01, 09.02). </P>
<UL>
<LI>DPNB versus local block</LI>
</UL>
<P>
<BR/>A single trial compared DPNB to local block using 1% lidocaine (<LINK REF="STD-Masciello-1990" TYPE="STUDY">Masciello 1990</LINK>) and included 20 patients. Local block was performed by injecting lidocaine subcutaneously into the foreskin at the 10 and 2 o'clock positions at the level of the corona. Results for serum cortisol significantly favoured the local block administration group [MD 306 nmol/dL, 95% CI 141 to 471; Metagraph 10.01]. </P>
<UL>
<LI>Ring block versus EMLA</LI>
</UL>
<P>
<BR/>Ring block was compared to EMLA in a single trial that included 28 patients (<LINK REF="STD-Lander-1997" TYPE="STUDY">Lander 1997</LINK>). Results for heart rate [MD -3 bpm, 95% CI -20 to 14; Metagraph 11.01] and cry time [MD -16 %, CI -36 to 3; Metagraph 11.02] were not significantly different between the groups.</P>
<UL>
<LI>Buffered lidocaine DPNB versus lidocaine DPNB</LI>
</UL>
<P>
<BR/>Two trials compared buffered lidocaine DPNB to lidocaine DPNB and included 234 patients (<LINK REF="STD-Newton-1999" TYPE="STUDY">Newton 1999</LINK>; <LINK REF="STD-Stang-1997" TYPE="STUDY">Stang 1997</LINK>). In clinical trials with adult subjects, buffering lidocaine with sodium bicarbonate had shown potential to decrease the burning sensation of injection, and enhance the speed of anaesthesia. The results for all outcomes measured (behavioral distress score, cry time, heart rate, oxygen saturation and serum cortisol; Metagraphs 12.01, 12.02, 12.03, 12.04, 12.05) were not significantly different between the groups. </P>
<UL>
<LI>EMLA versus topical lidocaine </LI>
</UL>
<P>
<BR/>One trial compared EMLA to 30% topical lidocaine, and included 40 patients (<LINK REF="STD-Woodman-1999" TYPE="STUDY">Woodman 1999</LINK>). Cry time and oxygen saturation (Metagraphs 13.01, 13.03) were not significantly different. Heart rate was significant and favoured EMLA [MD -12 bpm, 95% CI -19 to -4; Metagraph 13.02]. </P>
<UL>
<LI>EMLA versus sucrose</LI>
</UL>
<P>
<BR/>Two studies (<LINK REF="STD-Mohan-1998" TYPE="STUDY">Mohan 1998</LINK>; <LINK REF="STD-Zahorodny-1998" TYPE="STUDY">Zahorodny 1998</LINK>) compared EMLA to sucrose (67 patients). Cry time, heart rate, oxygen saturation (Metagraphs 14.01, 14.02, 14.03) were not significant. Systolic and diastolic blood pressures mean differences could not be calculated because no standard deviations were provided (Metagraphs 14.04, 14.05), but both means were larger in the sucrose group, indicating higher mean blood pressure. </P>
<UL>
<LI>EMLA versus music</LI>
</UL>
<P>
<BR/>A small pilot study (<LINK REF="STD-Joyce-2001" TYPE="STUDY">Joyce 2001</LINK>) compared EMLA to music, and included 12 patients. None of the outcome results (cry time, heart rate, oxygen saturation, respiratory rate; Metagraphs 15.01, 15.02, 15.03, 15.04) were significantly different.</P>
<P>ENVIRONMENTAL COMPARISONS</P>
<UL>
<LI>Music versus no treatment</LI>
</UL>
<P>
<BR/>Three studies compared the provision of music or other soothing sounds during the circumcision procedure (<LINK REF="STD-Joyce-2001" TYPE="STUDY">Joyce 2001</LINK>; <LINK REF="STD-Marchette-1989" TYPE="STUDY">Marchette 1989</LINK>; <LINK REF="STD-Marchette-1991" TYPE="STUDY">Marchette 1991</LINK>). In one trial that included 12 patients (<LINK REF="STD-Joyce-2001" TYPE="STUDY">Joyce 2001</LINK>) the effect of the intervention on the outcomes of cry time, heart rate, oxygen saturation and respiratory rate (Metagraphs 16.01, 16.02, 16.03, 16.04) was not significant. In a second study, music was compared with intrauterine sounds and no treatment (<LINK REF="STD-Marchette-1989" TYPE="STUDY">Marchette 1989</LINK>). Although 103 infants were randomised, 45 records were deleted from analysis due to missing data or prolonged circumcisions related to physician training. The researchers did not report standard deviations, but they did report that during all steps of the circumcision procedure in which infants were touched with surgical instruments the interventions did not offset pain as indicated by heart rate, systolic blood pressure, facial expression, and behavioral state outcomes. In the third study (<LINK REF="STD-Marchette-1991" TYPE="STUDY">Marchette 1991</LINK>) 121 infants were randomised to six groups and received either classical music, intrauterine sounds, a pacifier, music and a pacifier, intrauterine sounds and a pacifier, or no treatment. The researchers did not report means and standard deviations but they did state that the interventions tested did not greatly reduce circumcision pain as assessed by heart rate, blood pressure, transcutaneous oxygen saturation, and time crying. </P>
<P>COMPLICATIONS/ADVERSE EFFECTS <U>
<BR/>
</U>
<BR/>Ten studies reported adverse effects (see Additional Tables - <LINK REF="TBL-08" TYPE="TABLE">Table 8</LINK>). Adverse effects including gagging, choking, and emesis were reported in untreated groups, while DPNB groups exhibited minor bleeding, swelling and hematoma at the block injection site post-circumcision. EMLA use was associated with erythema and minor skin pallor. In one study (<LINK REF="STD-Holliday-1999" TYPE="STUDY">Holliday 1999</LINK>), two subjects who received EMLA had redness and blistering of the foreskin, leading to closure of the EMLA arm of the study. Methaemoglobin levels were measured in two trials of EMLA and found to be within normal limits (<LINK REF="STD-Lander-1997" TYPE="STUDY">Lander 1997</LINK>; <LINK REF="STD-Taddio-1997" TYPE="STUDY">Taddio 1997</LINK>). All adverse effects of pain interventions were reported to be transient in nature and were not considered serious. Several authors reported on the questionable clinical utility of topical anaesthetic interventions (<LINK REF="STD-Herschel-1998" TYPE="STUDY">Herschel 1998</LINK>; <LINK REF="STD-Howard-1999" TYPE="STUDY">Howard 1999</LINK>; <LINK REF="STD-Lander-1997" TYPE="STUDY">Lander 1997</LINK>) given the dexterity required to apply the creams properly and the lengthy application time. </P>
<P>SUBGROUP AND SENSITIVITY ANALYSES</P>
<P>We examined two subgroups: length of wait time after penile block interventions (a priori) and choice of clamp for all procedures (post-hoc) on the most frequently reported outcome heart rate. One study compared different lengths of wait time and two anaesthetics (<LINK REF="STD-Spencer-1992" TYPE="STUDY">Spencer 1992</LINK>) but did not report means and SDs. The authors did report that DPNB groups that received either anaesthetic exhibited decreased pain responses compared to the control group. We made indirect (or between study) comparisons. Six trials comparing DPNB to no treatment prescribed and reported wait times. The trials with the longer wait time (&gt;5 minutes) did not perform significantly better than short wait time trials (&lt;/=5 minutes) [Metagraph 01.04]. In fact, the probability under the null hypothesis was close to significant (P=0.09 vs P=0.65) when <LINK REF="STD-Maxwell-1987" TYPE="STUDY">Maxwell 1987</LINK> was removed and favoured shorter wait times. A similar and statistically significant result was calculated when comparing wait times in DPNB vs EMLA (P=0.04; Metagraph 07.04). Using an indirect comparison, the Mogen clamp trial performed significantly better on reducing heart rate compared to the Gomco clamp trials when <LINK REF="STD-Maxwell-1987" TYPE="STUDY">Maxwell 1987</LINK> was again removed (P=0.05 vs P=0.07) under the DPNB versus no treatment comparison (Metagraph 01.05). Sucrose dose (a priori) was not analysed because there were too few studies under the same comparison and not enough information was provided.<BR/>
<U>
<BR/>
</U>Post-hoc, we considered two other potential treatment effect size modifiers: control intervention and choice of pacifiers. For ethical considerations, use of saline DPNB in pain research was generally abandoned since the early 1990's. Among the included studies for this review, three used both saline DPNB treatment (sham) and no treatment control arms (<LINK REF="STD-Arnett-1990" TYPE="STUDY">Arnett 1990</LINK>, <LINK REF="STD-Holve-1983" TYPE="STUDY">Holve 1983</LINK>, <LINK REF="STD-Stang-1988-A" TYPE="STUDY">Stang 1988 A</LINK>). In one study saline DPNB was used to blind comparison of lidocaine DPNB with another active intervention (<LINK REF="STD-Howard-1999" TYPE="STUDY">Howard 1999</LINK>). The researchers wanted to control for the effects of the injection and fluid volume compression on penile sensation. None of the studies found statistical differences between these control arms. In our review, the two control arms were displayed separately in the metagraphs when the data were reported separately in the referenced study (<LINK REF="STD-Stang-1988-A" TYPE="STUDY">Stang 1988 A</LINK>). Visually, we also see no difference. Other concerns for blinding involve placebo creams. One study (<LINK REF="STD-Mohan-1998" TYPE="STUDY">Mohan 1998</LINK>) did not use a placebo cream and one study (<LINK REF="STD-Benini-1993" TYPE="STUDY">Benini 1993</LINK>) reported using petroleum jelly as a placebo for EMLA cream. </P>
<P>In nine trials pacifiers were made available to all patients (<LINK REF="STD-Butler-O_x0027_Hara-1998" TYPE="STUDY">Butler O'Hara 1998</LINK>; <LINK REF="STD-Holliday-1999" TYPE="STUDY">Holliday 1999</LINK>; <LINK REF="STD-Howard-1994" TYPE="STUDY">Howard 1994</LINK>; <LINK REF="STD-Howard-1999" TYPE="STUDY">Howard 1999</LINK>; <LINK REF="STD-Kurtis-1999-A" TYPE="STUDY">Kurtis 1999 A</LINK>; <LINK REF="STD-Mohan-1998" TYPE="STUDY">Mohan 1998</LINK>; <LINK REF="STD-Spencer-1992" TYPE="STUDY">Spencer 1992</LINK>; <LINK REF="STD-Stang-1988-A" TYPE="STUDY">Stang 1988 A</LINK>; <LINK REF="STD-Stang-1997" TYPE="STUDY">Stang 1997</LINK>). In one (<LINK REF="STD-Butler-O_x0027_Hara-1998" TYPE="STUDY">Butler O'Hara 1998</LINK>) all infants were provided with sugar pacifiers although sucrose was not the intervention under study and its use may have affected results obtained on outcome measures. In another (<LINK REF="STD-Herschel-1998" TYPE="STUDY">Herschel 1998</LINK>) only one out of the three study groups received a pacifier because it was used to deliver a sucrose intervention. At least two studies (<LINK REF="STD-Kass-2001" TYPE="STUDY">Kass 2001</LINK>; <LINK REF="STD-Zolnoski-1993" TYPE="STUDY">Zolnoski 1993</LINK>) strictly prohibited the use of pacifiers and used oral syringes to deliver the sucrose intervention. The remaining studies did not report pacifier use. There were too few studies to compare within outcomes, and we could not identify obvious deviations with use or non-use of pacifiers. Of mention, <LINK REF="STD-Blass-1991-A" TYPE="STUDY">Blass 1991 A</LINK> and <LINK REF="STD-Zahorodny-1999" TYPE="STUDY">Zahorodny 1999</LINK> both found that in a water via pacifier group, cry time was significantly reduced compared with the no treatment control group (P&lt;0.001; P&lt;0.001). <U>
<BR/>
</U>
</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>This systematic review incorporates data from 35 trials enrolling 1997 neonates to examine a variety of interventions for circumcision pain relief. Although the results are generally applicable to current practice, the review identified a number of important limitations of the primary studies included in the review and thus the results should be interpreted with some caution. Sample size in the majority of the trials was small (total sample size was &lt; or = to 80 in 32 out of 35 trials), and there were some differences in the characteristics of the study subjects. <LINK REF="STD-Butler-O_x0027_Hara-1998" TYPE="STUDY">Butler O'Hara 1998</LINK> enrolled neonates from an NICU that were between 3 and 105 days postnatal age at the time of circumcision (although still less than 28 days after reaching 40 weeks corrected gestational age). <LINK REF="STD-Holliday-1999" TYPE="STUDY">Holliday 1999</LINK> enrolled low birthweight neonates aged 25 - 27 days at circumcision. Each of these groups of subjects could have experienced numerous painful or invasive treatments during their stay in NICU prior to circumcision. Accordingly, their responses during circumcision, regardless of the intervention, could have been different from those of the healthy newborns that were recruited for the remainder of the trials.</P>
<P>All of the studies included in this review were described as randomised, but 15 of the trial reports did not include sufficient information or describe adequate procedures for assurance of blinding of randomisation. Nine of the trials were double-blind for all interventions, but some interventions such as block technique could not be blinded. In six trials of DPNB, a standardized approach to the circumcision procedure was not described in the reports, making it impossible to tell whether every infant underwent exactly the same surgical process. The impact of this could be intensified within individual trials where more than one operator performed the circumcisions (e.g. <LINK REF="STD-Howard-1999" TYPE="STUDY">Howard 1999</LINK>, <LINK REF="STD-Macke-2001" TYPE="STUDY">Macke 2001</LINK>). Other differences that may have affected outcome results between trials of the same comparison include the variability in wait time after block administration, length of fasting prior to circumcision, provision of pacifiers or other non-study interventions, and use of different surgical clamps. Finally, differences between trials in the structure of pain interventions were evident, especially in trials of oral sucrose where the dose and method of delivery varied substantially. </P>
<P>The studies included in this review reported on measurement of a variety of pain outcomes (physiological, behavioral, biochemical). Techniques and methods for measurement of outcomes were more dissimilar than similar across the trials, even within a single outcome variable (e.g. heart rate), and this presented significant challenges to combining outcome results. In particular, the dissimilarity in outcome measures severely limited the feasibility of combining pain scores across the included studies. None of the reports included in this review offered a definition of pain, and in general, the reports did not differentiate between the painful versus the distressing/stressful aspects of the circumcision procedure (e.g. removal of foreskin versus application of restraints). Reasons for selection of pain scores as outcome measures were not articulated in most cases, and among the included studies, a variety were used that differed in conceptual development and in measurement technique. Some pain scores were author-devised measures with no reported psychometric testing (<LINK REF="STD-Arnett-1990" TYPE="STUDY">Arnett 1990</LINK>; <LINK REF="STD-Holliday-1999" TYPE="STUDY">Holliday 1999</LINK>; <LINK REF="STD-Weatherstone-1993" TYPE="STUDY">Weatherstone 1993</LINK>), while others measured behavioral indicators that were not conceptually linked to the neonate's experience of pain (<LINK REF="STD-Dixon-1984" TYPE="STUDY">Dixon 1984</LINK>; <LINK REF="STD-Macke-2001" TYPE="STUDY">Macke 2001</LINK>; <LINK REF="STD-Newton-1999" TYPE="STUDY">Newton 1999</LINK>; <LINK REF="STD-Stang-1988-A" TYPE="STUDY">Stang 1988 A</LINK>). Others were subjective in their measurement technique (<LINK REF="STD-Howard-1999" TYPE="STUDY">Howard 1999</LINK>; <LINK REF="STD-Stang-1997" TYPE="STUDY">Stang 1997</LINK>). In six trials, researchers employed validated pain scales developed specifically to measure neonatal pain (<LINK REF="STD-Benini-1993" TYPE="STUDY">Benini 1993</LINK>; <LINK REF="STD-Butler-O_x0027_Hara-1998" TYPE="STUDY">Butler O'Hara 1998</LINK>; <LINK REF="STD-Howard-1994" TYPE="STUDY">Howard 1994</LINK>; <LINK REF="STD-Joyce-2001" TYPE="STUDY">Joyce 2001</LINK>; <LINK REF="STD-Kass-2001" TYPE="STUDY">Kass 2001</LINK>; <LINK REF="STD-Taddio-1997" TYPE="STUDY">Taddio 1997</LINK>). </P>
<P>Sixteen trials included in this review either did not report outcome data, or did not report data in a format that could be analysed in this review. One of the strengths of this review was that we were able to obtain additional information for three trials. Where means and standard deviations were not available, data were imputed or derived from graphs contained in the reports, and missing standard deviations were either calculated from other summary statistics or substituted with singular or mean standard deviations from similar trials allowing us to maximize the data included under each comparison. </P>
<P>DPNB was identified as the most effective intervention and demonstrated decreases in time crying and heart rate that were statistically and clinically significant (time crying 54% less, heart rate 30 beats per minute less) when compared with placebo or no treatment. EMLA also reduced pain responses when compared with placebo but the differences in time crying (15% less) and heart rate (15 beats per minutes less) were not as large as those observed with DPNB. Topical lidocaine demonstrated statistically significant decreases in time crying (60 seconds less), heart rate (9 beats per minute less) and serum B-endorphin levels (49 pg/ml less) compared to placebo. The issue of the statistical versus clinical significance of the outcome results was not discussed in any of the study reports, and no author identified a threshold for clinically significant (as opposed to statistically significant) intervention effects. It should be emphasized that none of the interventions examined in these trials completely eliminated pain responses to circumcision.</P>
<P>Ease of administration of the pain interventions will influence the applicability of the results of this review to current clinical practice. The relative ease of establishing the different penile blocks was not systematically evaluated, but it was suggested that the ring block technique is easier and safer because it eliminates the risk of injection of lidocaine into the dorsal vessels (<LINK REF="STD-Hardwick-Smith-1998" TYPE="STUDY">Hardwick Smith 1998</LINK>). A single study reported on use of local penile block (<LINK REF="STD-Masciello-1990" TYPE="STUDY">Masciello 1990</LINK>) which appears to be similar in technique to ring block. Few adverse effects were reported with use of any of the penile blocks. EMLA and lidocaine topical anaesthetics are effective for circumcision pain when compared with placebo or no treatment, but their use may be precluded because of difficulties in application and the time required for maximum anaesthetic effect. Adverse effects such as transient skin reactions were reported but not considered serious, and methaemoglobin levels, when measured, were within normal range. </P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Circumcision is a painful procedure and routine or elective newborn circumcision is not recommended by either the American Academy of Pediatrics or the Canadian Paediatric Society. However, if circumcision is performed, the results of this review show that DPNB, RB and the topical anaesthetics EMLA and lidocaine cream can be recommended over no treatment for attenuation of circumcision pain. DPNB demonstrated the most consistent results, has been the most comprehensively studied, and was the most effective in terms of clinically significant reductions in pain responses. RB is also effective to reduce circumcision pain compared with placebo. The RB technique may be easier and safer to use because it eliminates the risk of injection of lidocaine into the dorsal vessels. </P>
<P>EMLA and lidocaine topical anaesthetics are effective for circumcision pain when compared with placebo or no treatment, but their use may be precluded because of difficulties in application and the time required for maximum anaesthetic effect. Adverse effects with EMLA use such as transient skin reactions were reported but not considered serious, and methaemoglobin levels, when measured, were within normal range. Topical anaesthetics are a less effective alternative to no treatment when expertise with penile blocks is not readily available. </P>
<P>Results for oral sucrose, oral analgesics and environmental modification interventions were either inconsistent or did not produce significantly different outcome results. These therapies cannot be recommended as treatments for circumcision pain.</P>
<P>None of the studied interventions completely eliminated the pain response to circumcision.</P>
<P>Circumcisions performed using the Mogen clamp take less time than is required using Gomco clamps. Shorter procedure time may reduce the total amount of pain experienced during circumcision, and may be important in terms of practitioner time to do the surgery. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Future studies should compare two or more active interventions for pain relief - a placebo or no-treatment control group is no longer acceptable. The impact of different "wait times" on the effectiveness of penile blocks and the relative acceptability and ease of administration of DPNB versus RB for practitioners should be systematically investigated. Use of the Mogen clamp in combination DPNB and RB should be investigated further to identify an optimal target time for circumcision surgery and to maximize anaesthetic effect. Although sucrose cannot be recommended as an intervention for circumcision pain at this time, research to determine the optimal dose and delivery method and the effect of combining oral sucrose with other interventions and comfort measures (e.g. nonnutritive sucking) should be pursued. </P>
<P>Lidocaine block and topical anaesthetic interventions could be useful in other situations where neonates undergo acute procedural pain. The pain associated with chest tube insertion, lumbar puncture, insertion of percutaneous central lines and other procedures commonly performed on high risk neonates may be significantly reduced with use of an appropriately adapted lidocaine block technique or topical anaesthetics. Further research should be pursued to identify situations where this potential can be examined.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We are grateful to Dr. J. R Holman, Dr. C Johnston, and Dr. J. F. Keck for their willingness to provide us with additional data from their studies. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>Two of the reviewers, Brady-Fryer and Lander, were authors of a trial, Lander 1997, included in this review.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Brady-Fryer - protocol development; study selection; data extraction; contact authors; data preparation &amp; analysis; write report <BR/>Wiebe - data extraction; data preparation &amp; analysis; write report <BR/>Lander - protocol development and review; review draft and final report<BR/>Brankston - study selection; data extraction<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Arnett-1990" NAME="Arnett 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arnett RM, Jones JS, Horger EO</AU>
<TI>Effectiveness of 1% lidocaine dorsal penile nerve block in infant circumcision</TI>
<SO>Americal Journal of Obstetrics and Gynecology</SO>
<YR>1990</YR>
<VL>163</VL>
<PG>1074-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Benini-1993" NAME="Benini 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benini F, Johnston CC, Faucher D, Aranda J V</AU>
<TI>Topical anesthesia during circumcision in newborn infants</TI>
<SO>JAMA</SO>
<YR>1993</YR>
<VL>270</VL>
<PG>850-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blass-1991-A" NAME="Blass 1991 A" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blass EM, Hoffmeyer LB</AU>
<TI>Sucrose as an analgesic for newborn infants</TI>
<SO>Pediatrics</SO>
<YR>1991</YR>
<VL>87</VL>
<PG>215-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blass-1991-B" NAME="Blass 1991 B" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blass EM, Hoffmeyer LB</AU>
<TI>Sucrose as an analgesic for newborn infants</TI>
<SO>Pediatrics</SO>
<YR>1991</YR>
<VL>87</VL>
<PG>215-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Butler-O_x0027_Hara-1998" NAME="Butler O'Hara 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Butler-O'Hara M, LeMoine C, Guillet R</AU>
<TI>Analgesia for neonatal circumcision: A randomized controlled trial of EMLA cream versus dorsal penile nerve block</TI>
<SO>Pediatrics</SO>
<YR>1998</YR>
<VL>101</VL>
<PG>e5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dixon-1984" NAME="Dixon 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dixon S, Snyder J, Holve R, Bromberger P</AU>
<TI>Behavioral effects of circumcision with and without anesthesia</TI>
<SO>Journal of Developmental and Behavioral Pediatrics</SO>
<YR>1984</YR>
<VL>5</VL>
<PG>246-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hardwick-Smith-1998" NAME="Hardwick Smith 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hardwick-Smith S, Mastrobattista JM, Wallace PA, Ritchey ML</AU>
<TI>Ring block for neonatal circumcision</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>1998</YR>
<VL>91</VL>
<PG>930-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herschel-1998" NAME="Herschel 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herschel M, Khoshnood B, Ellman C, Maydew N, Mittendorf R</AU>
<TI>Randomized trial of a sucrose pacifier for pain control</TI>
<SO>Archives of Pediatrics &amp; Adolescent Medicine</SO>
<YR>1998</YR>
<VL>152</VL>
<PG>279-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holliday-1999" NAME="Holliday 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holliday MA, Pinckert TL, Kiernan SC, Kunos I, Angelus P, Keszler M</AU>
<TI>Dorsal penile nerve block vs topical placebo for circumcision in low-birth-weight neonates</TI>
<SO>Archives of Pediatrics &amp; Adolescent Medicine</SO>
<YR>1999</YR>
<VL>153</VL>
<PG>476-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holve-1983" NAME="Holve 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holve RL, Bromberger PJ, Groveman HD, Klauber MR, Dixon SD, Snyder JM</AU>
<TI>Regional anesthesia during newborn circumcision. Effect on infant in pain response</TI>
<SO>Clinical Pediatrics</SO>
<YR>1983</YR>
<VL>22</VL>
<PG>813-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Howard-1994" NAME="Howard 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Howard CR, Howard FM, Weitzman ML</AU>
<TI>Acetaminophen analgesia in neonatal circumcision: the effect on pain</TI>
<SO>Pediatrics</SO>
<YR>1994</YR>
<VL>93</VL>
<PG>641-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Howard-1999" NAME="Howard 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Howard CR, Howard FM, Fortune K, Generelli P, Zolnoun D, tenHoopen C et al</AU>
<TI>A randomized, controlled trial of a eutectic mixture of local anesthetic cream (lidocaine and prilocaine) versus penile block for pain relief during circumcision</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1999</YR>
<VL>181</VL>
<PG>1506-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Joyce-2001" NAME="Joyce 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Joyce BA, Keck JF, Gerkensmeyer J</AU>
<TI>Evaluation of pain management interventions for neonatal circumcision pain</TI>
<SO>Journal of Pediatric Health Care</SO>
<YR>2001</YR>
<VL>15</VL>
<PG>105-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kass-2001" NAME="Kass 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kass FC, Holman JR</AU>
<TI>Oral glucose solution for analgesia in infant circumcision</TI>
<SO>Journal of Family Practice</SO>
<YR>2001</YR>
<VL>50</VL>
<PG>785-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaufman-2002" NAME="Kaufman 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaufman GE, Cimo S, Miller LW, Blass EM</AU>
<TI>An evaluation of the effects of sucrose on neonatal pain with 2 commonly used circumcision methods</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2002</YR>
<VL>186</VL>
<PG>564-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kurtis-1999-A" NAME="Kurtis 1999 A" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kurtis PS, DeSilva HN, Bernstein BA, Malakh L, Schechter NL</AU>
<TI>A comparison of the Mogen and Gomco clamps in combination with dorsal penile nerve block in minimizing the pain of neonatal circumcision</TI>
<SO>Pediatrics</SO>
<YR>1999</YR>
<VL>103</VL>
<PG>e23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kurtis-1999-B" NAME="Kurtis 1999 B" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kurtis PS, DeSilva HN, Bernstein BA, Malakh L, Schechter NL</AU>
<TI>A comparison of the Mogen and Gomco clamps in combination with dorsal penile nerve block in minimizing the pain of neonatal circumcision</TI>
<SO>Pediatrics</SO>
<YR>1999</YR>
<VL>103</VL>
<PG>e23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lander-1997" NAME="Lander 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lander J, Brady-Fryer B, Metcalfe J, Nazarali S, Muttitt S</AU>
<TI>Comparison of ring block, dorsal penile nerve block, and topical anesthesia for neonatal circumcision: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>1997</YR>
<VL>278</VL>
<PG>2157-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Macke-2001" NAME="Macke 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Macke JK</AU>
<TI>Analgesia for circumcision: Effects on newborn behavior and mother/infant interaction</TI>
<SO>Journal of Obstetric, Gynecologic, and Neonatal Nursing</SO>
<YR>2001</YR>
<VL>30</VL>
<PG>507-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marchette-1989" NAME="Marchette 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marchette L, Main R, Redick E</AU>
<TI>Pain reduction during neonatal circumcision</TI>
<SO>Pediatric Nursing</SO>
<YR>1989</YR>
<VL>15</VL>
<PG>207-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marchette-1991" NAME="Marchette 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marchette L, Main R, Redick E, Bagg A, Leatherland J</AU>
<TI>Pain reduction interventions during neonatal circumcision</TI>
<SO>Nursing Research</SO>
<YR>1991</YR>
<VL>40</VL>
<PG>241-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Masciello-1990" NAME="Masciello 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Masciello A L</AU>
<TI>Anesthesia for neonatal circumcision: Local anesthesia is better than dorsal penile block</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>1990</YR>
<VL>75</VL>
<PG>834-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maxwell-1987" NAME="Maxwell 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maxwell LG, Yaster M, Wetzel RC, Niebyl JR</AU>
<TI>Penile nerve block for newborn circumcision</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>1987</YR>
<VL>70</VL>
<PG>415-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mohan-1998" NAME="Mohan 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mohan CG, Risucci DA, Casimir M, Gulrajani-LaCorte, M</AU>
<TI>Comparison of analgesics in ameliorating the pain of circumcision</TI>
<SO>Journal of Perinatology</SO>
<YR>1998</YR>
<VL>18</VL>
<PG>13-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mudge-1989" NAME="Mudge 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mudge D, Younger J B</AU>
<TI>The effects of topical lidocaine on infant response to circumcision</TI>
<SO>Journal of Nurse-Midwifery</SO>
<YR>1989</YR>
<VL>34</VL>
<PG>335-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Newton-1999" NAME="Newton 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Newton CW, Mulnix N, Baer L, Bovee T</AU>
<TI>Plain and buffered lidocaine for neonatal circumcision</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>1999</YR>
<VL>93</VL>
<PG>350-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spencer-1992" NAME="Spencer 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spencer DM, Miller K A, O'Quin M, Tomsovic J P, Anderson B, Wong D et al</AU>
<TI>Dorsal penile nerve block in neonatal circumcision: Chloroprocaine versus lidocaine</TI>
<SO>American Journal of Perinatology</SO>
<YR>1992</YR>
<VL>9</VL>
<PG>214-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stang-1988-A" NAME="Stang 1988 A" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stang H J, Gunnar M R, Snellman L, Condon L M, Kestenbaum R</AU>
<TI>Local anesthesia for neonatal circumcision - Effects on distress and cortisol response</TI>
<SO>JAMA</SO>
<YR>1988</YR>
<VL>259</VL>
<PG>1507-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stang-1988-B" NAME="Stang 1988 B" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stang HJ, Gunnar MR, Snellman L, Condon LM, Kestenbaum R</AU>
<TI>Local anesthesia for neonatal circumcision - Effects on distress and cortisol response</TI>
<SO>JAMA</SO>
<YR>1988</YR>
<VL>259</VL>
<PG>1507-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stang-1997" NAME="Stang 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stang HJ, Snellman LW, Condon LM, Conroy MM, Liebo R, Brodersen L et al</AU>
<TI>Beyond dorsal penile nerve block: A more humane circumcision</TI>
<SO>Pediatrics</SO>
<YR>1997</YR>
<VL>100</VL>
<PG>e3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taddio-1997" NAME="Taddio 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taddio A, Stevens B, Craig K, Rastogi P, Ben-David S, Shennan A et al</AU>
<TI>Efficacy and safety of lidocaine-prilocaine cream for pain during circumcision</TI>
<SO>New England Journal of Medicine</SO>
<YR>1997</YR>
<VL>336</VL>
<PG>1197-1201</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weatherstone-1993" NAME="Weatherstone 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weatherstone KB, Rasmussen LB, Erenberg A, Jackson EM, Claflin KS, Leff RD</AU>
<TI>Safety and efficacy of a topical anesthetic for neonatal circumcision</TI>
<SO>Pediatrics</SO>
<YR>1993</YR>
<VL>92</VL>
<PG>710-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Williamson-1983" NAME="Williamson 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Williamson PS, Williamson ML</AU>
<TI>Physiologic stress reduction by a local anesthetic during newborn circumcision</TI>
<SO>Pediatrics</SO>
<YR>1983</YR>
<VL>71</VL>
<PG>36-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Williamson-1986" NAME="Williamson 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Williamson PS, Evans ND</AU>
<TI>Neonatal cortisol response to circumcision with anesthesia</TI>
<SO>Clinical Pediatrics</SO>
<YR>1986</YR>
<VL>25</VL>
<PG>412-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Williamson-1997" NAME="Williamson 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Williamson ML</AU>
<TI>Circumcision anesthesia: A study of nursing implications for dorsal penile nerve block</TI>
<SO>Pediatric Nursing</SO>
<YR>1997</YR>
<VL>23</VL>
<PG>59-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Woodman-1999" NAME="Woodman 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Woodman PJ</AU>
<TI>Topical lidocaine-prilocaine versus lidocaine for neonatal circumcision: A randomized controlled trial</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>1999</YR>
<VL>93</VL>
<PG>775-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zahorodny-1998" NAME="Zahorodny 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Zahorodny W, Surez Y, Marshall R, Regan M, Holland B, Brendel D</AU>
<TI>Efficacy of EMLA and sucrose for crying associated with circumcision</TI>
<SO>Pediatrric Research</SO>
<YR>1998</YR>
<VL>43 Supplement 2</VL>
<PG>204A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zahorodny-1999" NAME="Zahorodny 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Zahorodny W, David ES, Estrada P, Co J, Marshall R</AU>
<TI>Efficacy of a sucrose pacifier for newborn pain</TI>
<SO>Pediatric Research</SO>
<YR>1999</YR>
<VL>45 PART 2 of 2</VL>
<PG>17A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Zolnoski-1993" NAME="Zolnoski 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="BOOK">
<AU>Zolnoski BAP</AU>
<SO>Effect of sucrose ingestion on pain during newborn circumcision [Masters thesis]</SO>
<YR>1993</YR>
<PB>Univ. of Florida</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="Digital Dissertations - AAT 1358079"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Malnory-2003" NAME="Malnory 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malnory M, Johnson TS, Kirby RS</AU>
<TI>Newborn behavioral and physiological responses to circumcision</TI>
<SO>MCN. The American Journal of Maternal Child Nursing</SO>
<YR>2003</YR>
<VL>28</VL>
<PG>313-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mintz-1989" NAME="Mintz 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mintz MR, Grillo R</AU>
<TI>Dorsal penile nerve block for circumcision</TI>
<SO>Clinical Pediatrics</SO>
<YR>1989</YR>
<VL>28</VL>
<PG>590-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olson-1998" NAME="Olson 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olson T, Wessman Downey V</AU>
<TI>Infant physiological responses to noxious stimuli of circumcision with anesthesia and analgesia</TI>
<SO>Pediatric Nursing</SO>
<YR>1998</YR>
<VL>24</VL>
<PG>385-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Russell-1996" NAME="Russell 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Russell CT, Chaseling J</AU>
<TI>Topical anesthesia in neonatal circumcision: a study of 208 consecutive cases</TI>
<SO>Australian Family Physician</SO>
<YR>1996</YR>
<VL>25</VL>
<PG>530-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taddio-2000" NAME="Taddio 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taddio A, Pollock N, Gilbert-MacLeod C, Ohlsson K, Koren G</AU>
<TI>Combined analgesia and local anesthesia to minimize pain during circumcision</TI>
<SO>Archives of Pediatrics &amp; Adolescent Medicine</SO>
<YR>2000</YR>
<VL>154</VL>
<PG>620-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taeusch-2002" NAME="Taeusch 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taeusch HW, Martinez AM, Partridge JC, Sniderman S, Armstrong-Wells J, Fuentes-Afflick E</AU>
<TI>Pain during Mogen or Plastibell circumcision</TI>
<SO>Journal of Perinatology</SO>
<YR>2002</YR>
<VL>22</VL>
<PG>214-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-AAP-1999" NAME="AAP 1999" TYPE="JOURNAL_ARTICLE">
<AU>American Academy of Pediatrics Task Force on Circumcision</AU>
<TI>Circumcision Policy Statement</TI>
<SO>Pediatrics</SO>
<YR>1999</YR>
<VL>103</VL>
<PG>686-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Abu_x002d_Saad-1998" NAME="Abu-Saad 1998" TYPE="JOURNAL_ARTICLE">
<AU>Abu-Saad H, Bours G, Stevens B, Hamers J</AU>
<TI>Assessment of pain in the neonate</TI>
<SO>Seminars in Perinatology</SO>
<YR>1998</YR>
<VL>22</VL>
<PG>402-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anand-2001" NAME="Anand 2001" TYPE="JOURNAL_ARTICLE">
<AU>Anand KJS</AU>
<TI>Consensus statement for the prevention and management of pain in the newborn</TI>
<SO>Archives of Pediatrics &amp; Adolescent Medicine</SO>
<YR>2001</YR>
<VL>155</VL>
<PG>173-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anders-1974" NAME="Anders 1974" TYPE="JOURNAL_ARTICLE">
<AU>Anders TF, Chalemian RJ</AU>
<TI>The effects of circumcision on sleep-wake states in human neonates</TI>
<SO>Psychosomatic Medicine</SO>
<YR>1974</YR>
<VL>36</VL>
<PG>174-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Auerbach-1978" NAME="Auerbach 1978" TYPE="JOURNAL_ARTICLE">
<AU>Auerbach MR, Scanlon JW</AU>
<TI>Recurrence of pneumothroax as a possible complication of circumcision</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1978</YR>
<VL>132</VL>
<PG>583</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bellieni-2002" NAME="Bellieni 2002" TYPE="JOURNAL_ARTICLE">
<AU>Bellieni CV et al</AU>
<TI>Effect of multisensory stimulation on analgesia in term neonates: A randomized controlled trial</TI>
<SO>Pediatric Research</SO>
<YR>2002</YR>
<VL>51</VL>
<PG>460-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berde-2002" NAME="Berde 2002" TYPE="JOURNAL_ARTICLE">
<AU>Berde CB, Sethna NF</AU>
<TI>Analgesics for the treatment of pain in children</TI>
<SO>New England Journal of Mecicine</SO>
<YR>2002</YR>
<VL>347</VL>
<PG>1094-1103</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brazelton-1973" NAME="Brazelton 1973" TYPE="BOOK_SECTION">
<AU>Brazelton TB</AU>
<TI>Neonatal behavioral assessment scale</TI>
<SO>Clinics in Developmental Medicine</SO>
<YR>1973</YR>
<VL>50</VL>
<PG>1-66</PG>
<PB>JB Lippincott</PB>
<CY>Philadelphia, PA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brazelton-1984" NAME="Brazelton 1984" TYPE="BOOK">
<AU>Brazelton TB</AU>
<SO>Neonatal behavioral assessment scale</SO>
<YR>1984</YR>
<PB>J B Lippincott</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Campos-1994" NAME="Campos 1994" TYPE="JOURNAL_ARTICLE">
<AU>Campos RG</AU>
<TI>Rocking and pacifiers: two comforting interventions for heelstick pain</TI>
<SO>Research in Nursing &amp; Health</SO>
<YR>1994</YR>
<VL>17</VL>
<PG>321-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carbajal-1999" NAME="Carbajal 1999" TYPE="JOURNAL_ARTICLE">
<AU>Carbajal R, Chauvet X, Couderc S, Olivier-Martin M</AU>
<TI>Randomized trial of analgesic effects of sucrose, glucose, and pacifiers in term infants</TI>
<SO>BMJ</SO>
<YR>1999</YR>
<VL>319</VL>
<PG>1393-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Connelly-1992" NAME="Connelly 1992" TYPE="JOURNAL_ARTICLE">
<AU>Connelly KP, Shropshire LC, Salzberg A</AU>
<TI>Gastric rupture associated with prolonged crying in a newborn undergoing circumcision</TI>
<SO>Clinical Pediatrics</SO>
<YR>1992</YR>
<VL>31</VL>
<PG>560-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Corff-1995" NAME="Corff 1995" TYPE="JOURNAL_ARTICLE">
<AU>Corff KE, Seideman R, Venkataraman PS, Lutes L, Yates B</AU>
<TI>Facilitated tucking: a nonpharmacologic comfort measure for pain in preterm neonates</TI>
<SO>Journal of Obstetric, Gynecologic, and Neonatal Nursing</SO>
<YR>1995</YR>
<VL>24</VL>
<PG>143-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CPS-1996" NAME="CPS 1996" TYPE="JOURNAL_ARTICLE">
<AU>Canadian Pediatric Society Fetus and Newborn Committee</AU>
<TI>Neonatal circumcision revisited</TI>
<SO>CMAJ</SO>
<YR>1996</YR>
<VL>154</VL>
<PG>769-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dalens-1989" NAME="Dalens 1989" TYPE="JOURNAL_ARTICLE">
<AU>Dalens B, Vanneuvile G, Dechelotte P</AU>
<TI>Penile block via the subpubic space in 100 children</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>1989</YR>
<VL>69</VL>
<PG>41-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2001" NAME="Deeks 2001" TYPE="BOOK_SECTION">
<AU>Deeks JJ, Altman DG, and Bradburn MJ</AU>
<TI>Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis</TI>
<SO>Egger M, Davey Smith G, and Altman DG. Systematic reviews in health care</SO>
<YR>2001</YR>
<PG>300</PG>
<EN>2nd</EN>
<PB>BMJ Books</PB>
<CY>London, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fitzgerald-1993" NAME="Fitzgerald 1993" TYPE="BOOK_SECTION">
<AU>Fitzgerald M, Anand KJS</AU>
<TI>Developmental neuroanatomy and neurophysiology of pain</TI>
<SO>Pain in infants, children and adolescents</SO>
<YR>1993</YR>
<PG>11-31</PG>
<ED>Schecter N L, Berde C B, Yaster M</ED>
<PB>Williams &amp; Wilkins</PB>
<CY>Baltimore</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Follmann-1992" NAME="Follmann 1992" TYPE="JOURNAL_ARTICLE">
<AU>Follmann D, Elliot P, Suh I, Cutler J</AU>
<TI>Variance imputation for overviews of clinical trials with continuous response</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1992</YR>
<VL>45</VL>
<PG>769-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Frank-1997" NAME="Frank 1997" TYPE="JOURNAL_ARTICLE">
<AU>Frank LS, Miaskowski C</AU>
<TI>Measurement of neonatal responses to painful stimuli: A research review</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>1997</YR>
<VL>14</VL>
<PG>343-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gibbons-2001" NAME="Gibbons 2001" TYPE="JOURNAL_ARTICLE">
<AU>Gibbons S, Stevens B</AU>
<TI>Mechanisms of sucrose and non-nutritive sucking in procedural pain management in infants</TI>
<SO>Pain Research &amp; Management</SO>
<YR>2001</YR>
<VL>6</VL>
<PG>21-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gibbons-2002" NAME="Gibbons 2002" TYPE="JOURNAL_ARTICLE">
<AU>Gibbonns S, Stevens B, Hodnett E, Pinelli J, Ohlsson A, Darlington G</AU>
<TI>Efficiacy and safety of sucrose for procedural pain relief in preterm and term neonates</TI>
<SO>Nursing Research</SO>
<YR>2002</YR>
<VL>51</VL>
<PG>375-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gray-2000" NAME="Gray 2000" TYPE="JOURNAL_ARTICLE">
<AU>Gray L, Watt L, Blass EM</AU>
<TI>Skin-to-skin contact is analgesic in healthy newborns</TI>
<SO>Pediatrics</SO>
<YR>2000</YR>
<VL>105</VL>
<PG>e14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grunau-1987" NAME="Grunau 1987" TYPE="JOURNAL_ARTICLE">
<AU>Grunau RVE, Craig KD</AU>
<TI>Pain expression in neonates: facial action and cry</TI>
<SO>Pain</SO>
<YR>1987</YR>
<VL>28</VL>
<PG>395-410</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gunnar-1981" NAME="Gunnar 1981" TYPE="JOURNAL_ARTICLE">
<AU>Gunnar MR, Fisch RO, Korsvik S, Donhowe JM</AU>
<TI>The effects of circumcision on serum cortisol and behavior</TI>
<SO>Psychoneuroendocrinology</SO>
<YR>1981</YR>
<VL>6</VL>
<PG>269-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haouari-1999" NAME="Haouari 1999" TYPE="JOURNAL_ARTICLE">
<AU>Haouri N, Wood C, Griffiths G, Levene M</AU>
<TI>The analgesic effect of sucrose in full term infants: a randomized controlled trial</TI>
<SO>BMJ</SO>
<YR>1999</YR>
<VL>310</VL>
<PG>1498-1500</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Howard--1998" NAME="Howard  1998" TYPE="JOURNAL_ARTICLE">
<AU>Howard CR, Howard FM, Garfunkel LC, de Blieck EA, Weitzman M</AU>
<TI>Neonatal circumcision and pain relief: Current training practices</TI>
<SO>Pediatrics</SO>
<YR>1998</YR>
<VL>101</VL>
<PG>423-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johnston-1997" NAME="Johnston 1997" TYPE="JOURNAL_ARTICLE">
<AU>Johnston C, Stremler R, Stevens B, Horton L</AU>
<TI>Effectiveness of oral sucrose and simulated rocking on pain response in preterm neonates</TI>
<SO>Pain</SO>
<YR>1997</YR>
<VL>72</VL>
<PG>193-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kharasch-2003" NAME="Kharasch 2003" TYPE="JOURNAL_ARTICLE">
<AU>Kharasch S, Saxe G, Zuckerman B</AU>
<TI>Pain treatment: opportunities and challenges</TI>
<SO>Archives of Pediatrics &amp; Adolescent Medicine</SO>
<YR>2003</YR>
<VL>157</VL>
<PG>1054-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kirya-1978" NAME="Kirya 1978" TYPE="JOURNAL_ARTICLE">
<AU>Kirya C, Werthmann MW</AU>
<TI>Neonatal circumcision and penile dorsal nerve block - a painless procedure</TI>
<SO>Journal of Pediatrics</SO>
<YR>1978</YR>
<VL>92</VL>
<PG>998-1000</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lawrence-1993" NAME="Lawrence 1993" TYPE="JOURNAL_ARTICLE">
<AU>Lawrence J, Alcock D, McGrath P, Kay J, MacMurray SB, Dulberg C</AU>
<TI>The development of a tool to assess neonatal pain</TI>
<SO>Neonatal Network</SO>
<YR>1993</YR>
<VL>12</VL>
<PG>59-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maxwell-1999" NAME="Maxwell 1999" TYPE="JOURNAL_ARTICLE">
<AU>Maxwell LG, Yaster M</AU>
<TI>Analgesia for neonatal circumcision: No more studies, just do it</TI>
<SO>Archives of Pediatrics &amp; Adolescent Medicine</SO>
<YR>1999</YR>
<VL>153</VL>
<PG>444-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McGrath-1990" NAME="McGrath 1990" TYPE="BOOK">
<AU>McGrath PA</AU>
<SO>Pain in children</SO>
<YR>1990</YR>
<PB>The Guilford Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mitchell-2000" NAME="Mitchell 2000" TYPE="JOURNAL_ARTICLE">
<AU>Mitchell A, Brooks S, Roane D</AU>
<TI>The premature infant and painful procedures</TI>
<SO>Pain Management Nursing</SO>
<YR>2000</YR>
<VL>1</VL>
<PG>58-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mitchell-2003" NAME="Mitchell 2003" TYPE="JOURNAL_ARTICLE">
<AU>Mitchell A, Waltman P A</AU>
<TI>Oral sucrose and pain relief for preterm infants</TI>
<SO>Pain Management Nursing</SO>
<YR>2003</YR>
<VL>4</VL>
<PG>62-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Myron-1991" NAME="Myron 1991" TYPE="JOURNAL_ARTICLE">
<AU>Myron AV, Maguire DP</AU>
<TI>Pain perception in the neonate: Implications for circumcision</TI>
<SO>Journal of Professional Nursing</SO>
<YR>1991</YR>
<VL>7</VL>
<PG>188-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Poma-1980" NAME="Poma 1980" TYPE="JOURNAL_ARTICLE">
<AU>Poma PA</AU>
<TI>Painless neonatal circumcision</TI>
<SO>International Journal of Gynaecology and Obstetrics</SO>
<YR>1980</YR>
<VL>18</VL>
<PG>308-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rawlings-1980" NAME="Rawlings 1980" TYPE="JOURNAL_ARTICLE">
<AU>Rawlings DJ, Miller A, Engel RR</AU>
<TI>The effect of circumcision on transcutaneous pO2 in term infants</TI>
<SO>American journal of diseases of children</SO>
<YR>1980</YR>
<VL>134</VL>
<PG>676-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ross-1988" NAME="Ross 1988" TYPE="BOOK">
<AU>Ross DM, Ross SA</AU>
<SO>Childhood pain</SO>
<YR>1988</YR>
<PB>Urban &amp; Schwarzenberg</PB>
<CY>Baltimore</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ryan-1994" NAME="Ryan 1994" TYPE="JOURNAL_ARTICLE">
<AU>Ryan CA, Finer NN</AU>
<TI>Changing attitudes and practices regarding local anesthesia for newborn circumcision</TI>
<SO>Pediatrics</SO>
<YR>1994</YR>
<VL>94</VL>
<PG>230-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Snellman-1995" NAME="Snellman 1995" TYPE="JOURNAL_ARTICLE">
<AU>Snellman LW, Stang HJ</AU>
<TI>Prospective evaluation of complications of dorsal penile block for neonatal circumcision</TI>
<SO>Pediatrics</SO>
<YR>1995</YR>
<VL>95</VL>
<PG>705-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stang-1991" NAME="Stang 1991" TYPE="JOURNAL_ARTICLE">
<AU>Stang HJ</AU>
<TI>Response to : Pain perception in the neonate: Implications for circumcision</TI>
<SO>Journal of Professional Nursing</SO>
<YR>2001</YR>
<VL>7</VL>
<PG>194-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stang-1998" NAME="Stang 1998" TYPE="JOURNAL_ARTICLE">
<AU>Stang HJ, Snellman LW</AU>
<TI>Circumcision practice patterns in the United States</TI>
<SO>Pediatrics</SO>
<YR>1998</YR>
<VL>101</VL>
<PG>e5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stevens-1996" NAME="Stevens 1996" TYPE="JOURNAL_ARTICLE">
<AU>Stevens B, Johnston CC, Petryshun P, Taddio A</AU>
<TI>Premature infant pain profile: Development and initial validation</TI>
<SO>Clinical Journal of Pain</SO>
<YR>1996</YR>
<VL>12</VL>
<PG>13-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stevens-1997" NAME="Stevens 1997" TYPE="JOURNAL_ARTICLE">
<AU>Stevens B, Taddio A, Ohlsson A, Einarson T</AU>
<TI>The efficacy of sucrose for relieving procedural pain in neonates - a systematic review and meta-analysis</TI>
<SO>Acta Paediatrica</SO>
<YR>1997</YR>
<VL>86</VL>
<PG>837-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stevens-1999" NAME="Stevens 1999" TYPE="BOOK_SECTION">
<AU>Stevens B</AU>
<TI>Pain in infants</TI>
<SO>Pain Clinical Manual</SO>
<YR>1999</YR>
<PG>626-673</PG>
<EN>2nd</EN>
<ED>McCaffery M, Pasero C</ED>
<PB>Mosby</PB>
<CY>St. Louis</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sweet-1998" NAME="Sweet 1998" TYPE="BOOK_SECTION">
<AU>Sweet SD, McGrath PJ</AU>
<TI>Physiological measures of pain</TI>
<SO>Measurement of pain in infants and children</SO>
<YR>1998</YR>
<PG>59 - 81</PG>
<ED>Finley G A, McGrath P J</ED>
<PB>IASP Press</PB>
<CY>Seattle</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Taddio-1997b" NAME="Taddio 1997b" TYPE="JOURNAL_ARTICLE">
<AU>Taddio A, Katz J, Ilersich A L, Koren G</AU>
<TI>Effect of neonatal circumcision on pain response during subsequent routine vaccination</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>349</VL>
<PG>599-603</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Taddio-1998" NAME="Taddio 1998" TYPE="JOURNAL_ARTICLE">
<AU>Taddio A, Ohlsson A, Einarson TR, Stevens B, Koren G</AU>
<TI>A systematic review of lidocaine-prilocaine cream (EMLA) in the treatment of acute pain in neonates</TI>
<SO>Pediatrics</SO>
<YR>1998</YR>
<VL>101</VL>
<PG>e1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Taddio-2001" NAME="Taddio 2001" TYPE="JOURNAL_ARTICLE">
<AU>Taddio A</AU>
<TI>Pain management for neonatal circumcision</TI>
<SO>Paediatric Drugs</SO>
<YR>2001</YR>
<VL>3</VL>
<PG>101-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Taddio-2002" NAME="Taddio 2002" TYPE="COCHRANE_REVIEW">
<AU>Taddio A, Ohlsson K, Ohlsson A</AU>
<TI>Lidocaine-prilocaine cream for analgesia during circumcision in newborn boys (Cochrane Review)</TI>
<SO>The Cochrane Library</SO>
<YR>2002</YR>
<NO>4</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Talbert-1976" NAME="Talbert 1976" TYPE="JOURNAL_ARTICLE">
<AU>Talbert LM, Kraybill EN, Potter HD</AU>
<TI>Adrenal cortical response to circumcision in the neonate</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>1976</YR>
<VL>48</VL>
<PG>208-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wellington-1993" NAME="Wellington 1993" TYPE="JOURNAL_ARTICLE">
<AU>Wellington N, Rieder MJ</AU>
<TI>Attitudes and practices regarding analgesia for neonatal circumcision</TI>
<SO>Pediatrics</SO>
<YR>1993</YR>
<VL>92</VL>
<PG>541-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yarrow-1975" NAME="Yarrow 1975" TYPE="BOOK">
<AU>Yarrow L, Rubenstein JL, Pedersen FA</AU>
<SO>Infant and environment</SO>
<YR>1975</YR>
<PB>John Wiley and Sons</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES>
<REFERENCE ID="REF-Brady_x002d_Fryer-2004" NAME="Brady-Fryer 2004" TYPE="COCHRANE_REVIEW">
<AU>Brady-Fryer B, Wiebe N, Lander JA</AU>
<TI>Pain relief for neonatal circumcision</TI>
<SO>The Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>4</NO>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Arnett-1990">
<CHAR_METHODS>
<P>RCT<BR/>Blinding of randomization - yes<BR/>Blinding of intervention - yes<BR/>Complete follow-up - no<BR/>Blinding of outcome measurement - can't tell<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>52 male NB; FT; BW &gt; 2000 g; 5 min Apgar scores &gt;/= 6</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>0.4 ml lidocaine DPNB (n=23) <BR/>0.4 ml saline DPNB (n=22)<BR/>no treatment control (n=7)<BR/>WT not reported; mean length for entire procedure was 4.4 minutes</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HR, infant irritability, O2sat </P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- no treatment control group added after study start; results for saline DPNB group and no treatment group were combined for analysis (n=29)<BR/>- data missing for 3 subjects (1 in each group) and cases deleted from analysis<BR/>- procedure not standardized<BR/>- lower dose lidocaine used (0.4 ml total)<BR/>- subjects fasted 90 minutes prior to circumcision<BR/>- Gomco clamp<BR/>- adverse effects reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Benini-1993">
<CHAR_METHODS>
<P>RCT<BR/>Blinding of randomization - can't tell<BR/>Blinding of intervention - no <BR/>Complete follow-up - no<BR/>Blinding of outcome measurement - yes<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>28 male NB; FT; BW &gt; 2500g; 5 min Apgar &gt; 7; &lt; 7 d age</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>0.5 ml (0.5g) LP cream (n=14)<BR/>0.5 ml (0.5 g) petroleum jelly (n=14) <BR/>applied and covered with occlusive dressing 45 - 60 min prior</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HR, O2sat, % time crying, facial action<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- 1 withdrawal from placebo group because infant not FT<BR/>- procedure standardized to 9 phases <BR/>- Gomco clamp<BR/>- no adverse effects reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Blass-1991-A">
<CHAR_METHODS>
<P>RCT<BR/>Blinding of randomization - can't tell<BR/>Blinding of intervention - partial<BR/>Complete follow-up - can't tell<BR/>Blinding of outcome measurement - yes<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>30 male NB, FT; 28 - 54 h age; Apgars &gt; 8</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1.5 ml 24% sucrose by nipple <BR/>1.5 ml water by nipple <BR/>no treatment control<BR/>*comparison is sucrose versus water (placebo)<BR/>number subjects per group not specified<BR/>3 min WT after intervention<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>% time crying <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- assumed distribution was equal (10/group) for data analysis<BR/>- procedure not standardized<BR/>- infants fasted for at least 1 hr prior<BR/>- Gomco clamp</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Blass-1991-B">
<CHAR_METHODS>
<P>see Blass A</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>see Blass A</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>* comparison is sucrose versus no treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Butler-O_x0027_Hara-1998">
<CHAR_METHODS>
<P>RCT<BR/>Blinding of randomization - yes<BR/>Blinding of intervention - no<BR/>Complete follow-up - no<BR/>Blinding of outcome measurement - yes<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>50 male infants in NICU; &gt;/= 34.5 weeks (post-menstrual) at time of circumcision and stable for discharge<BR/>participants were 3 -105 days age at time of circumcision</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>0.5 ml (0.5g) LP cream (n=25)<BR/>0.7 - 1.0 ml lidocaine DPNB + placebo cream (n=25) <BR/>creams applied 60 min prior and covered with occlusive dressing<BR/>3 min WT after DPNB</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HR; RR; NIPS score (primary outcome)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- non-randomized, no treatment group (n=20) also had data collected<BR/>- outcome data for 6 subjects (4 LP cream, 2 DPNB) lost due to technical difficulties <BR/>- infants fasted for 2 to 3 hours before circumcision<BR/>- all subjects had sugar pacifiers during procedure<BR/>- procedure standardized <BR/>- Plastibell clamp</P>
<P>- adverse effects reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Dixon-1984">
<CHAR_METHODS>
<P>RCT<BR/>Blinding of randomization - yes<BR/>Blinding of intervention - can't tell<BR/>Complete follow-up - yes<BR/>Blinding of outcome measurement - partial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>31 male NB, FT, AGA, &lt; 7 days age, &gt; 2500 gm, 5 min Apgar &gt; 7</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>0.8 ml lidocaine DPNB (n=15)<BR/>0.8 ml saline DPNB (n=8)<BR/>no treatment control (n=8)<BR/>4 - 5 min WT</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Brazelton Neonatal Assessment Scale</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- Holve 1983 is primary study report<BR/>- circumcision procedure not standardized<BR/>- all circumcisions performed by single physician<BR/>- Gomco clamp<BR/>- adverse effects reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hardwick-Smith-1998">
<CHAR_METHODS>
<P>RCT<BR/>Blinding of randomization - yes<BR/>Blinding of intervention - no<BR/>Complete follow-up - can't tell<BR/>Blinding of outcome measurement - no <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>40 male NB; FT; Apgar &gt;/= 7; 6 hr - 5 days age; fasting 30 -120 min prior; normal exam</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1.0 ml 5% lidocaine RB (n=20)<BR/>no treatment control (n=20)<BR/>3 min WT</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HR; RR; O2sat; behavioral state; cry time </P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- O2sat not recorded in up to 50% of infants<BR/>- single operator performed all circumcisions<BR/>- Gomco clamp<BR/>- no adverse effects reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Herschel-1998">
<CHAR_METHODS>
<P>RCT <BR/>Blinding of randomization - yes<BR/>Blinding of intervention - no<BR/>Complete follow-up - no<BR/>Blinding of outcome measurement - yes<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>120 male NB; FT; &gt; 2500g; Apgar &gt;/= 8 at 5 min; &gt;/= 12 hr age</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>0.8 ml 1% lidocaine DPNB (n=40)<BR/>10 ml 50% oral sucrose via nipple (n=40)<BR/>no treatment control (n=40)<BR/> 3 min WT for DPNB; 2 min WT for sucrose group</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HR; O2sat (%)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- 1 withdrawal from sucrose group, circumcision contraindicated<BR/>- O2 sat data missing - 31% intervals control, 10% intervals DPNB, 8% sucrose<BR/>- infants fasted 30 min prior to circumcision<BR/>- sucrose group had nipple throughout procedure, other groups did not have pacifier<BR/>- Gomco clamp</P>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Holliday-1999">
<CHAR_METHODS>
<P>RCT <BR/>Blinding of randomization - yes<BR/>Blinding of intervention - no<BR/>Complete follow-up - no<BR/>Blinding of outcome measurement - can't tell <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>50 male preterm/low birthweight NICU patients,<BR/>subjects weighed 1600 to 2500g at time of circumcision <BR/>25-27 days age, 36 week GA at circumcision</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>0.8 ml 1% lidocaine DPNB + placebo cream (n= 19)<BR/>LP cream (n=12) (group enrollment stopped, excluded from data analyses)<BR/>placebo cream (n=19)<BR/>DPNB 5 min WT<BR/>cream applied 1 hr prior and covered with occlusive dressing</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HR, RR, O2sat, systolic BP, behavioral score, serum B-endorphin <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- LP cream group discontinued due to redness and blistering of foreskin in 2 infants<BR/>- procedure not standardized<BR/>- all circumcisions performed by single operator<BR/>- pacifiers provided<BR/>- Gomco clamp<BR/>- no adverse effects reported for DPNB group<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Holve-1983">
<CHAR_METHODS>
<P>RCT<BR/>Blinding of randomization - yes<BR/>Blinding of intervention - partial<BR/>Complete follow-up - yes<BR/>Blinding of outcome measurement - can't tell</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>31 male NB; FT, &lt; 7 days age, &gt; 2500 gm, 5 min Apgar &gt; 7</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>0.8 ml 1% lidocaine DPNB (n=15)<BR/>0.8 ml saline DPNB (n=8)<BR/>no treatment control (n=8)<BR/>4-5 min WT</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HR; % time crying per interval; clinical observation of anesthesia effectiveness (good, fair, poor)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- procedure standardized <BR/>- Gomco clamp<BR/>- adverse effects reported<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Howard-1994">
<CHAR_METHODS>
<P>RCT<BR/>Blinding of randomization - yes<BR/>Blinding of intervention - yes<BR/>Complete follow-up - yes<BR/>Blinding of outcome measurement - yes<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>44 male NB, healthy, AGA, FT, Apgars &gt; 7, &gt;/= 24 h age</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>acetaminophen 15 mg/kg/dose (n= 23)<BR/>placebo (n= 21)<BR/>given 2 hr prior and q 6H X 24 hr following</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HR; RR; cry time; post-operative comfort score; feeding behavior pre/post <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- infants fasted 2 - 3 h prior to circumcision<BR/>- all had pacifiers <BR/>- procedure standardized <BR/>- single operator performed all circumcisions <BR/>- Gomco clamp<BR/>- no adverse effects reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Howard-1999">
<CHAR_METHODS>
<P>RCT<BR/>Blinding of randomization - yes<BR/>Blinding of intervention - yes<BR/>Complete follow-up - unclear<BR/>Blinding of outcome measurement - yes<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>62 male NB; healthy; AGA; FT</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1g LP cream + 0.8 ml saline DPNB (n=31)<BR/> 0.8 ml 1% lidocaine DPNB + 1g placebo cream (n=31)<BR/> 4 min WT for DPNB<BR/>creams applied 1 hr prior and covered with occlusive dressing</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HR; RR; behavioral distress score <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- 2 infants withdrawn (1 tachypnea, 1 parents withdrew consent)<BR/>- procedure standardized <BR/>- 3 operators performed the circumcisions<BR/>- all subjects had pacifiers<BR/>- Gomco clamp<BR/>- no adverse effects reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Joyce-2001">
<CHAR_METHODS>
<P>RCT; <BR/>Blinding of randomization - yes<BR/>Blinding of intervention - yes<BR/>Complete follow-up - yes<BR/>Blinding of outcome measurement - yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>23 male NB, FT; 5 min Apgar &gt; 7; BW &gt; 2500 g; age &lt; 7 d</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LP cream (1 - 2 g) + music (n=6)<BR/>LP cream + no music (n=5)<BR/>placebo cream + music (n=7)<BR/>placebo cream + no music (n=5)<BR/>cream applied 1 hr prior and covered with occlusive dressing<BR/>music started just prior to procedure and continued to 10 min post procedure</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HR, O2sat, cry duration; RR, Riley Infant pain scale, salivary cortisol, infant state<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- pilot study<BR/>- no adverse effects reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kass-2001">
<CHAR_METHODS>
<P>RCT <BR/>Blinding of randomization - can't tell<BR/>Blinding of intervention - no<BR/>Complete follow-up - yes<BR/>Blinding of outcome measurement - can't tell<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>71 healthy male NB</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>lidocaine DPNB (n=24)<BR/>2ml D50W orally (n=23)<BR/>2 ml H2O orally (n=24)<BR/>WT 2 to 6 min</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>time cry (primary outcome); HR; O2sat ; modified behavioral pain scale<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- additional data obtained from authors<BR/>- no pacifiers used <BR/>- Gomco clamp </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kaufman-2002">
<CHAR_METHODS>
<P>RCT<BR/>Blinding of randomization - can't tell<BR/>Blinding of intervention - partial<BR/>Complete follow-up - can't tell<BR/>Blinding of outcome measurement - can't tell<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>57 NB; healthy; male; FT; Apgar &gt; 7 at 5 min</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Mogen + water pacifier (15) <BR/>Mogen + 24% sucrose pacifier (n=14) <BR/>Gomco+ water pacifier (n=14)<BR/>Gomco + 24% sucrose pacifier (n=14)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>time crying; grimacing, procedure length</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- all subjects had EMLA cream applied between 1 and 3 hr before procedure<BR/>- single operator performed all circumcisions<BR/>-procedure standardized<BR/>- infants fasted from 15 min to 4 hr before procedure<BR/>- no adverse effects reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kurtis-1999-A">
<CHAR_METHODS>
<P>RCT<BR/>Blinding of randomization - can't tell<BR/>Blinding of intervention - no<BR/>Complete follow-up - can't tell<BR/>Blinding of outcome measurement - can't tell<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>48 male NB; FT; 5 min Apgar &gt;/= 7</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Mogen clamp and 0.8 ml 1% lidocaine DPNB (n=16) <BR/>Mogen clamp and no DPNB (n=16)<BR/>Gomco clamp and 0.8 mL 1% lidocaine DPNB (n=8)<BR/>Gomco clamp and no DPNB (n=8)<BR/>5 minute WT</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>time crying, HR, O2sat, salivary cortisol, RR</P>
<P>
<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- all subjects had pacifiers <BR/>- infants fasted 1 - 2 hr before procedure<BR/>- Mogen = 8 procedural steps; Gomco = 13 procedural steps</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kurtis-1999-B">
<CHAR_METHODS>
<P>see Kurtis 1999 A</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>see Kurtis 1999 A</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>comparison is Mogen versus Gomco for patients receiving no DPNB</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lander-1997">
<CHAR_METHODS>
<P>RCT<BR/>Blinding of randomization - yes<BR/>Blinding of intervention - partial<BR/>Complete follow-up - no<BR/>Blinding of outcome measurement - yes<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>54 male NB; FT; AGA; 1-3 d age</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2g LP cream (n=15)<BR/>placebo cream (n=12)<BR/>0.8 ml 1% lidocaine DPNB (n=14)<BR/>0.8 ml 1% lidocaine RB (n=13)<BR/>- penile blocks 8 min WT; creams applied 90 min prior and covered with occlusive dressing</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HR; time cry; O2 sat, RR, palmar sweat, metHgb level</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- 2 withdrawals, 1 in placebo group, 1 in RB group (1 parents unable to remain in hospital, 1 required phototherapy)<BR/>- procedure standardized <BR/>- Gomco clamp<BR/>- adverse effects reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Macke-2001">
<CHAR_METHODS>
<P>RCT <BR/>Blinding of randomization - yes<BR/>Blinding of intervention - yes<BR/>Complete follow-up - yes<BR/>Blinding of outcome measurement - yes<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>60 male NB; FT; Apgar &gt;/= 8</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>acetaminophen 10 mg/kg (n=29)<BR/>placebo (n=31)<BR/>given 1 hr prior to circumcision</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HR , Nursing Child Assessment Feeding Scale, cry time, infant state <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- 12 operators performed circumcisions in analgesia group, 21 performed circumcisions in placebo group<BR/>- Gomco clamp</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Marchette-1989">
<CHAR_METHODS>
<P>RCT <BR/>Blinding of randomization - can't tell<BR/>Blinding of intervention - can't tell<BR/>Complete follow-up - no<BR/>Blinding of outcome measurement - can't tell<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>103 male NB; Apgar &gt;/= 8</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>classical music (n=25)<BR/>intrauterine sounds (n=15)<BR/>control (no nurse present) (n=18)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HR; heart rhythm; BP; TcpO2; MDFMCS; BNAS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- 103 subjects randomized, 45 cases deleted due to missing data or prolonged circumcisions<BR/>- procedure standardized <BR/>- Gomco clamp<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Marchette-1991">
<CHAR_METHODS>
<P>RCT<BR/>Blinding of randomization - can't tell<BR/>Blinding of intervention - can't tell<BR/>Complete follow-up - can't tell<BR/>Blinding of outcome measurement - can't tell <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>121 male NB; Apgar =/&gt; 6; normal delivery; 2 - 9 days age</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>taped music (n=20)<BR/>intrauterine sounds (n=20)<BR/>pacifier (n=20)<BR/>music and pacifier (n=20)<BR/>intrauterine sounds and pacifier (n=20)<BR/>control - no treatment (n=21)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HR, rhythm, BP; tcPO2; rate pressure product, BNAS; crying</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- cases excluded if circumcision longer than 15 min or if bleeding <BR/>- Gomco clamp</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Masciello-1990">
<CHAR_METHODS>
<P>RCT<BR/>Blinding of randomization - can't tell<BR/>Blinding of intervention - no<BR/>Complete follow-up - no<BR/>Blinding of outcome measurement - can't tell<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>30 male NB, healthy, FT</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>0.8 ml 1% lidocaine DPNB (n=10)<BR/>0.8 ml 1% lidocaine local block (n=10)<BR/>no treatment control (n=10)<BR/>5 min WT<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>plasma cortisol, HR, O2sat, cry </P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- cortisol levels obtained for first 3 cases lost (1 in each group)<BR/>- all fasted for at least 3 hours prior<BR/>- procedure standardized <BR/>- single operator performed all circumcisions<BR/>- Gomco clamp</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Maxwell-1987">
<CHAR_METHODS>
<P>RCT; <BR/>Blinding of randomization - yes<BR/>Blinding of intervention - yes<BR/>Complete follow-up - yes<BR/>Blinding of outcome measurement - can't tell<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>30 male NB; FT; healthy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>0.8 ml 1% lidocaine DPNB (n=20) <BR/>no treatment control (n=10)<BR/>5 min WT</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HR, O2sat, BP, plasma lidocaine </P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- subjects fasted for 2 hr prior<BR/>- procedure not standardized<BR/>- Gomco clamp<BR/>- no adverse effects observed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Mohan-1998">
<CHAR_METHODS>
<P>RCT<BR/>Blinding of randomization - can't tell<BR/>Blinding of intervention - can't tell<BR/>Complete follow-up - yes<BR/>Blinding of outcome measurement - can't tell<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>60 male NB; FT; BW&gt;/= 2500 g; 5 min Apgar &gt;/= 7; &lt; 5 days age</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>5 g LP cream + 2 ml 24% sucrose via pacifier (n=19)<BR/>5 g LP cream + water via pacifier (n=20)<BR/>2 ml 24% sucrose via pacifier (n=21)<BR/>water via pacifier (n=19) - non-randomized control<BR/>- cream applied 45-60 min prior, covered with occlusive dressing</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HR; O2sat; BP; cry duration</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- control group not randomized<BR/>- all received pacifiers<BR/>- procedure standardized<BR/>- Gomco clamp<BR/>- no adverse effects reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Mudge-1989">
<CHAR_METHODS>
<P>RCT<BR/>Blinding of randomization - yes<BR/>Blinding of intervention - yes<BR/>Complete follow-up - yes<BR/>Blinding of outcome measurement - can't tell <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>44 male NB; 5 min Apgar &gt; 7; BW 2.5 - 4.5 kg; FT; age 12 - 72 h</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>4% lidocaine cream (n=20)<BR/>placebo cream (n=24)<BR/>cream applied 2 hr prior covered with occlusive dressing</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HR, RR, O2sat, cry time, behavior <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- Gomco clamp<BR/>- procedure standardized <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Newton-1999">
<CHAR_METHODS>
<P>RCT<BR/>Blinding of randomization - yes<BR/>Blinding of intervention - no<BR/>Complete follow-up - no<BR/>Blinding of outcome measurement - can't tell<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>194 male NB; healthy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>0.8 ml 1% lidocaine DPNB (n=92)<BR/>0.8 ml 1% buffered lidocaine (n=102)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HR (primary outcome variable); O2sat; number crying/phase; modified BNAS <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- complete data on crying for 165 subjects; complete data on BNAS for 194<BR/>- complete data on HR, O2 sat for 143 subjects due to technical difficulties<BR/>- procedure standardized <BR/>- Mogen clamp<BR/>- adverse effects reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Spencer-1992">
<CHAR_METHODS>
<P>RCT<BR/>Blinding of randomization - can't tell<BR/>Blinding of intervention - can't tell<BR/>Complete follow-up - can't tell<BR/>Blinding of outcome measurement - can't tell<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>75 male NB; BW 2500 - 4500 g; &gt;12 hr age; 5 min Apgar &gt; 6; normal exam</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>lidocaine DPNB - 5 min WT (n=15) <BR/>lidocaine DPNB with 2 min WT (n=15) <BR/>1% chloroprocaine DPNB with 3 min WT (n=15) <BR/>1% chloroprocaine DPNB with 5 min WT (n=15) <BR/>no treatment control (n=15)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>cry duration, O2Sat, HR, BNAS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- all received pacifiers <BR/>- fed 60 to 90 min prior to circumcision<BR/>- procedure standardized <BR/>- Gomco clamp</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Stang-1988-A">
<CHAR_METHODS>
<P>RCT<BR/>Blinding of randomization - can't tell<BR/>Blinding of intervention - partial<BR/>Complete follow-up - can't tell<BR/>Blinding of outcome measurement - can't tell<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>60 male NB; &gt; 24 hr age; BW &gt; 3000 g; 5 min Apgar &gt; 7; uncomplicated delivery</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>0.8 ml 1% lidocaine DPNB (n=20)<BR/>saline DPNB (n=20)<BR/>no treatment control (n=20)<BR/>5 min WT<BR/>*comparison is DPNB versus no treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>% time cry, modal behavior state, plasma cortisol</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- all handling avoided for 2 hr prior <BR/>- 1/2 had blood sample for cortisol at 30 min, 1/2 at 90 min<BR/>- all received pacifiers and continuously soothed <BR/>- procedure standardized to 3 periods<BR/>- Gomco and Plastibell used at operator's discretion<BR/>- adverse effects reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Stang-1988-B">
<CHAR_METHODS>
<P>see Stang A</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>see Stang A</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>*comparison is DPNB versus sham (saline) treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>see Stang A</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>see Stang A</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Stang-1997">
<CHAR_METHODS>
<P>RCT<BR/>Blinding of randomization - can't tell<BR/>Blinding of intervention - partial<BR/>Complete follow-up - can't tell<BR/>Blinding of outcome measurement - can't tell<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>83 male NB, &gt; 20 hr age; BW 3000 - 4000 gm; 5 min Apgar &gt;/= 8; FT</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>group 1 = 0.8 ml 1% lidocaine DPNB, padded restraint , water via pacifier (n=20)<BR/>group 2 = 0.8 ml 1% lidocaine DPNB, regular restraint, 24% sucrose via pacifier (n=20)<BR/>group 3 = 0.8 ml 1% buffered lidocaine DPNB, regular restraint, water via pacifier (n=20)<BR/>group 4 = 0.8 ml 1% lidocaine DPNB, regular restraint, water via pacifier (n=20) (control)<BR/>5 min WT</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>behavioral distress scale, plasma cortisol 30 min post-circ<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- 5th arm of study (24% sucrose only) abandoned due to high behavioral distress scores<BR/>- no forced preoperative fasting period<BR/>- all handling avoided for 1 hr prior<BR/>- procedure standardized <BR/>- all given pacifiers<BR/>- Gomco and Plastibell methods used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Taddio-1997">
<CHAR_METHODS>
<P>RCT<BR/>Blinding of randomization - can't tell<BR/>Blinding of intervention - yes<BR/>Complete follow-up - no<BR/>Blinding of outcome measurement - yes<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>68 male NB, BW &gt;/= 2500 g; FT; no jaundice or metHgb</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1 g (1ml) LP cream (n=38)<BR/>1 g (1ml) placebo cream (n=30)<BR/>creams covered with occlusive dressing for 60 - 80 min prior</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HR, time cry, NFCS, systolic/diastolic BP, metHgb <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- 68 subjects randomized, 8 in the LP group included in safety analysis only, 59 subjects in the efficacy analysis<BR/>- 1 withdrawal<BR/>- procedure standardized <BR/>- Gomco clamp<BR/>- adverse effects reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Weatherstone-1993">
<CHAR_METHODS>
<P>RCT<BR/>Blinding of randomization - yes<BR/>Blinding of intervention - yes<BR/>Complete follow-up - yes<BR/>Blinding of outcome measurement - yes<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>30 male NB; BW &gt;/= 2500 g; FT; Apgar &gt;/= 7; 6-72 hr age</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>0.5 g 30% lidocaine cream (n=15)<BR/>placebo cream (n=15)<BR/>applied 20 min prior to circumcision and covered with occlusive dressing</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HR, RR, O2 sat, BP, Newborn Pain Behavior Scale, serum B-endophin (15 min post), serum lidocaine</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- procedure not standardized<BR/>- Gomco and Plastibell clamps<BR/>- no adverse effects reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Williamson-1983">
<CHAR_METHODS>
<P>RCT<BR/>Blinding of randomization - yes<BR/>Blinding of intervention - no<BR/>Complete follow-up - can't tell<BR/>Blinding of outcome measurement - can't tell<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>30 male NB; BW = 2500 - 4000 g; 24 - 72 hr age; FT; Apgar score &gt; 7; systolic BP &gt; 40 mm Hg</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>0.6 to 0.8 1% ml lidocaine DPNB (n=20)<BR/>no treatment control (n=10)<BR/>4 min WT</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>TcpO2, time cry; HR, RR</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- fasted at least 2 hr prior<BR/>- PI performed all circumcisions<BR/>- Gomco clamp<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Williamson-1986">
<CHAR_METHODS>
<P>RCT<BR/>Blinding of randomization - yes<BR/>Blinding of intervention - no<BR/>Complete follow-up - yes<BR/>Blinding of outcome measurement - can't tell<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>24 male NB; Apgar &gt; 7; BW 2500 - 4500 g; FT; 24 - 72 hr age; normal physical exam</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>lidocaine DPNB (n= 11)<BR/>no treatment control (n=13)<BR/>5 min WT</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>plasma cortisol pre and 30 min post circumcision</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- 6 additional infants circumcised after study completed to serve as controls for blood sampling/injections<BR/>- all circumcisions done by PI<BR/>- Gomco clamp</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Williamson-1997">
<CHAR_METHODS>
<P>RCT<BR/>Blinding of randomization - yes<BR/>Blinding of intervention - no<BR/>Complete follow-up - yes<BR/>Blinding of outcome measurement - yes<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>30 male NB; FT; &gt;/= 24 hr age; BW 2500- 4500g; Apgar &gt; 7</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>lidocaine DPNB (n=20)<BR/>no treatment control (n=10)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>TcPO2, RR, HR, cardiac rhythm, cry time and type</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- procedure standardized <BR/>- fasting at least 2 hr prior<BR/>- Gomco clamp<BR/> - adverse effects reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Woodman-1999">
<CHAR_METHODS>
<P>RCT<BR/>Blinding of randomization - yes<BR/>Blinding of intervention - yes<BR/>Complete follow-up - yes<BR/>Blinding of outcome measurement - can't tell<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>61 male NB; Apgar &gt; 7; FT; BW &gt; 2500 g; 6-72 hr age</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1 g (1 ml) LP cream (n=20)<BR/>30% lidocaine cream (n=20)<BR/>placebo cream (n=21) <BR/>creams applied 1 hr prior and covered with occlusive dressing</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HR; time crying; O2sat <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- all subjects fasted for at least 1 hr prior<BR/>- procedure standardized<BR/>- all circumcisions performed by same operator<BR/>- Gomco clamp</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Zahorodny-1998">
<CHAR_METHODS>
<P>RCT<BR/>Blinding of randomization - can't tell<BR/>Blinding of intervention - yes<BR/>Complete follow-up - can't tell<BR/>Blinding of outcome measurement - can't tell<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>53 healthy male NB</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1g LP cream + 2 ml 50% sucrose <BR/>1g LP cream + 2 ml H2O <BR/>1g placebo cream + 2 ml 50% sucrose <BR/>1g placebo cream + 2mL H2O<BR/>creams applied 1 hr prior; sucrose or H2O oral 2 min prior<BR/>total n=53, allocation not clear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>time cry</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>abstract only, number of subjects per group not reported<BR/>assumed equal distribution to groups<BR/>unable to obtain additional data</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Zahorodny-1999">
<CHAR_METHODS>
<P>RCT<BR/>Blinding of randomization - can't tell<BR/>Blinding of intervention - yes<BR/>Complete follow-up - can't tell<BR/>Blinding of outcome measurement - can't tell<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>61; healthy male NB</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>10 ml 50% sucrose via pacifier<BR/>10 ml H2O via pacifier<BR/>no treatment control<BR/>total n=61, allocation not clear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HR, time cry</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>abstract only, unable to obtain additional data <BR/>assumed equal distribution to groups</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Zolnoski-1993">
<CHAR_METHODS>
<P>RCT<BR/>Blinding of randomization - yes<BR/>Blinding of intervention - can't tell<BR/>Complete follow-up - yes<BR/>Blinding of outcome measurement - yes<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>20 male NB, 8 - 120 hr age, FT; no maternal medication, BW &gt; 2700 g, 5 min Apgar &gt;/= 7</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2.4 ml 24% sucrose (n=10)<BR/>2.4 ml water via syringe (n=10)<BR/>given 3 min prior</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>cry time, HR</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- pilot study - Master's thesis<BR/>- procedure standardized <BR/>- Gomco clamp</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Participant Characteristics: NB = newborn; AGA = growth appropriate for gestational age; BW = birthweight; FT = full-term &gt;/= 37 weeks gestation; NICU - neonatal intensive care unit; <BR/>Interventions: DPNB = dorsal penile nerve block as described in Kirya (1978) using 1% lidocaine without epinephrine; RB = ring block following the procedure outlined by Broadman (1987); local block = local anesthesia performed by injecting 0.4 ml of 1% lidocaine without epinephrine subcutaneously into two positions on the foreskin at the level of the corona; LP cream = a lidocaine-prilocaine cream commonly known as EMLA (eutectic mixture of local anesthetics); D50W = 50% dextrose oral solution; control/no treatment group = group receiving no intervention for pain; placebo group = group receiving sham intervention which mimics active interventions; WT = the time from completion of administration of pain relief intervention to the start of circumcision procedure; <BR/>Scales: NIPS = Neonatal Infant Pain Scale consisting of six behavioral components with a composite score of 0 to 7 (Lawrence, 1993); NFCS score = evaluates the presence or absence of 10 discrete facial actions at outlined in Grunau (1987), scored from videotape in 2 sec intervals for the first 20 sec of each circumcision phase; BNAS = Brazelton Neonatal Behavioral Assessment Scale; MDFMCS = Maximally Discriminative Facial Movement Coding System for coding facial movements of three facial regions to determine emotions demonstrated; NCAFS = Nursing Child Assessment Feeding Scale measures mother-infant interaction using 76 behavioral items grouped into six subscales based on concepts of adaptation and synchronism - mother and infant are observed during natural feeding session; MBPS = modified behavioral pain scale; <BR/>Physiological measures: HR= heart rate in beats/minute (bpm); TcpO2 = transcutaneous oxygen saturation; O2sat = % oxygen saturation in the blood; BP = blood pressure; RR = respiratory rate in breaths/minute; <BR/>Biochemical measures: [PC] = plasma cortisol concentration; metHgb = methemoglobin</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Malnory-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study subjects not randomized to treatment groups, intervention chosen by physician</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mintz-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a clinical trial, no comparison between groups</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Olson-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study subjects not randomized to treatment groups, intervention chosen by physician</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Russell-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a clinical trial, all subjects received EMLA, Plastibell technique</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Taddio-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cohort design with two study groups; all recruited subjects assigned to Group 1; Group 2 data obtained from previously conducted RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Taeusch-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial of head to head comparison of surgical devices (clamps) used for circumcision procedure, procedural differences have indirect effect on circumcision pain</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Arnett-1990">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Benini-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Blass-1991-A">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Blass-1991-B">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Butler-O_x0027_Hara-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Dixon-1984">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Hardwick-Smith-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Herschel-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Holliday-1999">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Holve-1983">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Howard-1994">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Howard-1999">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Joyce-2001">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kass-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kaufman-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kurtis-1999-A">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kurtis-1999-B">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Lander-1997">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Macke-2001">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Marchette-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Marchette-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Masciello-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Maxwell-1987">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Mohan-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Mudge-1989">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Newton-1999">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Spencer-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Stang-1988-A">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Stang-1988-B">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Stang-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Taddio-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Weatherstone-1993">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Williamson-1983">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Williamson-1986">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Williamson-1997">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Woodman-1999">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Zahorodny-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Zahorodny-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Zolnoski-1993">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES>
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Trials assessing pain/behavior scores</TITLE>
<TABLE COLS="5" ROWS="17">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>scale</P>
</TH>
<TH>
<P>measurement method</P>
</TH>
<TH>
<P>data reported</P>
</TH>
<TH>
<P>data preparation</P>
</TH>
</TR>
<TR>
<TD>
<P>Arnett 1990</P>
</TD>
<TD>
<P>infant irritability<BR/>irritabilify graded subjectively on a scale of 1 to 6 with 1 representing the least crying/agitation and 6 the most</P>
</TD>
<TD>
<P>nurse and physician rating of infant irritability graded before, during and 1 hour after circumsion</P>
</TD>
<TD>
<P>mean/SD of assessment during procedure</P>
</TD>
<TD>
<P>data entered into meta-analysis as reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Benini 1993</P>
</TD>
<TD>
<P>Neonatal Facial Action Coding System<BR/>(Grunau , 1990b)<BR/>10 facial actions scored, 7 (brow bulge, eye squeeze, nasolabial furrow, open mouth, vertical stretching of mouth, horizontal stretching of mouth, taut tongue) entered into analysis</P>
</TD>
<TD>
<P>facial actions videotaped continuously, second by analysis of facial actions<BR/>10 facial actions scored, 7 facial actions entered into analysis <BR/>total score computed by summing 7 categories</P>
</TD>
<TD>
<P>outcome data (means/SDs) obtained from authors</P>
</TD>
<TD>
<P>calculate arithmetic mean of scores across phases of the procedure<BR/>calculate variance for the arithmetic mean using general formula for linear combinations of variance (i.e. Var (X+Y) = Var(x) + Var(Y) + 2Cov(X,Y))<BR/>"procedure" = [application of dorsal clamp, incision, adhesion lysis, Gomco clamp on, foreskin excision, Gomco clamp off, restraints removed]<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Butler-O'Hara 1998</P>
</TD>
<TD>
<P>Neonatal Infant Pain Scale (NIPS)<BR/>consists fo 6 behavioral components with a composite score of 0 to 6<BR/>5 components used - facial expression, cry, breathing pattern, arm movements, state of arousal<BR/>(Lawrence, 1993)</P>
</TD>
<TD>
<P>procedure videotaped<BR/>NIPS scores assigned for each of 6 events (clamping of foreskin, adhesion lysis, dorsal cut, adhesion lysis, tying of Plastibell, foreskin excision)<BR/>mean NIPS score calculated for each infant</P>
</TD>
<TD>
<P>mean(SD) NIPS score/group</P>
</TD>
<TD>
<P>data entered into meta-analysis as reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Dixon 1984<BR/>(Holve 1983 is primary study report)</P>
</TD>
<TD>
<P>Brazelton Neonatal Assessment Scale (BNAS)<BR/>consists of 27 behavioral items, each scored on scale of 1 to 9, and 20 reflexes scored on 3 point scale<BR/>scale examines organization and integration of behavior in response to positive and adversive situations</P>
</TD>
<TD>
<P>examinations conducted prior to (exam 1), following the circumcision (exam 2), and 1 day after circumcision (exam 3)</P>
</TD>
<TD>
<P>mean scores/item for 3 exam times</P>
</TD>
<TD>
<P>states "variation in item scores precluded determination of statistically significant differences between groups'<BR/>not included in meta-analysis</P>
</TD>
</TR>
<TR>
<TD>
<P>Hardwick-Smith 1998</P>
</TD>
<TD>
<P>behavioral state (Stang et al 1988) score 1 - 6 in order of increasing arousal<BR/>
<BR/>
</P>
</TD>
<TD>
<P>scored at baseline, 10 intervals during procedure, and 2 hr post-circumcision</P>
</TD>
<TD>
<P>p values</P>
</TD>
<TD>
<P>not included in meta-analysis</P>
</TD>
</TR>
<TR>
<TD>
<P>Holliday 1999</P>
</TD>
<TD>
<P>behavioral scale - includes 8 behavior state variables (sleep state, cry, facial expression, torso movement, soothability, response to distress, need for tactile stimulation, environmental noise)<BR/>each variable scored 1 to 6, scores totaled for each infant<BR/>
</P>
</TD>
<TD>
<P>assessed 20 min before, during and after circumcision</P>
</TD>
<TD>
<P>means scores/group reported in graph format<BR/>
</P>
</TD>
<TD>
<P>graph extractions to obtain mean/SD</P>
</TD>
</TR>
<TR>
<TD>
<P>Howard 1994</P>
</TD>
<TD>
<P>Postoperative Comfort Score<BR/>(Attia 1987)<BR/>10 behaviors, each scored 0, 1, or 2, possible scores 0 to 20, lower score = less comfortable<BR/>
</P>
</TD>
<TD>
<P>assessed baseline, and postcircumcision at 30, 60, 90, 120, 360 min</P>
</TD>
<TD>
<P>mean/SD scores/group/interval<BR/>mean/SD change from baseline scores/group/interval</P>
</TD>
<TD>
<P>data entered into meta-analysis as reported for 30 min post-circumcision scores</P>
</TD>
</TR>
<TR>
<TD>
<P>Howard 1999</P>
</TD>
<TD>
<P>behavioral distress scale (from Stang et al 1997) score 0 - 3 based on Brazelton statte assessment <BR/>score 0 = neutral to 3 = sustained cry</P>
</TD>
<TD>
<P>videotape of procedure assessed and scores assigned every 30 s of the procedure</P>
</TD>
<TD>
<P>mean/SE scores / group for stages 2 to 6 of procedure</P>
</TD>
<TD>
<P>data entered into meta-analysis as reported<BR/>"procedure" = [block administration to recovery; includes 4 min WT and Gomco clamp left on for 5 min]</P>
</TD>
</TR>
<TR>
<TD>
<P>Joyce 2001</P>
</TD>
<TD>
<P>Riley Infant Pain Scale<BR/>6 categories of behavior (vocal, facial expression, body movement, sleep, consolability, response to touch)<BR/>rates on scale of 0 (no pain) to 3 (severe pain)<BR/>
</P>
</TD>
<TD>
<P>videotape of procedure assessed at baseline, undressing, restraints, cleanse, clamping, cutting, end of procedure, 15 min post and 30 min post</P>
</TD>
<TD>
<P>RIPS score / group / phase presented in graphic format<BR/>p values</P>
</TD>
<TD>
<P>not included in meta-analysis</P>
</TD>
</TR>
<TR>
<TD>
<P>Kass 2001</P>
</TD>
<TD>
<P>MBPS - modified behavioral pain scale<BR/>(Taddio et al, 1995)<BR/>rates facial expression, crying, and body movements to obtain a score of 0 to 10</P>
</TD>
<TD>
<P>scored at 30 s intervals</P>
</TD>
<TD>
<P>mean/SD for baseline and procedure MBPS / group obtained from authors</P>
</TD>
<TD>
<P>mean/SD procedure scores entered into meta-analysis</P>
</TD>
</TR>
<TR>
<TD>
<P>Macke 2001</P>
</TD>
<TD>
<P>Nursing Child Assessment Feeding Scale (NCAFS)<BR/>76 behavioral binary items (yes,no) grouped into 6 subscales based on concepts of adaptation and synchronism</P>
</TD>
<TD>
<P>scored during feeding interaction before and after circumcision</P>
</TD>
<TD>
<P>mean/SD score pre/post circumcision<BR/>
</P>
</TD>
<TD>
<P>data included as reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Newton 1999</P>
</TD>
<TD>
<P>Brazelton Neonatal Assessment Scale -<BR/>scale categorized to 6 level\s - (deep sleep (1), light sleep (2) drowsy (3), quiet alert (4) active alert (5) crying (6)<BR/>(Brazelton, 1984)</P>
</TD>
<TD>
<P>3 evaluations - baseline, injection, clamp application</P>
</TD>
<TD>
<P>modal state/group</P>
</TD>
<TD>
<P>data not included</P>
</TD>
</TR>
<TR>
<TD>
<P>Stang 1988</P>
</TD>
<TD>
<P>behavioral state <BR/>6 levels = quiet sleep (1), active sleep (2), drowsy (3), alert (4), active awake (5), crying (6) (Brazelton, 1973)<BR/>
</P>
</TD>
<TD>
<P>assessed at baseline, during injection, during circumcision, and 30 min from the start of the circumcision</P>
</TD>
<TD>
<P>modal response / group / time period</P>
</TD>
<TD>
<P>data not included</P>
</TD>
</TR>
<TR>
<TD>
<P>Stang 1997</P>
</TD>
<TD>
<P>behavioral state scale and behavioral distress scale <BR/>4 levels - neutral (0), minimal fuss (1), moderate fuss (2), sustained cry (3)<BR/>(Brazelton, 1973)</P>
</TD>
<TD>
<P>behavioral state and distress scored every 30 s beginning 2 min before circumcision <BR/>scores averaged for 5 periods - preinjection, injection, 2 min post-injection, 4 min post-injection, circumcision</P>
</TD>
<TD>
<P>mean/SD /group / study period</P>
</TD>
<TD>
<P>mean/SD for circumcision period included<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Taddio 1997</P>
</TD>
<TD>
<P>Neonatal Facial Coding System (Grunau et al, 1987; 1990)<BR/>codes presence or absence of 10 discrete facial actions (brow bulge, eye squeeze, nasolabial furrow, open mouth, vertical stretching of mouth, horizontal stretching of mouth, lip pursing, taut tongue, chin quiver, tongue protrusion)<BR/>higher score = more pain</P>
</TD>
<TD>
<P>facial actions continuously recorded on videotape<BR/>facial actions scored from videotape in 2 s intervals for first 20 s of each phase <BR/>raw scores of each facial action expressed as proportion of time observed/phase; poorly correlated facial actions deleted leaving 6 facial actions; the six scores were weighted and totaled to arrive at overal score for facial action</P>
</TD>
<TD>
<P>mean/95% confidence intervals for facial activity score / group / 13 phases reported in graph format <BR/>data extracted from graphs</P>
</TD>
<TD>
<P>data extraction to obtain mean/SD facial score for circumcision phases <BR/>circumcision (7 phases) = [application of forceps to foreskin excision]<BR/>calculate arithmetic mean/group across phases of circumcision<BR/>calculate variance for the arithmetic mean using general formula for linear combinations of variance (i.e. Var (X+Y) = Var(x) + Var(Y) + 2Cov(X,Y))<BR/>SE = ((high CI - low CI)/2)/1.96<BR/>SD = SE (sqrt(n))</P>
</TD>
</TR>
<TR>
<TD>
<P>Weatherstone 1993</P>
</TD>
<TD>
<P>newborn pain behavior scale<BR/>adapted from 3 other scales (Brazelton 1973; Yarrow 1975; Ross 1988)<BR/>score includes assessment of behavioral state, leg and arm movement, facial expression, torso movement, respiratory pattern, soothability, response to distress by caregivers, tactile stimulation<BR/>
</P>
</TD>
<TD>
<P>videotape of procedure scored in 30 s intervals</P>
</TD>
<TD>
<P>increase in mean/SD % of time behavior observed post-cirucmcision compared to pre- circumcision/group</P>
</TD>
<TD>
<P>data not included</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" NO="2">
<TITLE>Trials assessing heart rate outcome variables</TITLE>
<TABLE COLS="4" ROWS="28">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>measurement method</P>
</TH>
<TH>
<P>data reported</P>
</TH>
<TH>
<P>preparation of data</P>
</TH>
</TR>
<TR>
<TD>
<P>Arnett 1990</P>
</TD>
<TD>
<P>HR measured by pulse oximetry at baseline, every min for 4 min, and 5 min post-circumcision</P>
</TD>
<TD>
<P>mean HR/group/phase reported in graph format</P>
</TD>
<TD>
<P>graph extraction for means <BR/>graph extraction for SDs (averaged over 4 phases of the circumcision procedure)<BR/>"procedure" = [min 1 to min 4]; steps not described or standardized</P>
</TD>
</TR>
<TR>
<TD>
<P>Benini 1993</P>
</TD>
<TD>
<P>HR measured continuously by pulse oximeter</P>
</TD>
<TD>
<P>outcome data (mean/SDs) obtained from authors</P>
</TD>
<TD>
<P>calculate arithmetic mean/group across phases of the procedure<BR/>calculate variance for the arithmetic mean using general formula for linear combinations of variance (i.e. Var (X+Y) = Var(x) + Var(Y) + 2Cov(X,Y))<BR/>"procedure" = [application of dorsal clamp, incision, adhesion lysis, Gomco clamp on, foreskin excision, Gomco clamp off, restraints removed]</P>
</TD>
</TR>
<TR>
<TD>
<P>Butler-O'Hara<BR/>1998</P>
</TD>
<TD>
<P>HR monitored continuously using cardiac monitor</P>
</TD>
<TD>
<P>mean/SD heart rate (bpm) at completion of circumcision by group<BR/>mean/SD heart rate (bpm) change from baseline at completion of circumcision by group</P>
</TD>
<TD>
<P>data entered into meta-analysis as reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Joyce 2001</P>
</TD>
<TD>
<P>HR monitored continuously using cardiac monitor<BR/>
</P>
</TD>
<TD>
<P>data (bpm) obtained from authors</P>
</TD>
<TD>
<P>calculate arithmetic mean/group across phases of the procedure<BR/>calculate variance for the arithmetic mean using general formula for linear combinations of variance (i.e. Var (X+Y) = Var(x) + Var(Y) + 2Cov(X,Y))<BR/>"procedure" = [cut, end of procedure]<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Hardwick-Smith 1998</P>
</TD>
<TD>
<P>HR monitored continuously using cardiac monitor<BR/>highest HR recorded at start of each interval</P>
</TD>
<TD>
<P>increase in HR from baseline per group for operative interval reported in graph format<BR/>
</P>
</TD>
<TD>
<P>graphs did not depict SDs (whiskers); researchers reported control infants had signifcantly greater increase over baseline during 7 out 10 operative intervals; they did not comment on differences between the groups/interval</P>
</TD>
</TR>
<TR>
<TD>
<P>Herschel 1998</P>
</TD>
<TD>
<P>HR monitored continuously using cardiac monitor<BR/>
</P>
</TD>
<TD>
<P>mean/SD HR (bpm) change from baseline during procedure by group<BR/>
</P>
</TD>
<TD>
<P>data entered into meta-analysis as reported<BR/> "procedure" = lateral clamp of foreskin to foreskin excision</P>
</TD>
</TR>
<TR>
<TD>
<P>Holliday 1999</P>
</TD>
<TD>
<P>HR monitored continuously using cardiac monitor<BR/>HR recorded every 5 min before, during, 5 and 20 min after circumcision</P>
</TD>
<TD>
<P>mean/SD HR (bpm)/group reported in graph format for 4 time points (before, during, 5 min after, 20 min after)</P>
</TD>
<TD>
<P>graph extraction to obtain mean/SD during procedure</P>
</TD>
</TR>
<TR>
<TD>
<P>Holve 1983</P>
</TD>
<TD>
<P>HR continuously recorded using monitor</P>
</TD>
<TD>
<P>mean change in HR from baseline (bpm) weighted averages/group for 6 phases reported in graphic format</P>
</TD>
<TD>
<P>no SDs, SEs depicted on graphs</P>
</TD>
</TR>
<TR>
<TD>
<P>Howard 1994</P>
</TD>
<TD>
<P>HR counted via auscultation every 30 s <BR/>
</P>
</TD>
<TD>
<P>mean/SD HR (bpm) / group / phase<BR/>mean/SD HR (bpm) change from baseline by group/phase</P>
</TD>
<TD>
<P>calculate arithmetic mean/group across phases of the procedure<BR/>calculate variance for the arithmetic mean using general formula for linear combinations of variance (i.e. Var (X+Y) = Var(x) + Var(Y) + 2Cov(X,Y))<BR/>"procedure" = [dissection, clamp on, excision, clamp off]<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Howard 1999</P>
</TD>
<TD>
<P>HR recorded every 60 s using cardiac monitor</P>
</TD>
<TD>
<P>- mean/SE HR (bpm) during procedure by group<BR/>
</P>
</TD>
<TD>
<P>means included as reported<BR/>convert SE to SD using formula: <BR/>SD = SE (sqrt (n))<BR/>"procedure" = [block administration to recovery; includes 4 min WT and Gomco clamp left on for 5 min]</P>
</TD>
</TR>
<TR>
<TD>
<P>Kass 2001</P>
</TD>
<TD>
<P>HR monitored at 1 min intervals during procedure</P>
</TD>
<TD>
<P>mean/SD HR (bpm) during procedure by group obtained from authors</P>
</TD>
<TD>
<P>mean/SD entered into meta-analysis</P>
</TD>
</TR>
<TR>
<TD>
<P>Kurtis 1999</P>
</TD>
<TD>
<P>HR monitored continuously using cardiac monitor</P>
</TD>
<TD>
<P>mean/SD % HR change from baseline during procedure by clamp used (Mogen, Gomco) and by penile block status (block, no block)</P>
</TD>
<TD>
<P>data entered into meta-analysis as reported<BR/>"procedure" = [lysing adhesions to 60 sec after closing clamp]</P>
</TD>
</TR>
<TR>
<TD>
<P>Lander 1997</P>
</TD>
<TD>
<P>HR monitored continuously using cardiac monitor</P>
</TD>
<TD>
<P>mean/SD HR (bpm) change from baseline by phase by group</P>
</TD>
<TD>
<P>calculate arithmetic mean/group across phases of the procedure<BR/>calculate variance for the arithmetic mean using general formula for linear combinations of variance (i.e. Var (X+Y) = Var(x) + Var(Y) + 2Cov(X,Y))<BR/>"procedure" = [separation, clamp on, clamp off]<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Macke 2001</P>
</TD>
<TD>
<P>HR recorded every 15 s using cardiac monitor <BR/>
</P>
</TD>
<TD>
<P>mean/SD HR (bpm) during circumcision by group</P>
</TD>
<TD>
<P>data included as reported<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Marchette 1989</P>
</TD>
<TD>
<P>HR monitored</P>
</TD>
<TD>
<P>mean HR /phase / group<BR/>no SDs reported</P>
</TD>
<TD>
<P>not included</P>
</TD>
</TR>
<TR>
<TD>
<P>Marchette 1991</P>
</TD>
<TD>
<P>HR monitored and data collected during 14 cirumcision steps</P>
</TD>
<TD>
<P>RMANOVA over 14 steps</P>
</TD>
<TD>
<P>not included</P>
</TD>
</TR>
<TR>
<TD>
<P>Masciello 1990</P>
</TD>
<TD>
<P>HR monitored continuously using cardiac monitor<BR/>peak HR during each step recorded</P>
</TD>
<TD>
<P>mean HR as a percent of baseline HR reported in graphic format</P>
</TD>
<TD>
<P>not included</P>
</TD>
</TR>
<TR>
<TD>
<P>Maxwell 1987</P>
</TD>
<TD>
<P>HR monitored continuously by pulse oximeter<BR/>peak HR during each period recorded</P>
</TD>
<TD>
<P>mean/SD HR change / group / period as a % of control (baseline) reported in graph format</P>
</TD>
<TD>
<P>graph extraction to obtain mean/SD during circumcision procedure</P>
</TD>
</TR>
<TR>
<TD>
<P>Mohan 1998</P>
</TD>
<TD>
<P>HR monitored continuously by pulse oximeter<BR/>HR recorded at each of 9 steps</P>
</TD>
<TD>
<P>mean HR / group / procedure step reported in graph format</P>
</TD>
<TD>
<P>graph extraction to obtain mean HR / group / procedure step<BR/>substituted weighted average treatment-specific SDs from 5 studies: Benini 1993, Joyce 2001, Lander 1997, Taddio 1997, Woodman 1999 for EMLA and from 3 studies: Herschel 1998, Kass 2001, Zolnoski 1993 for sucrose</P>
</TD>
</TR>
<TR>
<TD>
<P>Mudge 1989</P>
</TD>
<TD>
<P>HR measured by monitor at 5 time points during circumcision</P>
</TD>
<TD>
<P>mean HR / group / event reported in graph format<BR/>RMANOVA for 4 events (adhesion breakdown to clamp off)</P>
</TD>
<TD>
<P>graph extraction to obtain mean HR/group for events 2 - 5<BR/>calculate arithmetic mean HR / group across 4 phases of the procedure<BR/>(adhesion breakdown, clamp on, tighten clamp, clamp off)<BR/>substitute SDs from Woodman 1999 who applies same outcome to same comparison</P>
</TD>
</TR>
<TR>
<TD>
<P>Newton 1999</P>
</TD>
<TD>
<P>HR monitored continuouslly by pulse oximeter<BR/>HR recorded at 10 s intervals</P>
</TD>
<TD>
<P>mean/SD HR / group at baseline, injection, clamp application</P>
</TD>
<TD>
<P>included as reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Spencer 1992</P>
</TD>
<TD>
<P>HR monitored by pulse oximeter<BR/>recorded highest HR for each of 6 events</P>
</TD>
<TD>
<P>mean change in HR (bpm) from baseline / group / event</P>
</TD>
<TD>
<P>no SDs, not included</P>
</TD>
</TR>
<TR>
<TD>
<P>Taddio 1997</P>
</TD>
<TD>
<P>HR continuously monitored by cardiac monitor<BR/>
</P>
</TD>
<TD>
<P>mean/SD HR (bpm) change from baseline during procedure<BR/>
</P>
</TD>
<TD>
<P>data included as reported<BR/>"procedure" = [forcep application, lysis of adhesions, dorsal incision, clamp application, pull foreskin through clamp, tighten clamp, cut foreskin]<BR/>procedure does not include clamp removal at 5 min after cut foreskin</P>
</TD>
</TR>
<TR>
<TD>
<P>Weatherstone 1993</P>
</TD>
<TD>
<P>HR monitored at 5 min intervals for 20 min</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>not included</P>
</TD>
</TR>
<TR>
<TD>
<P>Williamson 1983</P>
</TD>
<TD>
<P>HR monitored continuously</P>
</TD>
<TD>
<P>mean/SD HR (bpm) change from baseline for 3 min "dissection" period<BR/>
</P>
</TD>
<TD>
<P>mean/SD data included as reported<BR/>dissection does not include clamp application</P>
</TD>
</TR>
<TR>
<TD>
<P>Woodman 1999<BR/>
</P>
</TD>
<TD>
<P>HR monitored continuously using pulse oximeter<BR/>recorded peak heart rate during or immediately following 7 stages of circumcision procedure</P>
</TD>
<TD>
<P>mean/SD peak HR (bpm) / group<BR/>
</P>
</TD>
<TD>
<P>calculate arithmetic mean/group across phases of the procedure<BR/>calculate variance for the arithmetic mean using general formula for linear combinations of variance (i.e. Var (X+Y) = Var(x) + Var(Y) + 2Cov(X,Y))<BR/>"procedure" = [clamp, adhesionlysis, dorsal clamp, bell on, clamp tightening, bell off]<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Zolnoski 1993</P>
</TD>
<TD>
<P>HR monitored continuously using cardiac monitor<BR/>HR (bpm) recorded at beginning of 7 procedure steps</P>
</TD>
<TD>
<P>- mean/SD HR (bpm) /group for 4 procedure steps</P>
</TD>
<TD>
<P>calculate arithmetic mean/group across phases of the procedure<BR/>calculate variance for the arithmetic mean using general formula for linear combinations of variance (i.e. Var (X+Y) = Var(x) + Var(Y) + 2Cov(X,Y))<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" NO="3">
<TITLE>Trials assessing cry outcome variables</TITLE>
<TABLE COLS="4" ROWS="20">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>measurement method</P>
</TH>
<TH>
<P>data reported</P>
</TH>
<TH>
<P>data preparation</P>
</TH>
</TR>
<TR>
<TD>
<P>Benini 1993</P>
</TD>
<TD>
<P>cry tape recorded<BR/>
</P>
</TD>
<TD>
<P>% time crying/phase (duration of time crying) reported in graph format</P>
</TD>
<TD>
<P>means, SEs (assumed) extracted from graph; calculate arithmetic mean/group across phases of the procedure<BR/>calculate variance for the arithmetic mean using general formula for linear combinations of variance (i.e. Var (X+Y) = Var(x) + Var(Y) + 2Cov(X,Y))<BR/>"procedure" = [dorsal clamp, incision, lysis, clamp on, foreskin cut, clamp off, unrestrained]<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Blass 1991</P>
</TD>
<TD>
<P>cry tape recorded</P>
</TD>
<TD>
<P>mean % time crying (duration of time crying) during entire procedure reported in graph format</P>
</TD>
<TD>
<P>- graph extraction of group mean/SE;<BR/>- SD calulated using formula: <BR/>SD = SE (sqrt (n))</P>
</TD>
</TR>
<TR>
<TD>
<P>Holve 1983</P>
</TD>
<TD>
<P>cry tape recorded<BR/>
</P>
</TD>
<TD>
<P>mean % time crying /interval reported in graphic format</P>
</TD>
<TD>
<P>no SDs, not included</P>
</TD>
</TR>
<TR>
<TD>
<P>Hardwick-<BR/>Smith 1998</P>
</TD>
<TD>
<P>cry tape recorded</P>
</TD>
<TD>
<P>mean/SD minutes crying/group during operative interval (lateral clamping to clamp removal)</P>
</TD>
<TD>
<P>convert reported time to seconds<BR/>data included in meta-analysis</P>
</TD>
</TR>
<TR>
<TD>
<P>Howard 1994</P>
</TD>
<TD>
<P>used stopwatch to time crying during each phase</P>
</TD>
<TD>
<P>mean/SD % time crying by group/phase<BR/>mean/SD % time crying change from baseline/group/phase</P>
</TD>
<TD>
<P>calculate arithmetic mean/group across phases of the procedure<BR/>calculate variance for the arithmetic mean using general formula for linear combinations of variance (i.e. Var (X+Y) = Var(x) + Var(Y) + 2Cov(X,Y))<BR/>"procedure" = [dissection, clamp on, excision, clamp off]<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Joyce 2001</P>
</TD>
<TD>
<P>behavior videotaped<BR/>calculated total time crying from start of foreskin cut until crying ceased or 30 min elapsed</P>
</TD>
<TD>
<P>cry time (min) for each subject obtained from authors</P>
</TD>
<TD>
<P>calculate mean/SD time crying in min and sec/group</P>
</TD>
</TR>
<TR>
<TD>
<P>Kass 2001</P>
</TD>
<TD>
<P>primary outcome variable<BR/>behavior videotaped</P>
</TD>
<TD>
<P>mean/SD time crying (s) /group during procedure obtained from authors</P>
</TD>
<TD>
<P>mean/SD included in meta-analysis</P>
</TD>
</TR>
<TR>
<TD>
<P>Kurtis 1999</P>
</TD>
<TD>
<P>behavior videotaped<BR/>calculated time crying using stopwatch</P>
</TD>
<TD>
<P>mean/SD % time crying during procedure<BR/>reported by clamp used (Mogen, Gomco) and by penile block status (block, no block)</P>
</TD>
<TD>
<P>mean/SD included as reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Lander 1997</P>
</TD>
<TD>
<P>behavior videotaped<BR/>proportion of time crying calculated/subject</P>
</TD>
<TD>
<P>mean/SD % time crying/interval</P>
</TD>
<TD>
<P>calculate arithmetic mean/group across phases of the procedure<BR/>calculate variance for the arithmetic mean using general formula for linear combinations of variance (i.e. Var (X+Y) = Var(x) + Var(Y) + 2Cov(X,Y))- "procedure" = [separation, clamp on, clamp off)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Macke 2001</P>
</TD>
<TD>
<P>continuous vocalizations of 15 s or more classified as crying and tape recorded<BR/>total s used to calculate % time crying</P>
</TD>
<TD>
<P>mean/SD % time crying during circumcision period by group</P>
</TD>
<TD>
<P>data included as reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Mohan 1998</P>
</TD>
<TD>
<P>stopwatch used to measure duration of crying</P>
</TD>
<TD>
<P>mean % time crying / group during entire procedure</P>
</TD>
<TD>
<P>not included</P>
</TD>
</TR>
<TR>
<TD>
<P>Mudge 1989</P>
</TD>
<TD>
<P>crying time tape recorded during procedure <BR/>measured by stop watch</P>
</TD>
<TD>
<P>mean total crying time (s)/group for entire procedure<BR/>t-statistic, p value</P>
</TD>
<TD>
<P>mean crying time included as reported<BR/>SD imputed from t statistic<BR/>procedure includes 5 events (baseline, adhesion breakdown, clamp on, tighten clamp, clamp off)</P>
</TD>
</TR>
<TR>
<TD>
<P>Spencer 1992</P>
</TD>
<TD>
<P>cry duration measured by modified Brazelton Neonatal behavioral Scale (Stang et al, 1988)<BR/>6 behavioral states <BR/>recorded for each of 6 events</P>
</TD>
<TD>
<P>mean % change from baseline / group</P>
</TD>
<TD>
<P>no SDs, not included</P>
</TD>
</TR>
<TR>
<TD>
<P>Stang 1988</P>
</TD>
<TD>
<P>not described</P>
</TD>
<TD>
<P>mean/SEM % time crying during circumcision period/group</P>
</TD>
<TD>
<P>means included as reported<BR/>SEM converted to SD using formula: <BR/>SD = SEM (sqrt (n))</P>
</TD>
</TR>
<TR>
<TD>
<P>Taddio 1997</P>
</TD>
<TD>
<P>behavior videotaped<BR/>calculated % of time crying during each phase</P>
</TD>
<TD>
<P>mean/SD % increase from baseline in time crying during procedure<BR/>
</P>
</TD>
<TD>
<P>data included as reported<BR/>"procedure" = [forcep application, lysis of adhesions, dorsal incision, clamp application, pull foreskin through clamp, tighten clamp, cut foreskin]<BR/>does not include clamp removal at 5 min after foreskin cut</P>
</TD>
</TR>
<TR>
<TD>
<P>Williamson 1983</P>
</TD>
<TD>
<P>time crying recorded using event marker</P>
</TD>
<TD>
<P>mean/SD % time crying change from baseline during 3 min dissection period</P>
</TD>
<TD>
<P>mean/SD data included as reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Woodman 1999</P>
</TD>
<TD>
<P>behavior videotaped<BR/>recorded time crying based on facial actions with or without audible cry</P>
</TD>
<TD>
<P>mean/SD time crying (s) for 6 phases by group</P>
</TD>
<TD>
<P>add time crying for 6 of 8 stages (clamp, adhesionlysis, dorsal clamp, clamp on, clamp tightening, clamp off) to obtain total time crying during procedure<BR/>add SD to obtain total SD for group</P>
</TD>
</TR>
<TR>
<TD>
<P>Zahorodny 1998</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>mean % time crying/group</P>
</TD>
<TD>
<P>substituted weighted average treatment-specific SDs from three other studies: Benini 1993, Lander 1997, Taddio 1997 for EMLA vs placebo/ no treatment<BR/>substituted treatment-specific SDs from Blass 1991 A (also versus water) for sucrose vs placebo/ no treatment<BR/>substituted with the SDs used in the two above comparisons for EMLA vs sucrose<BR/>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Zolnoski 1993</P>
</TD>
<TD>
<P>cry tape recorded, measured using stopwatch</P>
</TD>
<TD>
<P>time cry (s)/infant</P>
</TD>
<TD>
<P>mean/SD cry time (s)/group calculated</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" NO="4">
<TITLE>Trials assessing oxygen saturation outcome variables</TITLE>
<TABLE COLS="4" ROWS="18">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>measurement method</P>
</TH>
<TH>
<P>data reported</P>
</TH>
<TH>
<P>data preparation</P>
</TH>
</TR>
<TR>
<TD>
<P>Arnett 1990</P>
</TD>
<TD>
<P>measured by pulse oximetry at baseline, every min for 4 min during procedure, and 5 min postcircumcision</P>
</TD>
<TD>
<P>mean oxygen saturation (%) / group / phase and SDs presented graphically</P>
</TD>
<TD>
<P>graph extraction of means, graph extraction of SDs, averaged over 4 phases</P>
</TD>
</TR>
<TR>
<TD>
<P>Benini 1997</P>
</TD>
<TD>
<P>O2sat continuously monitored using pulse oximeter<BR/>
</P>
</TD>
<TD>
<P>outcome data (mean/SD) obtained from authors</P>
</TD>
<TD>
<P>calculate arithmetic mean/group across phases of the procedure<BR/>calculate variance for arithmetic mean using general formula for linear combinations of variance (i.e. Var (X+Y) = Var(x) + Var(Y) + 2Cov(X,Y))<BR/>procedure = [application of dorsal clamp, incision, adhesion lysis, Gomco clamp on, foreskin excision, Gomco clamp off, restraints removed]</P>
</TD>
</TR>
<TR>
<TD>
<P>Hardwick-Smith 1998</P>
</TD>
<TD>
<P>O2sat monitored continuously by pulse oximeter, lowest O2sat recorded at the start of each interval<BR/>during some intervals of procedure, O2sat not recorded in up to 50% of infants</P>
</TD>
<TD>
<P>mean/SD of O2sat (%)/group for operative intervals</P>
</TD>
<TD>
<P>data included in meta-analysis as reported<BR/>"operative interval" = [llateral clamp, blunt dissection, dorsal clamp, adhesion takedown, Gomco bell on, Gomco clamp applied, Gomco clamp removed]</P>
</TD>
</TR>
<TR>
<TD>
<P>Herschel 1998</P>
</TD>
<TD>
<P>O2sat continuously monitored via pulse oximetry<BR/>substantial proportion of data lost due to excessive motion (31% control, 10% DPNB, 8% sucrose)</P>
</TD>
<TD>
<P>mean/SD O2sat (%) change from baseline during operative procedure by group<BR/>
</P>
</TD>
<TD>
<P>data included in meta-analysis as reported<BR/>"operative procedure" = [lateral clamp of foreskin, adhesion lysis, dorsal clamp, dorsal cut, foreskin retraction, Gomco application, Gomco tightened, foreskin excision]</P>
</TD>
</TR>
<TR>
<TD>
<P>Holliday 1999</P>
</TD>
<TD>
<P>O2sat continuously monitored, recorded every 5 min before, during, 5min and 20 min after circumcision</P>
</TD>
<TD>
<P>mean/SD O2sat (%)/group reported in graph format for 4 time points (before, during, 5 min after, 20 min after)</P>
</TD>
<TD>
<P>graph extraction for mean/SD during procedure</P>
</TD>
</TR>
<TR>
<TD>
<P>Joyce 2001</P>
</TD>
<TD>
<P>O2sat monitored continuously using pulse oximeter<BR/>recorded O2sat (%) at each of 6 data collection points</P>
</TD>
<TD>
<P>raw data per subject per 6 phases obtained from authors</P>
</TD>
<TD>
<P>calculate mean/SD by group/phase<BR/>calculate arithmetic mean/group across phases of the procedure<BR/>calculate variance for arithmetic mean using general formula for linear combinations of variance (i.e. Var (X+Y) = Var(x) + Var(Y) + 2Cov(X,Y))<BR/>procedure = [cut, end]</P>
</TD>
</TR>
<TR>
<TD>
<P>Kass 2001</P>
</TD>
<TD>
<P>monitored O2sat at 1 min intervals during procedure</P>
</TD>
<TD>
<P>mean/SD O2sat during procedure by group data obtained from authors</P>
</TD>
<TD>
<P>mean/SD included in meta-analysis</P>
</TD>
</TR>
<TR>
<TD>
<P>Kurtis 1999</P>
</TD>
<TD>
<P>O2sat (%) monitored continuously and transferred to computer<BR/>
</P>
</TD>
<TD>
<P>- mean/SD % change from baseline during procedure reported by clamp used (Mogen, Gomco) and by penile block status (block, no block)</P>
</TD>
<TD>
<P>data included in meta-analysis as reported<BR/>procedure = [lysing adhesions to 60 sec after closing clamp]</P>
</TD>
</TR>
<TR>
<TD>
<P>Marchette 1991</P>
</TD>
<TD>
<P>tcpO2 monitored and recorded during 14 circumcision steps</P>
</TD>
<TD>
<P>RMANOVA over 14 steps</P>
</TD>
<TD>
<P>not included</P>
</TD>
</TR>
<TR>
<TD>
<P>Masciello 1990</P>
</TD>
<TD>
<P>O2sat monitored continuously by pulse oximeter<BR/>lowest level during each interval recorded</P>
</TD>
<TD>
<P>mean O2sat / group / interval reported in graphic format</P>
</TD>
<TD>
<P>not included</P>
</TD>
</TR>
<TR>
<TD>
<P>Maxwell 1987</P>
</TD>
<TD>
<P>O2sat monitored continuously<BR/>using pulse oximeter<BR/>peak value during period recorded</P>
</TD>
<TD>
<P>mean/SD O2sat /group / period reported in graph format</P>
</TD>
<TD>
<P>graph extraction to obtain mean/SD during circumcision period</P>
</TD>
</TR>
<TR>
<TD>
<P>Mohan 1998</P>
</TD>
<TD>
<P>O2sat monitored continuously<BR/>using pulse oximeter<BR/>recorded at each of 9 procedure steps</P>
</TD>
<TD>
<P>mean O2sat / group / procedure step reported in graph format</P>
</TD>
<TD>
<P>graph extraction to obtain mean O2sat / group / step<BR/>substituted weighted average treatment-specific SDs from 3 trials: Benini 1993, Joyce 2001, Woodman 1999 for EMLA and from 2 trials: Herschel 1998, Kass 2001 for sucrose</P>
</TD>
</TR>
<TR>
<TD>
<P>Mudge 1989</P>
</TD>
<TD>
<P>O2sat measured by pulse oximeter and recorded at five time points during circumcision</P>
</TD>
<TD>
<P>mean O2sat (%) /group/event reported in graph format</P>
</TD>
<TD>
<P>graph extraction to obtain mean O2sat/group for events 2 - 5<BR/>calculate arithmetic mean O2sat / group across 4 phases of the procedure<BR/>(adhesion breakdown, clamp on, tighten clamp, clamp off)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Spencer 1992</P>
</TD>
<TD>
<P>O2sat monitored by pulse oximeter<BR/>recorded lowest level for each of 6 events</P>
</TD>
<TD>
<P>mean O2sat % change from baseline / group / event</P>
</TD>
<TD>
<P>no SDs, not included</P>
</TD>
</TR>
<TR>
<TD>
<P>Weatherstone 1993</P>
</TD>
<TD>
<P>O2sat monitored at 5 min intervals for 20 min</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>not included</P>
</TD>
</TR>
<TR>
<TD>
<P>Williamson 1983</P>
</TD>
<TD>
<P>O2sat measured using transcutaneous electrode (tcpO2)</P>
</TD>
<TD>
<P>mean/SD O2sat (torr) change from baseline for 3 min dissection period<BR/>
</P>
</TD>
<TD>
<P>data included in meta-analysis as reported<BR/>dissection does not include clamp application</P>
</TD>
</TR>
<TR>
<TD>
<P>Woodman 1999</P>
</TD>
<TD>
<P>O2sat monitored continuously using pulse oximeter<BR/>recorded peak/nadir during or immediately following 7 stages of circumcision procedure</P>
</TD>
<TD>
<P>- mean/SD peak/nadir O2sat / stage / group</P>
</TD>
<TD>
<P>calculate arithmetic mean/group across phases of the procedure<BR/>calculate variance for arithmetic mean using general formula for linear combinations of variance (i.e. Var (X+Y) = Var(x) + Var(Y) + 2Cov(X,Y))<BR/>procedure = [clamp, adhesiolysis, dorsal clamp, clamp on, clamp tightening, clamp off)<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" NO="5">
<TITLE>Trials assessing respiratory rate outcome variables</TITLE>
<TABLE COLS="4" ROWS="10">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>measurement method</P>
</TH>
<TH>
<P>data reported</P>
</TH>
<TH>
<P>preparation of data</P>
</TH>
</TR>
<TR>
<TD>
<P>Butler-OHara 1998</P>
</TD>
<TD>
<P>RR monitored continuously starting after anesthetic administration, and 1 and 4 hr after procedure</P>
</TD>
<TD>
<P>RR variable and difficult to evaluate<BR/>not reported</P>
</TD>
<TD>
<P>not included in meta-analysis</P>
</TD>
</TR>
<TR>
<TD>
<P>Hardwick-Smith 1998</P>
</TD>
<TD>
<P>highest RR recorded at start of each interval (anesthesia/restraint, 3 min post restraint/anesthesia, lateral clamp, blunt dissection, dorsal clamp, adhesion breakdown, Gomco bell on, Gomco clamp on, Gomco clamp removed)</P>
</TD>
<TD>
<P>mean/SD increase from baseline RR/group for operative intervals (lateral clamping to Gomco clamp removal)</P>
</TD>
<TD>
<P>data included in meta-analysis as reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Holliday 1999</P>
</TD>
<TD>
<P>RR monitored continuously using cardiac monitor<BR/>HR recorded every 5 min before, during, 5 and 20 min after circumcision</P>
</TD>
<TD>
<P>mean/SD RR (bpm)/group reported in graph format for 4 time points (before, during, 5 min after, 20 min after)</P>
</TD>
<TD>
<P>graph extraction for mean/SD during procedure</P>
</TD>
</TR>
<TR>
<TD>
<P>Howard 1994</P>
</TD>
<TD>
<P>RR assessed by visual observation every 30 s</P>
</TD>
<TD>
<P>mean/SD RR (rpm) / group / phase<BR/>mean/SD RR (rpm) change from baseline by group/phase</P>
</TD>
<TD>
<P>calculate arithmetic mean/group across phases of the procedure<BR/>calculate variance for the arithmetic mean using general formula for linear combinations of variance (i.e. Var (X+Y) = Var(x) + Var(Y) + 2Cov(X,Y))<BR/>"procedure" = [dissection, clamp on, excision, clamp off]</P>
</TD>
</TR>
<TR>
<TD>
<P>Howard 1999</P>
</TD>
<TD>
<P>RR counted and recorded every 60 s</P>
</TD>
<TD>
<P>mean/SE RR (rpm) by group for procedure</P>
</TD>
<TD>
<P>means included as reported<BR/>convert SE to SD using formula: SD = SE (sqrt (n))<BR/>"procedure" = [block administration to recovery; includes 4 min WT and Gomco clamp left on for 5 min]<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Joyce 2001</P>
</TD>
<TD>
<P>RR monitored continuously, recorded at 6 data collection points</P>
</TD>
<TD>
<P>raw data obtained from authors</P>
</TD>
<TD>
<P>calculate arithmetic mean/group across phases of the procedure<BR/>calculate variance for the arithmetic mean using general formula for linear combinations of variance (i.e. Var (X+Y) = Var(x) + Var(Y) + 2Cov(X,Y))<BR/>"procedure" = [cut, end of procedure]</P>
</TD>
</TR>
<TR>
<TD>
<P>Kurtis 1999</P>
</TD>
<TD>
<P>RR monitored continuously using physiologic monitor</P>
</TD>
<TD>
<P>mean/SD % change from baseline during procedure reported by clamp used (Mogen, Gomco) and by penile block status (block, no block)</P>
</TD>
<TD>
<P>data entered into meta-analysis as reported<BR/>"procedure" = [lysing adhesions to 60 sec after closing clamp]</P>
</TD>
</TR>
<TR>
<TD>
<P>Mudge 1989</P>
</TD>
<TD>
<P>RR measured by pneumography monitor at 5 time points</P>
</TD>
<TD>
<P>mean RR / group / event reported in graph format<BR/>RMANOVA for 4 events (adhesion breakdown to clamp off)</P>
</TD>
<TD>
<P>graph extraction to obtain mean RR/group for events 2 - 5<BR/>calculate arithmetic mean RR / group across 4 phases of the procedure<BR/>(adhesion breakdown, clamp on, tighten clamp, clamp off)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Weatherstone 1993</P>
</TD>
<TD>
<P>RR monitored at 5 min intervals for 20 min</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>not included</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-06" NO="6">
<TITLE>Trials assessing biochemical outcome variables</TITLE>
<TABLE COLS="4" ROWS="10">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>measurement method</P>
</TH>
<TH>
<P>data reported</P>
</TH>
<TH>
<P>data preparation</P>
</TH>
</TR>
<TR>
<TD>
<P>Masciello 1990</P>
</TD>
<TD>
<P>blood drawn via heel stick 30 minutes post-circumcision</P>
</TD>
<TD>
<P>mean/SD plasma cortisol levels in mg/dL</P>
</TD>
<TD>
<P>mg/dL multiplied by 27.59 = nmol/L<BR/>nmol/L included in meta-analysis</P>
</TD>
</TR>
<TR>
<TD>
<P>Stang 1988</P>
</TD>
<TD>
<P>blood drawn via heel stick for 1/2 subjects at 30 min post-circumcision, and 90 min for remaining 1/2 subjects</P>
</TD>
<TD>
<P>mean/SEM plasma cortisol levels in nmol/L and ug/dL</P>
</TD>
<TD>
<P>means (nmol/L) included in meta-analysis<BR/>SEM converted to SD using formula: <BR/>SD = SEM (sqrt(n))<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Williamson 1986</P>
</TD>
<TD>
<P>blood drawn by heel stick at baseline and 30 min post-circumcision</P>
</TD>
<TD>
<P>mean/SEM plasma cortisol levels in ug/dL</P>
</TD>
<TD>
<P>SEM converted to SD using formula: <BR/>SD = SEM (sqrt(n))<BR/>ug/dL</P>
</TD>
</TR>
<TR>
<TD>
<P>Holliday 1999</P>
</TD>
<TD>
<P>serum B-endorphin levels - blood sample taken before and 20 min post-circumcision</P>
</TD>
<TD>
<P>mean/SD / group in pmol/L</P>
</TD>
<TD>
<P>data included as reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Joyce 2001</P>
</TD>
<TD>
<P>salivary cortisol samples collected at baseline abd 30 min after procedure</P>
</TD>
<TD>
<P>mean/SD before/after<BR/>no units of measurement<BR/>results not broken down by group</P>
</TD>
<TD>
<P>not included</P>
</TD>
</TR>
<TR>
<TD>
<P>Kurtis 1999</P>
</TD>
<TD>
<P>salivary cortisol</P>
</TD>
<TD>
<P>collected sample at baseline and 30 min post-circumcision</P>
</TD>
<TD>
<P>mean/SD included as reported<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Stang 1997</P>
</TD>
<TD>
<P>plasma cortisol 30 min after beginning of circumcision</P>
</TD>
<TD>
<P>mean/SD / group<BR/>nmol/dL and ug/dL</P>
</TD>
<TD>
<P>mean /SD (nmol/dL) included as reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Weatherstone 1993</P>
</TD>
<TD>
<P>serum B-endorphin level taken pre-operatively and 15 min after circumcision</P>
</TD>
<TD>
<P>mean/SD B-endorphin level (pg/mL) for pre and post circumcision period/group</P>
</TD>
<TD>
<P>mean/SD level for post-circumcision period included as reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Williamson 1986</P>
</TD>
<TD>
<P>plasma cortisol obtained at baseline and 30 min after Gomco clamp applied</P>
</TD>
<TD>
<P>mean/SEM plasma cortisol levels (ug/dL)/group</P>
</TD>
<TD>
<P>ug/dL multiplied by 27.59 = nmol/L<BR/>SEM converted to SD using formula: <BR/>SD = SEM (sqrt(n))</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-07" NO="7">
<TITLE>Trials assessing blood pressure outcome variables</TITLE>
<TABLE COLS="4" ROWS="8">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>measurement method</P>
</TH>
<TH>
<P>data reported</P>
</TH>
<TH>
<P>data preparation</P>
</TH>
</TR>
<TR>
<TD>
<P>Holliday 1999</P>
</TD>
<TD>
<P>systolic BP monitored continuously using cardiac monitor<BR/>HR recorded every 5 min before, during, 5 and 20 min after circumcision</P>
</TD>
<TD>
<P>mean/SD BP (mmHg)/group reported in graph format for 4 time points (before, during, 5 min after, 20 min after)</P>
</TD>
<TD>
<P>graph extraction for mean/SD during procedure</P>
</TD>
</TR>
<TR>
<TD>
<P>Marchette 1991</P>
</TD>
<TD>
<P>systolic and diastolic BP monitored and recorded during 14 steps of the cirumcision procedure</P>
</TD>
<TD>
<P>RMANOVA over 14 steps</P>
</TD>
<TD>
<P>not included</P>
</TD>
</TR>
<TR>
<TD>
<P>Maxwell 1987</P>
</TD>
<TD>
<P>BP measured by Doppler every 5 min<BR/>
</P>
</TD>
<TD>
<P>mean/SD systolic BP change as a % of control / group / period reported in graph format</P>
</TD>
<TD>
<P>graph extraction to obtain mean/SD during circumcision period</P>
</TD>
</TR>
<TR>
<TD>
<P>Mohan 1998</P>
</TD>
<TD>
<P>systolic and diastolic BP measured over upper arm at each of 9 procedural steps<BR/>
</P>
</TD>
<TD>
<P>mean systolic and diastolic BP (mm Hg) reported in graph format</P>
</TD>
<TD>
<P>graph extraction to obtain mean / group / step<BR/>substituted treatment-specific SDs from Taddio 1997 for EMLA; no SDs available for sucrose</P>
</TD>
</TR>
<TR>
<TD>
<P>Taddio 1997</P>
</TD>
<TD>
<P>systolic and diastolic BP measured at baseline and during lysis of adhesions</P>
</TD>
<TD>
<P>mean/SD increase mm Hg in systolic and diastolic BP</P>
</TD>
<TD>
<P>data included as reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Weatherstone 1993</P>
</TD>
<TD>
<P>BP monitored at 5 min intervals for 20 min</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>not included</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-08" NO="8">
<TITLE>Trials reporting adverse effects</TITLE>
<TABLE COLS="3" ROWS="11">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>intervention(s)</P>
</TH>
<TH>
<P>adverse effects</P>
</TH>
</TR>
<TR>
<TD>
<P>Arnett 1990</P>
</TD>
<TD>
<P>0.4 ml lidocaine DPNB (n=23)<BR/>0.4 ml saline DPNB (n=22)<BR/>control (n=7)</P>
</TD>
<TD>
<P>lidocaine group - 1 emesis treated with suction<BR/>saline group - 2 bleeding post-procedure, 1 required suture<BR/>control - 1 bleeding post-procedure controlled with pressure</P>
</TD>
</TR>
<TR>
<TD>
<P>Butler-O'Hara<BR/>1998</P>
</TD>
<TD>
<P>0.5 ml LP cream (n=21)<BR/>0.7 ml - 1.0 ml lidocaine DPNB + placebo cream (n=23)</P>
</TD>
<TD>
<P>DPNB group - 10 hematoma; 1 penile edema on day 5<BR/>LP cream group - 3 erythema</P>
</TD>
</TR>
<TR>
<TD>
<P>Holve 1983 &amp; (primary study)<BR/>Dixon 1984<BR/>
</P>
</TD>
<TD>
<P>0.8 ml lidocaine DPNB (n=15)<BR/>0.8 ml saline DPNB (n=8)<BR/>control (n=8)</P>
</TD>
<TD>
<P>lidocaine group - 1 small unilateral hematoma</P>
</TD>
</TR>
<TR>
<TD>
<P>Holliday 1999</P>
</TD>
<TD>
<P>0.8 ml lidocaine DPNB + placebo cream (n=19)<BR/>placebo cream (n=19)<BR/>original protocol included LP cream group (n=12)</P>
</TD>
<TD>
<P>LP cream group - 2 redness and blistering of foreskin, LP cream group discontinued</P>
</TD>
</TR>
<TR>
<TD>
<P>Lander 1997</P>
</TD>
<TD>
<P>2 g LP cream (n=15)<BR/>placebo cream (n=12)<BR/>0.8 ml lidocaine DPNB (n=14)<BR/>0.8 ml lidocaine RB (n=13)</P>
</TD>
<TD>
<P>placebo group - 1 apnea and emesis, 1 choking and apnea<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Newton 1999</P>
</TD>
<TD>
<P>0.8 ml lidocaine DPNB (n=92)<BR/>0.8 ml buffered lidocaine DPNB (n=102)</P>
</TD>
<TD>
<P>lidocaine group - 4 had minor bleeding<BR/>buffered lidocaine group - 6 had minor bleeding</P>
</TD>
</TR>
<TR>
<TD>
<P>Stang 1988</P>
</TD>
<TD>
<P>0.8 ml lidocaine DPNB (n=20)<BR/>0.8 ml saline DPNB (n=20)<BR/>control (n=20)</P>
</TD>
<TD>
<P>occasional insignificant bleeding - groups and numbers not specified</P>
</TD>
</TR>
<TR>
<TD>
<P>Taddio 1997</P>
</TD>
<TD>
<P>1 g LP cream (n=29)<BR/>1 g placebo cream (n=30)</P>
</TD>
<TD>
<P>LP cream group - 12 minor foreskin pallor, 1 mild edema<BR/>placebo group - 4 minor foreskin pallor</P>
</TD>
</TR>
<TR>
<TD>
<P>Williamson 1997</P>
</TD>
<TD>
<P>lidocaine DPNB (n=20)<BR/>control (n=10)</P>
</TD>
<TD>
<P>DPNB group - 9 bleeding, 12 swelling, 1 erythema<BR/>control group - 5 bleeding, 5 swelling, 1 hematoma, 3 erythema</P>
</TD>
</TR>
<TR>
<TD>
<P>Zolnoski 1993</P>
</TD>
<TD>
<P>2.4 ml 24% sucrose (n=10)<BR/>2.4 ml water (n=10)</P>
</TD>
<TD>
<P>sucrose group - 1 gagging<BR/>water group - 2 regurgitation after circumcision</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>DPNB versus no treatment or sham</NAME>
<CONT_OUTCOME CHI2="55.51255247774274" CI_END="-2.0955511045016713" CI_START="-3.1499702846903355" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.6227606945960034" ESTIMABLE="YES" I2="94.5958168628567" I2_Q="94.5958168628567" ID="CMP-001.01" NO="1" P_CHI2="5.33739719088544E-12" P_Q="5.33739719088544E-12" P_Z="1.8370125698322932E-22" Q="55.51255247774274" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="84" TOTAL_2="89" UNITS="" WEIGHT="400.0" Z="9.750422977995608">
<NAME>Pain score</NAME>
<GROUP_LABEL_1>DPNB</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment or sham</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DPNB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.165160688947102E-31" CI_END="-1.1944550341950555" CI_START="-2.4055449658049453" DF="0.0" EFFECT_SIZE="-1.8000000000000005" ESTIMABLE="YES" I2="99.99999999999999" ID="CMP-001.01.01" NO="1" P_CHI2="0.0" P_Z="5.675466112668778E-9" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="27" WEIGHT="100.0" Z="5.826049874731349">
<NAME>infant irritability score</NAME>
<CONT_DATA CI_END="-1.1944550341950553" CI_START="-2.4055449658049453" EFFECT_SIZE="-1.8000000000000003" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="4.2" ORDER="17024" SD_1="1.2" SD_2="0.9" SE="0.3089571903266623" STUDY_ID="STD-Arnett-1990" TOTAL_1="22" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.917403227506735" CI_START="-4.542596772493264" DF="0.0" EFFECT_SIZE="-3.2299999999999995" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" NO="2" P_CHI2="1.0" P_Z="1.4139906578184886E-6" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="99.99999999999999" Z="4.823022426026009">
<NAME>modified behavioral pain scale (MBPS)</NAME>
<CONT_DATA CI_END="-1.917403227506735" CI_START="-4.542596772493264" EFFECT_SIZE="-3.2299999999999995" ESTIMABLE="YES" MEAN_1="4.4" MEAN_2="7.63" ORDER="17025" SD_1="2.8" SD_2="1.71" SE="0.669704536841932" STUDY_ID="STD-Kass-2001" TOTAL_1="24" TOTAL_2="24" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-6.515636076530672" CI_START="-11.084363923469326" DF="0.0" EFFECT_SIZE="-8.799999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.03" NO="3" P_CHI2="1.0" P_Z="4.34183610044641E-14" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="7.550321945969949">
<NAME>author-created behavioural score</NAME>
<CONT_DATA CI_END="-6.515636076530672" CI_START="-11.084363923469326" EFFECT_SIZE="-8.799999999999999" ESTIMABLE="YES" MEAN_1="14.1" MEAN_2="22.9" ORDER="17026" SD_1="4.1" SD_2="3.0" SE="1.1655132142672509" STUDY_ID="STD-Holliday-1999" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-6.615118038754899" CI_START="-12.9848819612451" DF="0.0" EFFECT_SIZE="-9.799999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.04" NO="4" P_CHI2="1.0" P_Z="1.630673038706657E-9" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.00000000000001" Z="6.030881923480605">
<NAME>crying component of behavioural score</NAME>
<CONT_DATA CI_END="-6.615118038754899" CI_START="-12.9848819612451" EFFECT_SIZE="-9.799999999999999" ESTIMABLE="YES" MEAN_1="6.9" MEAN_2="16.7" ORDER="17027" SD_1="6.1" SD_2="3.6" SE="1.624969635343834" STUDY_ID="STD-Holliday-1999" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.0822013940469484" CI_END="-1.404687905127949" CI_START="-2.0631552899867374" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-1.7339215975573432" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="0.6873143756635265" P_Q="0.4540698683367317" P_Z="5.591284399389814E-25" Q="0.5604729146879208" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="102" TOTAL_2="109" UNITS="" WEIGHT="100.0" Z="10.322223883442174">
<NAME>Cry time (by unit)</NAME>
<GROUP_LABEL_1>DPNB</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment or sham</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DPNB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.5217284793590276" CI_END="-1.2936747536740254" CI_START="-2.039987161550896" DF="4.0" EFFECT_SIZE="-1.6668309576124607" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" NO="1" P_CHI2="0.6407493461516368" P_Z="2.043651437647746E-18" STUDIES="5" TAU2="0.0" TOTAL_1="78" TOTAL_2="85" WEIGHT="77.84437079332355" Z="8.754855502217035">
<NAME>in %</NAME>
<CONT_DATA CI_END="-1.1746961819495847" CI_START="-2.5474474143989427" EFFECT_SIZE="-1.8610717981742637" ESTIMABLE="YES" MEAN_1="34.8" MEAN_2="91.0" ORDER="17028" SD_1="38.5" SD_2="16.8" SE="0.350198075902783" STUDY_ID="STD-Kurtis-1999-A" TOTAL_1="24" TOTAL_2="24" WEIGHT="23.00831699625586"/>
<CONT_DATA CI_END="-0.6825086283884472" CI_START="-2.537209260536306" EFFECT_SIZE="-1.6098589444623768" ESTIMABLE="YES" MEAN_1="47.33" MEAN_2="88.0" ORDER="17029" SD_1="29.97" SD_2="14.32" SE="0.47314661054425006" STUDY_ID="STD-Lander-1997" TOTAL_1="14" TOTAL_2="11" WEIGHT="12.604362844760066"/>
<CONT_DATA CI_END="-0.5867958388418782" CI_START="-2.294668351074186" EFFECT_SIZE="-1.440732094958032" ESTIMABLE="YES" MEAN_1="23.0" MEAN_2="71.1" ORDER="17030" SD_1="33.98" SD_2="31.75" SE="0.4356897692263194" STUDY_ID="STD-Stang-1988-A" TOTAL_1="10" TOTAL_2="20" WEIGHT="14.864751021232985"/>
<CONT_DATA CI_END="-0.4324342979672795" CI_START="-2.09891277678796" EFFECT_SIZE="-1.2656735373776198" ESTIMABLE="YES" MEAN_1="23.0" MEAN_2="68.0" ORDER="17031" SD_1="33.98" SD_2="34.88" SE="0.425129872784819" STUDY_ID="STD-Stang-1988-B" TOTAL_1="10" TOTAL_2="20" WEIGHT="15.612380162405355"/>
<CONT_DATA CI_END="-1.2061684137766961" CI_START="-3.1267425855945667" EFFECT_SIZE="-2.1664554996856316" ESTIMABLE="YES" MEAN_1="16.7" MEAN_2="93.1" ORDER="17032" SD_1="40.3" SD_2="15.3" SE="0.48995139374170005" STUDY_ID="STD-Williamson-1983" TOTAL_1="20" TOTAL_2="10" WEIGHT="11.75455976866928"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.2701873345325678" CI_START="-2.66910522488697" DF="0.0" EFFECT_SIZE="-1.969646279709769" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" NO="2" P_CHI2="1.0" P_Z="3.405964131836399E-8" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="22.155629206676455" Z="5.519174209054471">
<NAME>in seconds</NAME>
<CONT_DATA CI_END="-1.2701873345325678" CI_START="-2.66910522488697" EFFECT_SIZE="-1.969646279709769" ESTIMABLE="YES" MEAN_1="90.0" MEAN_2="225.0" ORDER="17033" SD_1="87.0" SD_2="39.0" SE="0.3568733663957317" STUDY_ID="STD-Kass-2001" TOTAL_1="24" TOTAL_2="24" WEIGHT="22.155629206676455"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="26.091658390489755" CI_END="-1.3847577928663204" CI_START="-1.8899763214359016" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-1.637367057151111" ESTIMABLE="YES" I2="73.17150218956012" I2_Q="33.56050178556918" ID="CMP-001.03" NO="3" P_CHI2="4.8502369339364915E-4" P_Q="0.22198877802644656" P_Z="5.60910655303037E-37" Q="3.0102575331696215" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="183" TOTAL_2="165" UNITS="" WEIGHT="100.0" Z="12.704128134708865">
<NAME>Heart rate (by unit)</NAME>
<GROUP_LABEL_1>DPNB</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment or sham</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DPNB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.8924095110858177" CI_END="-1.2101538566713073" CI_START="-1.9988991156718674" DF="2.0" EFFECT_SIZE="-1.6045264861715873" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.01" NO="1" P_CHI2="0.38821165627623677" P_Z="1.5334612454458506E-15" STUDIES="3" TAU2="0.0" TOTAL_1="65" TOTAL_2="70" WEIGHT="41.02844107187435" Z="7.974220039361739">
<NAME>in bpm</NAME>
<CONT_DATA CI_END="-0.8928815223200877" CI_START="-2.1857722072284185" EFFECT_SIZE="-1.539326864774253" ESTIMABLE="YES" MEAN_1="131.45" MEAN_2="156.75" ORDER="17034" SD_1="19.41" SD_2="12.98" SE="0.32982511288638144" STUDY_ID="STD-Arnett-1990" TOTAL_1="22" TOTAL_2="27" WEIGHT="15.269855469041502"/>
<CONT_DATA CI_END="-0.5904605707193633" CI_START="-2.0035870047954987" EFFECT_SIZE="-1.2970237877574309" ESTIMABLE="YES" MEAN_1="159.46" MEAN_2="180.77" ORDER="17035" SD_1="15.37" SD_2="16.77" SE="0.360498061500797" STUDY_ID="STD-Holliday-1999" TOTAL_1="19" TOTAL_2="19" WEIGHT="12.781931873086284"/>
<CONT_DATA CI_END="-1.2828944779632585" CI_START="-2.6853784658585997" EFFECT_SIZE="-1.9841364719109291" ESTIMABLE="YES" MEAN_1="133.03" MEAN_2="178.76" ORDER="17036" SD_1="22.19" SD_2="23.14" SE="0.3577831018727782" STUDY_ID="STD-Kass-2001" TOTAL_1="24" TOTAL_2="24" WEIGHT="12.97665372974656"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.889171795703255" CI_END="-1.0837313382196512" CI_START="-1.865571548384632" DF="2.0" EFFECT_SIZE="-1.4746514433021416" ESTIMABLE="YES" I2="48.57516959755817" ID="CMP-001.03.02" NO="2" P_CHI2="0.14304659833245037" P_Z="1.43024676299324E-13" STUDIES="3" TAU2="0.0" TOTAL_1="74" TOTAL_2="61" WEIGHT="41.75635049280529" Z="7.393489567420218">
<NAME>in bpm change-from-baseline</NAME>
<CONT_DATA CI_END="-1.0568127557748905" CI_START="-2.0639002233917894" EFFECT_SIZE="-1.56035648958334" ESTIMABLE="YES" MEAN_1="9.7" MEAN_2="36.8" ORDER="17037" SD_1="17.3" SD_2="17.1" SE="0.25691478913915666" STUDY_ID="STD-Herschel-1998" TOTAL_1="40" TOTAL_2="40" WEIGHT="25.166577384047507"/>
<CONT_DATA CI_END="0.012851476333743728" CI_START="-1.641330594511983" EFFECT_SIZE="-0.8142395590891196" ESTIMABLE="YES" MEAN_1="21.86" MEAN_2="46.7" ORDER="17038" SD_1="26.04" SD_2="33.47" SE="0.42199297637449046" STUDY_ID="STD-Lander-1997" TOTAL_1="14" TOTAL_2="11" WEIGHT="9.328072666736904"/>
<CONT_DATA CI_END="-1.0885529627891013" CI_START="-2.9633752382139726" EFFECT_SIZE="-2.025964100501537" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="54.1" ORDER="17039" SD_1="26.9" SD_2="17.8" SE="0.4782797771319346" STUDY_ID="STD-Williamson-1983" TOTAL_1="20" TOTAL_2="10" WEIGHT="7.261700442020876"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="17.299819550531062" CI_END="-1.5014838681041565" CI_START="-2.7191357014127804" DF="1.0" EFFECT_SIZE="-2.1103097847584684" ESTIMABLE="YES" I2="94.2195928860466" ID="CMP-001.03.03" NO="3" P_CHI2="3.192215976843826E-5" P_Z="1.0935512960226792E-11" STUDIES="2" TAU2="0.0" TOTAL_1="44" TOTAL_2="34" WEIGHT="17.215208435320363" Z="6.793618768856622">
<NAME>in % change-from-baseline</NAME>
<CONT_DATA CI_END="-0.9351011188031266" CI_START="-2.2473516433050094" EFFECT_SIZE="-1.591226381054068" ESTIMABLE="YES" MEAN_1="13.3" MEAN_2="32.1" ORDER="17040" SD_1="12.3" SD_2="10.9" SE="0.334763938228648" STUDY_ID="STD-Kurtis-1999-A" TOTAL_1="24" TOTAL_2="24" WEIGHT="14.822621852744625"/>
<CONT_DATA CI_END="-3.693040339737598" CI_START="-6.959260372839781" EFFECT_SIZE="-5.326150356288689" ESTIMABLE="YES" MEAN_1="3.1" MEAN_2="33.3" ORDER="17041" SD_1="4.05" SD_2="7.75" SE="0.833234707082811" STUDY_ID="STD-Maxwell-1987" TOTAL_1="20" TOTAL_2="10" WEIGHT="2.3925865825757384"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="28.120908977355036" CI_END="-1.3786634083197828" CI_START="-1.9284864273130524" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-1.6535749178164176" ESTIMABLE="YES" I2="78.66356309879019" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="8.91622504103351E-5" P_Q="0.5481164661061988" P_Z="4.444932421818478E-32" Q="1.2025358779887938" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="161" TOTAL_2="138" UNITS="" WEIGHT="300.0" Z="11.789056378880458">
<NAME>Heart rate (by wait time)</NAME>
<GROUP_LABEL_1>DPNB</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment or sham</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DPNB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.7684775766440651" CI_END="-1.2741078508424657" CI_START="-2.009085663002375" DF="2.0" EFFECT_SIZE="-1.6415967569224204" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.01" NO="1" P_CHI2="0.6809689758196824" P_Z="2.035863415086571E-18" STUDIES="3" TAU2="0.0" TOTAL_1="84" TOTAL_2="74" WEIGHT="100.0" Z="8.755286125578092">
<NAME>wait time after anesthetic administration &lt;/= 5 min</NAME>
<CONT_DATA CI_END="-1.0568127557748905" CI_START="-2.0639002233917894" EFFECT_SIZE="-1.56035648958334" ESTIMABLE="YES" MEAN_1="9.7" MEAN_2="36.8" ORDER="17042" SD_1="17.3" SD_2="17.1" SE="0.25691478913915666" STUDY_ID="STD-Herschel-1998" TOTAL_1="40" TOTAL_2="40" WEIGHT="53.261583493894896"/>
<CONT_DATA CI_END="-0.9351011188031266" CI_START="-2.2473516433050094" EFFECT_SIZE="-1.591226381054068" ESTIMABLE="YES" MEAN_1="13.3" MEAN_2="32.1" ORDER="17043" SD_1="12.3" SD_2="10.9" SE="0.334763938228648" STUDY_ID="STD-Kurtis-1999-A" TOTAL_1="24" TOTAL_2="24" WEIGHT="31.370030948619146"/>
<CONT_DATA CI_END="-1.0885529627891013" CI_START="-2.9633752382139726" EFFECT_SIZE="-2.025964100501537" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="54.1" ORDER="17044" SD_1="26.9" SD_2="17.8" SE="0.4782797771319346" STUDY_ID="STD-Williamson-1983" TOTAL_1="20" TOTAL_2="10" WEIGHT="15.368385557485956"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="26.149895522722176" CI_END="-0.986299624340817" CI_START="-2.013184785584927" DF="2.0" EFFECT_SIZE="-1.4997422049628721" ESTIMABLE="YES" I2="92.35178588663133" ID="CMP-001.04.02" NO="2" P_CHI2="2.097130153311255E-6" P_Z="1.0345518080143338E-8" STUDIES="3" TAU2="0.0" TOTAL_1="53" TOTAL_2="40" WEIGHT="100.0" Z="5.7249648135156095">
<NAME>wait time after anesthetic administration &gt; 5 min</NAME>
<CONT_DATA CI_END="-0.5904605707193633" CI_START="-2.0035870047954987" EFFECT_SIZE="-1.2970237877574309" ESTIMABLE="YES" MEAN_1="159.46" MEAN_2="180.77" ORDER="17045" SD_1="15.37" SD_2="16.77" SE="0.360498061500797" STUDY_ID="STD-Holliday-1999" TOTAL_1="19" TOTAL_2="19" WEIGHT="52.80581083621952"/>
<CONT_DATA CI_END="0.012851476333743728" CI_START="-1.641330594511983" EFFECT_SIZE="-0.8142395590891196" ESTIMABLE="YES" MEAN_1="21.86" MEAN_2="46.7" ORDER="17046" SD_1="26.04" SD_2="33.47" SE="0.42199297637449046" STUDY_ID="STD-Lander-1997" TOTAL_1="14" TOTAL_2="11" WEIGHT="38.53693210049028"/>
<CONT_DATA CI_END="-4.042666206861381" CI_START="-7.53271679064851" EFFECT_SIZE="-5.7876914987549455" ESTIMABLE="YES" MEAN_1="3.1" MEAN_2="33.3" ORDER="17047" SD_1="4.05" SD_2="6.75" SE="0.8903353865979688" STUDY_ID="STD-Maxwell-1987" TOTAL_1="20" TOTAL_2="10" WEIGHT="8.657257063290189"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.2828944779632585" CI_START="-2.6853784658585997" DF="0.0" EFFECT_SIZE="-1.9841364719109291" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.03" NO="3" P_CHI2="1.0" P_Z="2.928799856513263E-8" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0" Z="5.545640533399075">
<NAME>wait time after anesthetic administration - other wait time reported</NAME>
<CONT_DATA CI_END="-1.2828944779632585" CI_START="-2.6853784658585997" EFFECT_SIZE="-1.9841364719109291" ESTIMABLE="YES" MEAN_1="133.03" MEAN_2="178.76" ORDER="17048" SD_1="22.19" SD_2="23.14" SE="0.3577831018727782" STUDY_ID="STD-Kass-2001" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="32.69086532725485" CI_END="-1.4135322738511167" CI_START="-1.925026539766712" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-1.6692794068089143" ESTIMABLE="YES" I2="75.5283320893611" I2_Q="68.84566799488104" ID="CMP-001.05" NO="5" P_CHI2="7.00080180310314E-5" P_Q="0.07319729468615033" P_Z="1.7982381039738598E-37" Q="3.2098264852402885" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="183" TOTAL_2="165" UNITS="" WEIGHT="200.0" Z="12.792821876989507">
<NAME>Heart rate (by clamp)</NAME>
<GROUP_LABEL_1>DPNB</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment or sham</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DPNB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="29.48103884201456" CI_END="-1.338830100726173" CI_START="-1.8697277250802897" DF="7.0" EFFECT_SIZE="-1.6042789129032313" ESTIMABLE="YES" I2="76.25592490986433" ID="CMP-001.05.01" NO="1" P_CHI2="1.1819182334615874E-4" P_Z="2.2751983503510204E-32" STUDIES="8" TAU2="0.0" TOTAL_1="167" TOTAL_2="149" WEIGHT="100.00000000000001" Z="11.845330422311656">
<NAME>Gomco</NAME>
<CONT_DATA CI_END="-0.8928815223200877" CI_START="-2.1857722072284185" EFFECT_SIZE="-1.539326864774253" ESTIMABLE="YES" MEAN_1="131.45" MEAN_2="156.75" ORDER="17049" SD_1="19.41" SD_2="12.98" SE="0.32982511288638144" STUDY_ID="STD-Arnett-1990" TOTAL_1="22" TOTAL_2="27" WEIGHT="16.86156771920982"/>
<CONT_DATA CI_END="-1.0568127557748905" CI_START="-2.0639002233917894" EFFECT_SIZE="-1.56035648958334" ESTIMABLE="YES" MEAN_1="9.7" MEAN_2="36.8" ORDER="17050" SD_1="17.3" SD_2="17.1" SE="0.25691478913915666" STUDY_ID="STD-Herschel-1998" TOTAL_1="40" TOTAL_2="40" WEIGHT="27.789912594928307"/>
<CONT_DATA CI_END="-0.5904605707193633" CI_START="-2.0035870047954987" EFFECT_SIZE="-1.2970237877574309" ESTIMABLE="YES" MEAN_1="159.46" MEAN_2="180.77" ORDER="17051" SD_1="15.37" SD_2="16.77" SE="0.360498061500797" STUDY_ID="STD-Holliday-1999" TOTAL_1="19" TOTAL_2="19" WEIGHT="14.11430581627498"/>
<CONT_DATA CI_END="-1.2828944779632585" CI_START="-2.6853784658585997" EFFECT_SIZE="-1.9841364719109291" ESTIMABLE="YES" MEAN_1="133.03" MEAN_2="178.76" ORDER="17052" SD_1="22.19" SD_2="23.14" SE="0.3577831018727782" STUDY_ID="STD-Kass-2001" TOTAL_1="24" TOTAL_2="24" WEIGHT="14.329325256317762"/>
<CONT_DATA CI_END="0.047919713156512556" CI_START="-2.071969392895207" EFFECT_SIZE="-1.0120248398693474" ESTIMABLE="YES" MEAN_1="23.7" MEAN_2="37.9" ORDER="17053" SD_1="13.9" SD_2="12.6" SE="0.5407979745477811" STUDY_ID="STD-Kurtis-1999-B" TOTAL_1="8" TOTAL_2="8" WEIGHT="6.271844437083805"/>
<CONT_DATA CI_END="0.012851476333743728" CI_START="-1.641330594511983" EFFECT_SIZE="-0.8142395590891196" ESTIMABLE="YES" MEAN_1="21.86" MEAN_2="46.7" ORDER="17054" SD_1="26.04" SD_2="33.47" SE="0.42199297637449046" STUDY_ID="STD-Lander-1997" TOTAL_1="14" TOTAL_2="11" WEIGHT="10.300420280910974"/>
<CONT_DATA CI_END="-4.042666206861381" CI_START="-7.53271679064851" EFFECT_SIZE="-5.7876914987549455" ESTIMABLE="YES" MEAN_1="3.1" MEAN_2="33.3" ORDER="17055" SD_1="4.05" SD_2="6.75" SE="0.8903353865979688" STUDY_ID="STD-Maxwell-1987" TOTAL_1="20" TOTAL_2="10" WEIGHT="2.3139721137957303"/>
<CONT_DATA CI_END="-1.0885529627891013" CI_START="-2.9633752382139726" EFFECT_SIZE="-2.025964100501537" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="54.1" ORDER="17056" SD_1="26.9" SD_2="17.8" SE="0.4782797771319346" STUDY_ID="STD-Williamson-1983" TOTAL_1="20" TOTAL_2="10" WEIGHT="8.018651781478633"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.5553732185631155" CI_START="-3.4647761553485115" DF="0.0" EFFECT_SIZE="-2.5100746869558135" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.02" NO="2" P_CHI2="1.0" P_Z="2.5623837158166403E-7" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="5.1530830817947795">
<NAME>Mogen</NAME>
<CONT_DATA CI_END="-1.5553732185631155" CI_START="-3.4647761553485115" EFFECT_SIZE="-2.5100746869558135" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="29.1" ORDER="17057" SD_1="7.3" SD_2="9.0" SE="0.48710153651968163" STUDY_ID="STD-Kurtis-1999-A" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="145.60151336654113" CI_END="3.728859235043198" CI_START="2.6910397702520132" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="MD" EFFECT_SIZE="3.2099495026476057" ESTIMABLE="YES" I2="96.56596975924772" I2_Q="98.52503764890116" ID="CMP-001.06" NO="6" P_CHI2="8.881784197001252E-16" P_Q="5.551115123125783E-16" P_Z="7.858716207669334E-34" Q="67.79834070035835" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="149" TOTAL_2="144" UNITS="" WEIGHT="100.0" Z="12.124238619184943">
<NAME>Oxygen saturation (by unit)</NAME>
<GROUP_LABEL_1>DPNB</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment or sham</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours no treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DPNB</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="76.85631038039804" CI_END="6.2329743547004215" CI_START="4.733532463199993" DF="3.0" EFFECT_SIZE="5.483253408950207" ESTIMABLE="YES" I2="96.09661199561677" ID="CMP-001.06.01" NO="1" P_CHI2="3.3306690738754696E-16" P_Z="1.3293576369427946E-46" STUDIES="4" TAU2="0.0" TOTAL_1="85" TOTAL_2="80" WEIGHT="47.90538597217397" Z="14.334639122153428">
<NAME>in %</NAME>
<CONT_DATA CI_END="4.306354832166797" CI_START="0.9536451678332227" EFFECT_SIZE="2.6300000000000097" ESTIMABLE="YES" MEAN_1="96.18" MEAN_2="93.55" ORDER="17058" SD_1="2.54" SD_2="3.44" SE="0.8552987939521643" STUDY_ID="STD-Arnett-1990" TOTAL_1="22" TOTAL_2="27" WEIGHT="9.581902138486488"/>
<CONT_DATA CI_END="4.0840073093400955" CI_START="0.9159926906599047" EFFECT_SIZE="2.5" ESTIMABLE="YES" MEAN_1="97.8" MEAN_2="95.3" ORDER="17059" SD_1="2.0" SD_2="2.9" SE="0.8081818450923296" STUDY_ID="STD-Holliday-1999" TOTAL_1="19" TOTAL_2="19" WEIGHT="10.731718436477541"/>
<CONT_DATA CI_END="4.861132066880092" CI_START="1.1788679331199" EFFECT_SIZE="3.019999999999996" ESTIMABLE="YES" MEAN_1="98.2" MEAN_2="95.18" ORDER="17060" SD_1="2.24" SD_2="4.02" SE="0.9393703564977269" STUDY_ID="STD-Kass-2001" TOTAL_1="24" TOTAL_2="24" WEIGHT="7.943533803998369"/>
<CONT_DATA CI_END="10.670658120154057" CI_START="8.329341879845943" EFFECT_SIZE="9.5" ESTIMABLE="YES" MEAN_1="91.7" MEAN_2="82.2" ORDER="17061" SD_1="1.3" SD_2="1.65" SE="0.5972855263607181" STUDY_ID="STD-Maxwell-1987" TOTAL_1="20" TOTAL_2="10" WEIGHT="19.648231593211563"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.9468622857847369" CI_END="1.8383996242223248" CI_START="0.40051049783414105" DF="1.0" EFFECT_SIZE="1.119455061028233" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.02" NO="2" P_CHI2="0.3305194358254335" P_Z="0.002274561313483849" STUDIES="2" TAU2="0.0" TOTAL_1="64" TOTAL_2="64" WEIGHT="52.09461402782604" Z="3.051823067106345">
<NAME>in % change-from-baseline</NAME>
<CONT_DATA CI_END="3.0726745978382746" CI_START="0.32732540216172534" EFFECT_SIZE="1.7" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="-2.5" ORDER="17062" SD_1="2.1" SD_2="3.9" SE="0.7003570517957252" STUDY_ID="STD-Herschel-1998" TOTAL_1="40" TOTAL_2="40" WEIGHT="14.290533375898523"/>
<CONT_DATA CI_END="1.7439611896706917" CI_START="0.05603881032930824" EFFECT_SIZE="0.8999999999999999" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="-1.9" ORDER="17063" SD_1="1.1" SD_2="1.8" SE="0.4306003560921271" STUDY_ID="STD-Kurtis-1999-A" TOTAL_1="24" TOTAL_2="24" WEIGHT="37.804080651927514"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="16.852476501060877" CI_START="1.747523498939124" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="9.3" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.01580148838426905" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="2.4134686223336295">
<NAME>Transcutaneous oxygen saturation - change from baseline</NAME>
<GROUP_LABEL_1>DPNB</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment or sham</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours no treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DPNB</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="16.852476501060877" CI_START="1.747523498939124" DF="0.0" EFFECT_SIZE="9.3" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.01" NO="1" P_CHI2="1.0" P_Z="0.01580148838426905" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="10" WEIGHT="100.0" Z="2.4134686223336295">
<NAME>torr (TcpO2)</NAME>
<CONT_DATA CI_END="16.852476501060877" CI_START="1.7475234989391248" EFFECT_SIZE="9.3" ESTIMABLE="YES" MEAN_1="4.6" MEAN_2="-4.7" ORDER="17064" SD_1="8.5" SD_2="10.6" SE="3.853375143948484" STUDY_ID="STD-Williamson-1983" TOTAL_1="20" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.3952736972279585" CI_END="0.36187189617916343" CI_START="-0.5020845360713192" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.0701063199460779" ESTIMABLE="YES" I2="68.72690529465685" I2_Q="81.95984151516056" ID="CMP-001.08" NO="8" P_CHI2="0.04085869838436529" P_Q="0.01855285467828882" P_Z="0.7504203367500745" Q="5.543188552586046" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="43" TOTAL_2="43" UNITS="" WEIGHT="100.0" Z="0.318085165070262">
<NAME>Respiratory rate (by unit)</NAME>
<GROUP_LABEL_1>DPNB</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment or sham</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DPNB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.006563029027321088" CI_START="-1.3165956615504424" DF="0.0" EFFECT_SIZE="-0.6615793452888817" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.01" NO="1" P_CHI2="1.0" P_Z="0.04774825435972601" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="43.493009210078846" Z="1.9796021221004378">
<NAME>rpm</NAME>
<CONT_DATA CI_END="-0.006563029027321088" CI_START="-1.3165956615504424" EFFECT_SIZE="-0.6615793452888817" ESTIMABLE="YES" MEAN_1="53.6" MEAN_2="64.43" ORDER="17065" SD_1="19.91" SD_2="10.83" SE="0.33419813906186324" STUDY_ID="STD-Holliday-1999" TOTAL_1="19" TOTAL_2="19" WEIGHT="43.493009210078846"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.8520851446419123" CI_END="0.9598057742934826" CI_START="-0.18951366498083078" DF="1.0" EFFECT_SIZE="0.3851460546563259" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.02" NO="2" P_CHI2="0.3559632104351491" P_Z="0.18898120719606884" STUDIES="2" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="56.50699078992115" Z="1.3135989353677417">
<NAME>in % change-from-baseline</NAME>
<CONT_DATA CI_END="1.2905047313122515" CI_START="-0.12836019687804134" EFFECT_SIZE="0.581072267217105" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="-4.5" ORDER="17066" SD_1="6.7" SD_2="9.5" SE="0.36196198996056006" STUDY_ID="STD-Kurtis-1999-A" TOTAL_1="16" TOTAL_2="16" WEIGHT="37.07674303132769"/>
<CONT_DATA CI_END="0.9912725497860291" CI_START="-0.9687121139415649" EFFECT_SIZE="0.01128021792223213" ESTIMABLE="YES" MEAN_1="5.1" MEAN_2="5.0" ORDER="17067" SD_1="5.5" SD_2="10.5" SE="0.5000052753998805" STUDY_ID="STD-Kurtis-1999-B" TOTAL_1="8" TOTAL_2="8" WEIGHT="19.430247758593463"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="12.038971869647657" CI_END="-0.1309156992370507" CI_START="-1.1838169682294009" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.6573663337332258" ESTIMABLE="YES" I2="91.69364285565636" I2_Q="91.69364285565636" ID="CMP-001.09" NO="9" P_CHI2="5.210000146851357E-4" P_Q="5.210000146851357E-4" P_Z="0.014390693402195676" Q="12.038971869647657" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="39" TOTAL_2="29" UNITS="" WEIGHT="100.0" Z="2.4473602164033887">
<NAME>Systolic blood pressure (by unit)</NAME>
<GROUP_LABEL_1>DPNB</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment or sham</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DPNB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6100665148137085" CI_START="-0.661785358034251" DF="0.0" EFFECT_SIZE="-0.025859421610271268" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.01" NO="1" P_CHI2="1.0" P_Z="0.9364755619343896" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="68.53339250223542" Z="0.07970037407528716">
<NAME>in mmHg</NAME>
<CONT_DATA CI_END="0.6100665148137085" CI_START="-0.661785358034251" EFFECT_SIZE="-0.025859421610271268" ESTIMABLE="YES" MEAN_1="89.59" MEAN_2="89.95" ORDER="17068" SD_1="13.97" SD_2="13.28" SE="0.3244579703709264" STUDY_ID="STD-Holliday-1999" TOTAL_1="19" TOTAL_2="19" WEIGHT="68.53339250223542"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.0942741801525409" CI_START="-2.9712673299558596" DF="0.0" EFFECT_SIZE="-2.0327707550542002" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.02" NO="2" P_CHI2="1.0" P_Z="2.1834476790569982E-5" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="10" WEIGHT="31.46660749776459" Z="4.245255204207865">
<NAME>in % change-from-baseline</NAME>
<CONT_DATA CI_END="-1.0942741801525409" CI_START="-2.9712673299558596" EFFECT_SIZE="-2.0327707550542002" ESTIMABLE="YES" MEAN_1="5.4" MEAN_2="15.0" ORDER="17069" SD_1="3.75" SD_2="6.0" SE="0.47883358179252294" STUDY_ID="STD-Maxwell-1987" TOTAL_1="20" TOTAL_2="10" WEIGHT="31.46660749776459"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.7760372642168063" CI_END="1.9113420706738253" CI_START="-142.1238459436251" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-70.10625193647564" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.10" NO="10" P_CHI2="0.4274599053536512" P_Q="1.0" P_Z="0.05639810902431985" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="62" UNITS="" WEIGHT="100.0" Z="1.90794667304413">
<NAME>Serum cortisol (nmol/dL) 30 min post</NAME>
<GROUP_LABEL_1>DPNB</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment or sham</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DPNB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="174.8488972928435" CI_START="-141.7288972928436" EFFECT_SIZE="16.559999999999945" ESTIMABLE="YES" MEAN_1="549.04" MEAN_2="532.48" ORDER="17070" SD_1="121.39" SD_2="209.68" SE="80.7611254805732" STUDY_ID="STD-Masciello-1990" TOTAL_1="9" TOTAL_2="9" WEIGHT="20.700284251576473"/>
<CONT_DATA CI_END="38.87467014785983" CI_START="-188.87467014785983" EFFECT_SIZE="-75.0" ESTIMABLE="YES" MEAN_1="386.0" MEAN_2="461.0" ORDER="17071" SD_1="160.99" SD_2="125.21" SE="58.10038911229425" STUDY_ID="STD-Stang-1988-A" TOTAL_1="10" TOTAL_2="20" WEIGHT="39.996588733644884"/>
<CONT_DATA CI_END="-14.117583517917353" CI_START="-277.88241648208265" EFFECT_SIZE="-146.0" ESTIMABLE="YES" MEAN_1="386.0" MEAN_2="532.0" ORDER="17072" SD_1="160.99" SD_2="196.77" SE="67.28818362090034" STUDY_ID="STD-Stang-1988-B" TOTAL_1="10" TOTAL_2="20" WEIGHT="29.819710587878784"/>
<CONT_DATA CI_END="233.86013580077625" CI_START="-233.86013580077625" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="631.81" MEAN_2="631.81" ORDER="17073" SD_1="256.03" SD_2="328.04" SE="119.31858832378306" STUDY_ID="STD-Williamson-1986" TOTAL_1="11" TOTAL_2="13" WEIGHT="9.48341642689985"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.002228835949165564" CI_START="-1.0777711640508345" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.54" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.11" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.04905800382878558" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="24" UNITS="" WEIGHT="100.0" Z="1.9680872133032083">
<NAME>Salivary cortisol increase (ug/dL) from baseline to 30 min post</NAME>
<GROUP_LABEL_1>DPNB</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment or sham</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DPNB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.002228835949165564" CI_START="-1.0777711640508345" EFFECT_SIZE="-0.54" ESTIMABLE="YES" MEAN_1="0.52" MEAN_2="1.06" ORDER="17074" SD_1="0.98" SD_2="0.92" SE="0.2743780846447714" STUDY_ID="STD-Kurtis-1999-A" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="115.45254181838689" CI_START="-73.45254181838689" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="21.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.12" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.6630062289543363" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="19" UNITS="" WEIGHT="100.0" Z="0.43576639530233113">
<NAME>B-endorphin (pmol/L)</NAME>
<GROUP_LABEL_1>DPNB</GROUP_LABEL_1>
<GROUP_LABEL_2>no treatment or sham</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DPNB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="115.45254181838689" CI_START="-73.45254181838689" EFFECT_SIZE="21.0" ESTIMABLE="YES" MEAN_1="326.0" MEAN_2="305.0" ORDER="17075" SD_1="165.0" SD_2="130.0" SE="48.19095787647961" STUDY_ID="STD-Holliday-1999" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Ring block versus no treatment</NAME>
<CONT_OUTCOME CHI2="2.923426478036628" CI_END="-0.6938264823430754" CI_START="-1.8040784089259554" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-1.2489524456345154" ESTIMABLE="YES" I2="65.793564246856" I2_Q="65.793564246856" ID="CMP-002.01" NO="1" P_CHI2="0.08730244916740304" P_Q="0.08730244916740304" P_Z="1.0354591046722432E-5" Q="2.923426478036628" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="31" UNITS="" WEIGHT="100.0" Z="4.409633080990894">
<NAME>Cry time (by unit)</NAME>
<GROUP_LABEL_1>Ring block</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ring block</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.9761043189347469" CI_START="-3.0529395923156897" DF="0.0" EFFECT_SIZE="-2.0145219556252183" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.01" NO="1" P_CHI2="1.0" P_Z="1.4335056886055246E-4" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="11" WEIGHT="28.578469600929367" Z="3.80231454049114">
<NAME>in %</NAME>
<CONT_DATA CI_END="-0.9761043189347469" CI_START="-3.0529395923156897" EFFECT_SIZE="-2.0145219556252183" ESTIMABLE="YES" MEAN_1="41.0" MEAN_2="88.0" ORDER="17076" SD_1="27.91" SD_2="14.32" SE="0.5298146521473748" STUDY_ID="STD-Lander-1997" TOTAL_1="12" TOTAL_2="11" WEIGHT="28.578469600929367"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.097394335024289E-31" CI_END="-0.28575270582956136" CI_START="-1.5994852530335404" DF="0.0" EFFECT_SIZE="-0.9426189794315509" ESTIMABLE="YES" I2="100.0" ID="CMP-002.01.02" NO="2" P_CHI2="0.0" P_Z="0.00491433988677567" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="71.42153039907063" Z="2.8125956912033274">
<NAME>in seconds</NAME>
<CONT_DATA CI_END="-0.28575270582956125" CI_START="-1.5994852530335404" EFFECT_SIZE="-0.9426189794315508" ESTIMABLE="YES" MEAN_1="258.6" MEAN_2="377.4" ORDER="17077" SD_1="115.8" SD_2="130.8" SE="0.33514201219168666" STUDY_ID="STD-Hardwick-Smith-1998" TOTAL_1="20" TOTAL_2="20" WEIGHT="71.42153039907063"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-5.5969865380367025" CI_START="-52.943013461963304" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-29.270000000000003" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.015377836744259948" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="11" UNITS="" WEIGHT="100.0" Z="2.4233562794894645">
<NAME>Heart rate (bpm) change-from-baseline</NAME>
<GROUP_LABEL_1>Ring block</GROUP_LABEL_1>
<GROUP_LABEL_2>No treament</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ring block</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="-5.5969865380367025" CI_START="-52.943013461963304" EFFECT_SIZE="-29.270000000000003" ESTIMABLE="YES" MEAN_1="17.43" MEAN_2="46.7" ORDER="17078" SD_1="22.99" SD_2="33.47" SE="12.078290034252165" STUDY_ID="STD-Lander-1997" TOTAL_1="12" TOTAL_2="11" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="8.61704784614237" CI_START="-0.9370478461423692" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="3.84" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.11513997673083183" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" UNITS="" WEIGHT="100.0" Z="1.5755047768071915">
<NAME>Oxygen saturation (%) change-from-baseline</NAME>
<GROUP_LABEL_1>Ring block</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours no treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ring block</GRAPH_LABEL_2>
<CONT_DATA CI_END="8.61704784614237" CI_START="-0.9370478461423692" EFFECT_SIZE="3.84" ESTIMABLE="YES" MEAN_1="-5.02" MEAN_2="-8.86" ORDER="17079" SD_1="6.0" SD_2="9.1" SE="2.4373140954747705" STUDY_ID="STD-Hardwick-Smith-1998" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.639026004675158" CI_START="-16.01902600467516" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.69" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.2802781523888238" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" UNITS="" WEIGHT="99.99999999999999" Z="1.079694742465085">
<NAME>Respiratory rate (rpm) change-from-baseline</NAME>
<GROUP_LABEL_1>Ring block</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ring block</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.639026004675158" CI_START="-16.01902600467516" EFFECT_SIZE="-5.69" ESTIMABLE="YES" MEAN_1="2.45" MEAN_2="8.14" ORDER="17080" SD_1="18.39" SD_2="14.74" SE="5.270008064509959" STUDY_ID="STD-Hardwick-Smith-1998" TOTAL_1="20" TOTAL_2="20" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>EMLA versus placebo or no treatment</NAME>
<CONT_OUTCOME CHI2="0.45445676547327685" CI_END="-0.15656355750643886" CI_START="-1.0239713547877802" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.5902674561471095" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" NO="1" P_CHI2="0.5002260996207022" P_Q="0.5002260996207022" P_Z="0.007641903976085162" Q="0.45445676547327685" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="43" TOTAL_2="43" UNITS="" WEIGHT="99.99999999999997" Z="2.6674949404891555">
<NAME>Pain score</NAME>
<GROUP_LABEL_1>EMLA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EMLA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.026826329503990443" CI_START="-1.6087090477568138" DF="0.0" EFFECT_SIZE="-0.8177676886304021" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.01" NO="1" P_CHI2="1.0" P_Z="0.042719714170866716" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="13" WEIGHT="30.067552680887296" Z="2.026440012198158">
<NAME>neonatal facial coding system (NFCS)</NAME>
<CONT_DATA CI_END="-0.026826329503990443" CI_START="-1.6087090477568138" EFFECT_SIZE="-0.8177676886304021" ESTIMABLE="YES" MEAN_1="356.75" MEAN_2="423.86" ORDER="17081" SD_1="86.98" SD_2="70.69" SE="0.40354892506457063" STUDY_ID="STD-Benini-1993" TOTAL_1="14" TOTAL_2="13" WEIGHT="30.067552680887296"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.026172199050097045" CI_START="-1.0110790306082937" DF="0.0" EFFECT_SIZE="-0.4924534157790984" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.02" NO="2" P_CHI2="1.0" P_Z="0.06273636508529465" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="30" WEIGHT="69.93244731911268" Z="1.8610553188905614">
<NAME>NFCS - author-devised summary score</NAME>
<CONT_DATA CI_END="0.026172199050097045" CI_START="-1.0110790306082937" EFFECT_SIZE="-0.4924534157790984" ESTIMABLE="YES" MEAN_1="0.86" MEAN_2="1.06" ORDER="17082" SD_1="0.47" SD_2="0.32" SE="0.26460976779167783" STUDY_ID="STD-Taddio-1997" TOTAL_1="29" TOTAL_2="30" WEIGHT="69.93244731911268"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.185456081689295" CI_END="-0.479340785585062" CI_START="-1.078208667292912" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.778774726438987" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" NO="2" P_CHI2="0.5230357702750534" P_Q="0.630627176325526" P_Z="3.441325912732141E-7" Q="0.9220809803307395" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="96" TOTAL_2="93" UNITS="" WEIGHT="99.99999999999999" Z="5.097519711818734">
<NAME>Cry time (by unit)</NAME>
<GROUP_LABEL_1>EMLA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EMLA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.1432974557046696" CI_END="-0.3286207040562827" CI_START="-1.2650205305701283" DF="2.0" EFFECT_SIZE="-0.7968206173132055" ESTIMABLE="YES" I2="36.37255054018944" ID="CMP-003.02.01" NO="1" P_CHI2="0.20770256696333755" P_Z="8.510763630424601E-4" STUDIES="3" TAU2="0.0" TOTAL_1="42" TOTAL_2="37" WEIGHT="40.90151497617654" Z="3.3356258039626283">
<NAME>in %</NAME>
<CONT_DATA CI_END="0.12329131984857222" CI_START="-1.433131053396981" EFFECT_SIZE="-0.6549198667742043" ESTIMABLE="YES" MEAN_1="77.07" MEAN_2="88.33" ORDER="17083" SD_1="19.86" SD_2="12.32" SE="0.3970538197442438" STUDY_ID="STD-Benini-1993" TOTAL_1="14" TOTAL_2="13" WEIGHT="14.804955740192717"/>
<CONT_DATA CI_END="-0.5734969729199376" CI_START="-2.3531113517795896" EFFECT_SIZE="-1.4633041623497636" ESTIMABLE="YES" MEAN_1="57.33" MEAN_2="88.0" ORDER="17084" SD_1="23.66" SD_2="14.32" SE="0.45399160211540185" STUDY_ID="STD-Lander-1997" TOTAL_1="15" TOTAL_2="11" WEIGHT="11.3242704128564"/>
<CONT_DATA CI_END="0.35095479085008746" CI_START="-1.207187540752598" EFFECT_SIZE="-0.42811637495125526" ESTIMABLE="YES" MEAN_1="66.0" MEAN_2="76.0" ORDER="17085" SD_1="24.5" SD_2="20.57" SE="0.39749259269382325" STUDY_ID="STD-Zahorodny-1998" TOTAL_1="13" TOTAL_2="13" WEIGHT="14.772288823127427"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.1200776456538855" CI_END="-0.006776536330356353" CI_START="-1.1308536240615625" DF="1.0" EFFECT_SIZE="-0.5688150801959595" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.02" NO="2" P_CHI2="0.7289503497450202" P_Z="0.047300962268488726" STUDIES="2" TAU2="0.0" TOTAL_1="25" TOTAL_2="26" WEIGHT="28.383755186997984" Z="1.9835954014462258">
<NAME>in minutes</NAME>
<CONT_DATA CI_END="0.8869385419618318" CI_START="-1.6270085313370548" EFFECT_SIZE="-0.3700349946876115" ESTIMABLE="YES" MEAN_1="7.8" MEAN_2="9.0" ORDER="17086" SD_1="2.77" SD_2="3.08" SE="0.6413248133967205" STUDY_ID="STD-Joyce-2001" TOTAL_1="5" TOTAL_2="5" WEIGHT="5.674789849476334"/>
<CONT_DATA CI_END="0.009862417689504244" CI_START="-1.2468397033031065" EFFECT_SIZE="-0.618488642806801" ESTIMABLE="YES" MEAN_1="2.58" MEAN_2="3.7" ORDER="17087" SD_1="1.75" SD_2="1.8" SE="0.32059316673809224" STUDY_ID="STD-Woodman-1999" TOTAL_1="20" TOTAL_2="21" WEIGHT="22.70896533752165"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.6220389889066908E-31" CI_END="-0.4084784204393569" CI_START="-1.4890602786406388" DF="0.0" EFFECT_SIZE="-0.9487693495399978" ESTIMABLE="YES" I2="100.0" ID="CMP-003.02.03" NO="3" P_CHI2="0.0" P_Z="5.779346743586378E-4" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="30" WEIGHT="30.714729836825462" Z="3.4417637879452667">
<NAME>percent increase in time crying</NAME>
<CONT_DATA CI_END="-0.4084784204393568" CI_START="-1.4890602786406386" EFFECT_SIZE="-0.9487693495399977" ESTIMABLE="YES" MEAN_1="21.0" MEAN_2="46.0" ORDER="17088" SD_1="27.0" SD_2="25.0" SE="0.2756637026814711" STUDY_ID="STD-Taddio-1997" TOTAL_1="29" TOTAL_2="30" WEIGHT="30.714729836825462"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.6730303405350107" CI_END="-9.838611714547346" CI_START="-19.337434733286543" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-14.588023223916943" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.03" NO="3" P_CHI2="0.6139423170210938" P_Q="0.44986340053546503" P_Z="1.7429395371565284E-9" Q="0.5709963125712099" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="73" TOTAL_2="70" UNITS="" WEIGHT="100.0" Z="6.020114295866984">
<NAME>Heart rate (by unit)</NAME>
<GROUP_LABEL_1>EMLA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo or no tx</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EMLA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.7470898682284739" CI_END="-10.10367140288266" CI_START="-21.500023334556573" DF="2.0" EFFECT_SIZE="-15.801847368719617" ESTIMABLE="YES" I2="0.0" ID="CMP-003.03.01" NO="1" P_CHI2="0.688290203240578" P_Z="5.4717458634649686E-8" STUDIES="3" TAU2="0.0" TOTAL_1="39" TOTAL_2="39" WEIGHT="69.47169378461555" Z="5.435257162568233">
<NAME>in bpm</NAME>
<CONT_DATA CI_END="-6.6616242369759435" CI_START="-22.17837576302409" EFFECT_SIZE="-14.420000000000016" ESTIMABLE="YES" MEAN_1="148.45" MEAN_2="162.87" ORDER="17089" SD_1="11.41" SD_2="9.1" SE="3.9584277181729615" STUDY_ID="STD-Benini-1993" TOTAL_1="14" TOTAL_2="13" WEIGHT="37.47468410269448"/>
<CONT_DATA CI_END="28.75560072626469" CI_START="-39.97560072626466" EFFECT_SIZE="-5.609999999999985" ESTIMABLE="YES" MEAN_1="144.02" MEAN_2="149.63" ORDER="17090" SD_1="16.03" SD_2="35.78" SE="17.533791945839894" STUDY_ID="STD-Joyce-2001" TOTAL_1="5" TOTAL_2="5" WEIGHT="1.9099927587928514"/>
<CONT_DATA CI_END="-9.511348998189586" CI_START="-26.82865100181039" EFFECT_SIZE="-18.169999999999987" ESTIMABLE="YES" MEAN_1="137.36" MEAN_2="155.53" ORDER="17091" SD_1="14.12" SD_2="14.16" SE="4.417760259937802" STUDY_ID="STD-Woodman-1999" TOTAL_1="20" TOTAL_2="21" WEIGHT="30.087016923128214"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.354944159735327" CI_END="-3.229943720654182" CI_START="-20.42162857514773" DF="1.0" EFFECT_SIZE="-11.825786147900955" ESTIMABLE="YES" I2="26.196220499940104" ID="CMP-003.03.02" NO="2" P_CHI2="0.2444157957261216" P_Z="0.007008645246068152" STUDIES="2" TAU2="0.0" TOTAL_1="34" TOTAL_2="31" WEIGHT="30.528306215384454" Z="2.696433204183622">
<NAME>in bpm change-from-baseline</NAME>
<CONT_DATA CI_END="-0.5743723455440808" CI_START="-51.625627654455926" EFFECT_SIZE="-26.1" ESTIMABLE="YES" MEAN_1="20.6" MEAN_2="46.7" ORDER="17092" SD_1="23.61" SD_2="38.17" SE="13.0235187257515" STUDY_ID="STD-Lander-1997" TOTAL_1="15" TOTAL_2="11" WEIGHT="3.4619974290017095"/>
<CONT_DATA CI_END="-0.8709563367928244" CI_START="-19.129043663207177" EFFECT_SIZE="-10.0" ESTIMABLE="YES" MEAN_1="7.0" MEAN_2="17.0" ORDER="17093" SD_1="13.0" SD_2="16.0" SE="4.657760925821039" STUDY_ID="STD-Taddio-1997" TOTAL_1="19" TOTAL_2="20" WEIGHT="27.066308786382745"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="14.129053005290377" CI_END="1.9995803581041995" CI_START="-0.1918813716951614" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.903849493204519" ESTIMABLE="YES" I2="85.84476964414293" I2_Q="0.0" ID="CMP-003.04" NO="4" P_CHI2="8.549018146982723E-4" P_Q="1.0" P_Z="0.10593431014979235" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="39" TOTAL_2="39" UNITS="" WEIGHT="100.00000000000001" Z="1.6167404888132164">
<NAME>Oxygen saturation (%)</NAME>
<GROUP_LABEL_1>EMLA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo or no tx</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EMLA</GRAPH_LABEL_2>
<CONT_DATA CI_END="8.962114132625391" CI_START="2.837885867374592" EFFECT_SIZE="5.8999999999999915" ESTIMABLE="YES" MEAN_1="92.05" MEAN_2="86.15" ORDER="17094" SD_1="2.59" SD_2="5.05" SE="1.562331837104643" STUDY_ID="STD-Benini-1993" TOTAL_1="14" TOTAL_2="13" WEIGHT="12.804571293054135"/>
<CONT_DATA CI_END="6.108399346788808" CI_START="-0.7083993467888021" EFFECT_SIZE="2.700000000000003" ESTIMABLE="YES" MEAN_1="94.4" MEAN_2="91.7" ORDER="17095" SD_1="3.22" SD_2="2.18" SE="1.7390112133048483" STUDY_ID="STD-Joyce-2001" TOTAL_1="5" TOTAL_2="5" WEIGHT="10.334913439586593"/>
<CONT_DATA CI_END="1.07983375391117" CI_START="-1.4198337539111734" EFFECT_SIZE="-0.1700000000000017" ESTIMABLE="YES" MEAN_1="97.33" MEAN_2="97.5" ORDER="17096" SD_1="1.91" SD_2="2.17" SE="0.6376820001641361" STUDY_ID="STD-Woodman-1999" TOTAL_1="20" TOTAL_2="21" WEIGHT="76.86051526735928"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="12.169542220970023" CI_START="-20.789542220970013" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.309999999999995" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.05" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.6082298207889485" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="5" TOTAL_2="5" UNITS="" WEIGHT="100.0" Z="0.5126019072676881">
<NAME>Respiratory rate (rpm)</NAME>
<GROUP_LABEL_1>EMLA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EMLA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="12.169542220970023" CI_START="-20.789542220970013" EFFECT_SIZE="-4.309999999999995" ESTIMABLE="YES" MEAN_1="48.13" MEAN_2="52.44" ORDER="17097" SD_1="12.95" SD_2="13.63" SE="8.408084205096902" STUDY_ID="STD-Joyce-2001" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="9.503719794850511" CI_START="-15.503719794850511" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.06" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.6381754045672197" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="0.4702514171856056">
<NAME>Systolic blood pressure (mmHg) change-from-baseline</NAME>
<GROUP_LABEL_1>EMLA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo or no tx</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EMLA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="9.503719794850511" CI_START="-15.503719794850511" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="11.0" MEAN_2="14.0" ORDER="17098" SD_1="17.0" SD_2="21.0" SE="6.379566100947904" STUDY_ID="STD-Taddio-1997" TOTAL_1="22" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="13.600306046911292" CI_START="-23.600306046911292" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.07" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.5982884749553579" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="0.5268633697738322">
<NAME>Diastolic blood pressure (mmHg) change-from-baseline</NAME>
<GROUP_LABEL_1>EMLA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo or no tx</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EMLA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="13.600306046911292" CI_START="-23.600306046911292" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="19.0" MEAN_2="24.0" ORDER="17099" SD_1="22.0" SD_2="33.0" SE="9.490126448051154" STUDY_ID="STD-Taddio-1997" TOTAL_1="22" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Topical lidocaine versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="6.896916496482621" CI_START="-22.89691649648262" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-8.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.29254845543898855" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="12" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="1.0525474771925212">
<NAME>Pain score</NAME>
<GROUP_LABEL_1>Lidocaine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lidocaine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.896916496482621" CI_START="-22.89691649648262" DF="0.0" EFFECT_SIZE="-8.0" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.01" NO="1" P_CHI2="1.0" P_Z="0.29254845543898855" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="1.0525474771925212">
<NAME>% change- from-baseline in time spent in Brazelton state 6 (full cry)</NAME>
<CONT_DATA CI_END="6.896916496482621" CI_START="-22.89691649648262" EFFECT_SIZE="-8.0" ESTIMABLE="YES" MEAN_1="7.0" MEAN_2="15.0" ORDER="17100" SD_1="18.0" SD_2="20.0" SE="7.600607263188302" STUDY_ID="STD-Weatherstone-1993" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.19911876928999428" CI_END="-20.35903411818544" CI_START="-99.14423449773247" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-59.75163430795896" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.02" NO="2" P_CHI2="0.6554331020807254" P_Q="1.0" P_Z="0.002949812685290717" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="45" UNITS="" WEIGHT="100.0" Z="2.9729200585091093">
<NAME>Cry time (s)</NAME>
<GROUP_LABEL_1>Lidocaine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lidocaine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-14.480481506316359" CI_START="-121.51951849368365" EFFECT_SIZE="-68.0" ESTIMABLE="YES" MEAN_1="195.0" MEAN_2="263.0" ORDER="17101" SD_1="90.19" SD_2="90.19" SE="27.306378543605277" STUDY_ID="STD-Mudge-1989" TOTAL_1="20" TOTAL_2="24" WEIGHT="54.17574615532748"/>
<CONT_DATA CI_END="8.192490882547602" CI_START="-108.1924908825476" EFFECT_SIZE="-50.0" ESTIMABLE="YES" MEAN_1="172.0" MEAN_2="222.0" ORDER="17102" SD_1="80.67" SD_2="108.07" SE="29.690591940241017" STUDY_ID="STD-Woodman-1999" TOTAL_1="20" TOTAL_2="21" WEIGHT="45.82425384467251"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.1400864433525024" CI_END="-4.071057050764806" CI_START="-14.322355629591552" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-9.19670634017818" ESTIMABLE="YES" I2="12.287352785335173" I2_Q="0.0" ID="CMP-004.03" NO="3" P_CHI2="0.2856341047828356" P_Q="1.0" P_Z="4.36997965714686E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="45" UNITS="" WEIGHT="100.0" Z="3.5166692423475143">
<NAME>Heart rate (bpm)</NAME>
<GROUP_LABEL_1>Lidocaine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lidocaine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-4.7740844474642525" CI_START="-18.965915552535755" EFFECT_SIZE="-11.870000000000005" ESTIMABLE="YES" MEAN_1="148.4" MEAN_2="160.27" ORDER="17103" SD_1="9.75" SD_2="14.16" SE="3.620431604104682" STUDY_ID="STD-Mudge-1989" TOTAL_1="20" TOTAL_2="24" WEIGHT="52.17721538780281"/>
<CONT_DATA CI_END="1.1319325248705585" CI_START="-13.69193252487056" EFFECT_SIZE="-6.280000000000001" ESTIMABLE="YES" MEAN_1="149.25" MEAN_2="155.53" ORDER="17104" SD_1="9.75" SD_2="14.16" SE="3.7816677160064867" STUDY_ID="STD-Woodman-1999" TOTAL_1="20" TOTAL_2="21" WEIGHT="47.82278461219718"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.7498337539111717" CI_START="-1.7498337539111717" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.4329873826829723" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="45" UNITS="" WEIGHT="100.0" Z="0.7840898753160706">
<NAME>Oxygen saturation (%)</NAME>
<GROUP_LABEL_1>Lidocaine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lidocaine</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="91.43" MEAN_2="87.55" ORDER="17105" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Mudge-1989" TOTAL_1="20" TOTAL_2="24" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.7498337539111717" CI_START="-1.7498337539111717" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="97.0" MEAN_2="97.5" ORDER="17106" SD_1="1.91" SD_2="2.17" SE="0.6376820001641361" STUDY_ID="STD-Woodman-1999" TOTAL_1="20" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.05" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="24" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Respiratory rate (rpm)</NAME>
<GROUP_LABEL_1>Lidocaine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lidocaine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="41.53" MEAN_2="44.65" ORDER="17107" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Mudge-1989" TOTAL_1="20" TOTAL_2="24" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-9.265385678161088" CI_START="-88.7346143218389" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-49.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.06" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.015649371557394827" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" UNITS="" WEIGHT="100.0" Z="2.4169917559682514">
<NAME>B-endorphin (pg/mL)</NAME>
<GROUP_LABEL_1>lidocaine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lidocaine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-9.265385678161088" CI_START="-88.7346143218389" EFFECT_SIZE="-49.0" ESTIMABLE="YES" MEAN_1="65.0" MEAN_2="114.0" ORDER="17108" SD_1="57.0" SD_2="54.0" SE="20.273134932713294" STUDY_ID="STD-Weatherstone-1993" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Sucrose versus water or no treatment</NAME>
<CONT_OUTCOME CHI2="1.2282454702547287" CI_END="-0.2064572419039991" CI_START="-0.973980839094551" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5902190404992751" ESTIMABLE="YES" I2="18.58305003212366" I2_Q="18.58305003212366" ID="CMP-005.01" NO="1" P_CHI2="0.2677486007108597" P_Q="0.2677486007108597" P_Z="0.0025749582761524707" Q="1.2282454702547287" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="43" TOTAL_2="44" UNITS="" WEIGHT="200.0" Z="3.0143908711152445">
<NAME>Pain score</NAME>
<GROUP_LABEL_1>Sucrose</GROUP_LABEL_1>
<GROUP_LABEL_2>Water</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sucrose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours water</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.2611231384920293" CI_START="-1.078876861507971" DF="0.0" EFFECT_SIZE="-0.6700000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.01" NO="1" P_CHI2="1.0" P_Z="0.0013196775421689868" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="3.2116658907983644">
<NAME>behavioral distress score</NAME>
<CONT_DATA CI_END="-0.2611231384920293" CI_START="-1.078876861507971" EFFECT_SIZE="-0.6700000000000002" ESTIMABLE="YES" MEAN_1="0.45" MEAN_2="1.12" ORDER="17109" SD_1="0.8" SD_2="0.48" SE="0.20861447696648477" STUDY_ID="STD-Stang-1997" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.1121145293508228" CI_START="-1.1121145293508228" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.02" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="24" WEIGHT="100.0" Z="0.0">
<NAME>modified behavioral pain scale (MBPS)</NAME>
<CONT_DATA CI_END="1.1121145293508228" CI_START="-1.1121145293508228" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="7.63" MEAN_2="7.63" ORDER="17110" SD_1="2.13" SD_2="1.73" SE="0.5674157985162178" STUDY_ID="STD-Kass-2001" TOTAL_1="23" TOTAL_2="24" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="18.286756764014225" CI_END="0.44434473036062483" CI_START="-0.30756584092106365" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0683894447197806" ESTIMABLE="YES" I2="78.12624703429401" I2_Q="89.23379263601392" ID="CMP-005.02" NO="2" P_CHI2="0.0010845888252797309" P_Q="0.002306204282877755" P_Z="0.7214406816457252" Q="9.288321933544475" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="67" UNITS="" WEIGHT="100.0" Z="0.3565340179882834">
<NAME>Cry time (by unit)</NAME>
<GROUP_LABEL_1>Sucrose</GROUP_LABEL_1>
<GROUP_LABEL_2>Water</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sucrose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours water</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="8.998193735711265" CI_END="-0.045889717047843614" CI_START="-1.2204573665914653" DF="2.0" EFFECT_SIZE="-0.6331735418196545" ESTIMABLE="YES" I2="77.77331697068745" ID="CMP-005.02.01" NO="1" P_CHI2="0.011119048137116283" P_Z="0.03459106038010231" STUDIES="3" TAU2="0.0" TOTAL_1="23" TOTAL_2="33" WEIGHT="40.980411135462205" Z="2.1131134309928905">
<NAME>in %</NAME>
<CONT_DATA CI_END="0.20495867856447525" CI_START="-2.0798164106155905" EFFECT_SIZE="-0.9374288660255576" ESTIMABLE="YES" MEAN_1="29.2" MEAN_2="48.0" ORDER="17111" SD_1="18.66" SD_2="18.97" SE="0.5828614982729479" STUDY_ID="STD-Blass-1991-A" TOTAL_1="5" TOTAL_2="10" WEIGHT="10.830424305116276"/>
<CONT_DATA CI_END="-1.0279498402234182" CI_START="-4.039466062577334" EFFECT_SIZE="-2.5337079514003764" ESTIMABLE="YES" MEAN_1="29.2" MEAN_2="66.5" ORDER="17112" SD_1="18.66" SD_2="11.07" SE="0.7682580511959332" STUDY_ID="STD-Blass-1991-B" TOTAL_1="5" TOTAL_2="10" WEIGHT="6.233930662851483"/>
<CONT_DATA CI_END="0.768761123316062" CI_START="-0.768761123316062" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="76.0" MEAN_2="76.0" ORDER="17113" SD_1="18.66" SD_2="18.97" SE="0.3922322702763681" STUDY_ID="STD-Zahorodny-1998" TOTAL_1="13" TOTAL_2="13" WEIGHT="23.916056167494446"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.4109475848419875E-4" CI_END="1.0448924614130481" CI_START="0.06615074192394726" DF="1.0" EFFECT_SIZE="0.5555216016684977" ESTIMABLE="YES" I2="0.0" ID="CMP-005.02.02" NO="2" P_CHI2="0.9876115636618433" P_Z="0.02608780026957247" STUDIES="2" TAU2="0.0" TOTAL_1="33" TOTAL_2="34" WEIGHT="59.019588864537795" Z="2.224902260164432">
<NAME>in seconds</NAME>
<CONT_DATA CI_END="1.1367146042352383" CI_START="-0.030712754779459783" EFFECT_SIZE="0.5530009247278892" ESTIMABLE="YES" MEAN_1="256.0" MEAN_2="225.0" ORDER="17114" SD_1="68.0" SD_2="39.0" SE="0.29781857427565406" STUDY_ID="STD-Kass-2001" TOTAL_1="23" TOTAL_2="24" WEIGHT="41.48323794529697"/>
<CONT_DATA CI_END="1.4592574917966397" CI_START="-0.3362886784177328" EFFECT_SIZE="0.5614844066894534" ESTIMABLE="YES" MEAN_1="279.8" MEAN_2="242.0" ORDER="17115" SD_1="84.07" SD_2="35.31" SE="0.458055909286449" STUDY_ID="STD-Zolnoski-1993" TOTAL_1="10" TOTAL_2="10" WEIGHT="17.536350919240824"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.466503357256256" CI_END="2.0651151494996114" CI_START="-8.983395584880071" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.45914021769023" ESTIMABLE="YES" I2="55.22224344126348" I2_Q="77.35888386232962" ID="CMP-005.03" NO="3" P_CHI2="0.10717946076730689" P_Q="0.03558793268672322" P_Z="0.21971860944272104" Q="4.4167433880885225" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="72" TOTAL_2="74" UNITS="" WEIGHT="100.0" Z="1.2272767628401176">
<NAME>Heart rate (by unit)</NAME>
<GROUP_LABEL_1>Sucrose</GROUP_LABEL_1>
<GROUP_LABEL_2>Water or no tx</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sucrose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours water</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.04975996916773362" CI_END="9.779509630824805" CI_START="-5.453318549008363" DF="1.0" EFFECT_SIZE="2.1630955409082206" ESTIMABLE="YES" I2="0.0" ID="CMP-005.03.01" NO="1" P_CHI2="0.8234814738659395" P_Z="0.577774442518572" STUDIES="2" TAU2="0.0" TOTAL_1="33" TOTAL_2="34" WEIGHT="52.60734654617792" Z="0.556638505371198">
<NAME>in bpm</NAME>
<CONT_DATA CI_END="16.263727398184894" CI_START="-9.563727398184849" EFFECT_SIZE="3.3500000000000227" ESTIMABLE="YES" MEAN_1="182.11" MEAN_2="178.76" ORDER="17116" SD_1="22.03" SD_2="23.14" SE="6.58875749761052" STUDY_ID="STD-Kass-2001" TOTAL_1="23" TOTAL_2="24" WEIGHT="18.29971237219685"/>
<CONT_DATA CI_END="10.961447705340994" CI_START="-7.901447705340992" EFFECT_SIZE="1.5300000000000011" ESTIMABLE="YES" MEAN_1="172.53" MEAN_2="171.0" ORDER="17117" SD_1="10.72" SD_2="10.8" SE="4.812051537546123" STUDY_ID="STD-Zolnoski-1993" TOTAL_1="10" TOTAL_2="10" WEIGHT="34.30763417398107"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.6754953358783808" CI_START="-17.72450466412161" DF="0.0" EFFECT_SIZE="-9.699999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-005.03.02" NO="2" P_CHI2="1.0" P_Z="0.017826645526712887" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="40" WEIGHT="47.39265345382208" Z="2.3691992771892276">
<NAME>in bpm change-from-baseline</NAME>
<CONT_DATA CI_END="-1.6754953358783808" CI_START="-17.72450466412161" EFFECT_SIZE="-9.699999999999996" ESTIMABLE="YES" MEAN_1="27.1" MEAN_2="36.8" ORDER="17118" SD_1="19.2" SD_2="17.1" SE="4.094210264789498" STUDY_ID="STD-Herschel-1998" TOTAL_1="39" TOTAL_2="40" WEIGHT="47.39265345382208"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.211447855364" CI_END="3.128944983651608" CI_START="0.5135560529190948" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.8212505182853513" ESTIMABLE="YES" I2="87.821879678055" I2_Q="87.821879678055" ID="CMP-005.04" NO="4" P_CHI2="0.004162727025757151" P_Q="0.004162727025757151" P_Z="0.006339612440256596" Q="8.211447855364" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="62" TOTAL_2="64" UNITS="" WEIGHT="100.00000000000001" Z="2.7296784663414737">
<NAME>Oxygen saturation (by unit)</NAME>
<GROUP_LABEL_1>Sucrose</GROUP_LABEL_1>
<GROUP_LABEL_2>Water or no tx</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours water</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sucrose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.4057133887230138" CI_START="-3.065713388723039" DF="0.0" EFFECT_SIZE="-0.8300000000000125" ESTIMABLE="YES" I2="0.0" ID="CMP-005.04.01" NO="1" P_CHI2="1.0" P_Z="0.466840671416095" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="24" WEIGHT="34.21214594825422" Z="0.727629093860476">
<NAME>in %</NAME>
<CONT_DATA CI_END="1.4057133887230138" CI_START="-3.065713388723039" EFFECT_SIZE="-0.8300000000000125" ESTIMABLE="YES" MEAN_1="94.35" MEAN_2="95.18" ORDER="17119" SD_1="3.8" SD_2="4.02" SE="1.1406910567531077" STUDY_ID="STD-Kass-2001" TOTAL_1="23" TOTAL_2="24" WEIGHT="34.21214594825422"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.812253860469973" CI_START="1.5877461395300279" DF="0.0" EFFECT_SIZE="3.2" ESTIMABLE="YES" I2="0.0" ID="CMP-005.04.02" NO="2" P_CHI2="1.0" P_Z="1.0018857708261616E-4" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="40" WEIGHT="65.7878540517458" Z="3.890134738892744">
<NAME>in % change-from-baseline</NAME>
<CONT_DATA CI_END="4.812253860469973" CI_START="1.5877461395300279" EFFECT_SIZE="3.2" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="-2.5" ORDER="17120" SD_1="3.4" SD_2="3.9" SE="0.8225936155905031" STUDY_ID="STD-Herschel-1998" TOTAL_1="39" TOTAL_2="40" WEIGHT="65.7878540517458"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="191.73346203478968" CI_START="-53.93346203478963" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="68.90000000000003" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.05" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.2715992904326584" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" UNITS="" WEIGHT="100.0" Z="1.0993870586873347">
<NAME>Serum cortisol (nmol/dL) 30 min post</NAME>
<GROUP_LABEL_1>Sucrose</GROUP_LABEL_1>
<GROUP_LABEL_2>Water</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sucrose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours water</GRAPH_LABEL_2>
<CONT_DATA CI_END="191.73346203478968" CI_START="-53.93346203478963" EFFECT_SIZE="68.90000000000003" ESTIMABLE="YES" MEAN_1="441.1" MEAN_2="372.2" ORDER="17121" SD_1="217.8" SD_2="176.4" SE="62.671285290793264" STUDY_ID="STD-Stang-1997" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>Acetaminophen versus placebo</NAME>
<CONT_OUTCOME CHI2="4.898706969399467" CI_END="2.180726904341394" CI_START="-0.4082135165545444" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.8862566938934249" ESTIMABLE="YES" I2="79.58644992961091" I2_Q="79.58644992961091" ID="CMP-006.01" NO="1" P_CHI2="0.02687694655625994" P_Q="0.02687694655625994" P_Z="0.17963302483897836" Q="4.898706969399467" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="52" TOTAL_2="52" UNITS="" WEIGHT="200.0" Z="1.3418858055354774">
<NAME>Pain / behavior score</NAME>
<GROUP_LABEL_1>Acetaminophen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours acetamin</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.6300211323178113" CI_START="-1.230021132317811" DF="0.0" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" I2="0.0" ID="CMP-006.01.01" NO="1" P_CHI2="1.0" P_Z="0.7839948745691885" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="21" WEIGHT="100.0" Z="0.274116786143335">
<NAME>comfort score - change from baseline score at 30 min post</NAME>
<CONT_DATA CI_END="1.6300211323178113" CI_START="-1.230021132317811" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" MEAN_1="-3.5" MEAN_2="-3.7" ORDER="17122" SD_1="2.2" SD_2="2.6" SE="0.7296160253951783" STUDY_ID="STD-Howard-1994" TOTAL_1="23" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.04607478748888" CI_START="0.9539252125111157" DF="0.0" EFFECT_SIZE="3.9999999999999982" ESTIMABLE="YES" I2="0.0" ID="CMP-006.01.02" NO="2" P_CHI2="1.0" P_Z="0.010060093663958474" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="31" WEIGHT="100.0" Z="2.573756878971189">
<NAME>Nursing Child Assessment Feeding Scale (NCAFS) - total infant score</NAME>
<CONT_DATA CI_END="7.04607478748888" CI_START="0.9539252125111157" EFFECT_SIZE="3.9999999999999982" ESTIMABLE="YES" MEAN_1="16.4" MEAN_2="12.4" ORDER="17123" SD_1="6.28" SD_2="5.72" SE="1.5541483473757332" STUDY_ID="STD-Macke-2001" TOTAL_1="29" TOTAL_2="31" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.389823011927247" CI_END="4.735629759842954" CI_START="-8.258575078613127" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.7614726593850862" ESTIMABLE="YES" I2="28.048392391106344" I2_Q="0.0" ID="CMP-006.02" NO="2" P_CHI2="0.23843519546286196" P_Q="1.0" P_Z="0.5951562598854515" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="52" UNITS="" WEIGHT="100.0" Z="0.5313788746702507">
<NAME>Cry time (%)</NAME>
<GROUP_LABEL_1>Acetaminophen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acetamin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.785434720965183" CI_START="-17.285434720965185" EFFECT_SIZE="-6.75" ESTIMABLE="YES" MEAN_1="60.25" MEAN_2="67.0" ORDER="17124" SD_1="16.47" SD_2="18.95" SE="5.375320569187672" STUDY_ID="STD-Howard-1994" TOTAL_1="23" TOTAL_2="21" WEIGHT="38.03071626565333"/>
<CONT_DATA CI_END="9.553373035086913" CI_START="-6.953373035086891" EFFECT_SIZE="1.3000000000000114" ESTIMABLE="YES" MEAN_1="70.4" MEAN_2="69.1" ORDER="17125" SD_1="16.3" SD_2="16.3" SE="4.2109819875204115" STUDY_ID="STD-Macke-2001" TOTAL_1="29" TOTAL_2="31" WEIGHT="61.96928373434667"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.009963273968083872" CI_END="7.43704693472198" CI_START="-2.8871570049898385" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.2749449648660707" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.03" NO="3" P_CHI2="0.9204902465515616" P_Q="1.0" P_Z="0.38772049958402277" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="52" UNITS="" WEIGHT="100.00000000000003" Z="0.8637586440534217">
<NAME>Heart rate (bpm)</NAME>
<GROUP_LABEL_1>Acetaminophen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acetamin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="11.987797830228311" CI_START="-6.64779783022828" EFFECT_SIZE="2.670000000000016" ESTIMABLE="YES" MEAN_1="152.12" MEAN_2="149.45" ORDER="17126" SD_1="15.36" SD_2="16.1" SE="4.754065841885818" STUDY_ID="STD-Howard-1994" TOTAL_1="23" TOTAL_2="21" WEIGHT="30.692099099310404"/>
<CONT_DATA CI_END="8.300621277844465" CI_START="-4.100621277844477" EFFECT_SIZE="2.0999999999999943" ESTIMABLE="YES" MEAN_1="166.1" MEAN_2="164.0" ORDER="17127" SD_1="12.1" SD_2="12.4" SE="3.163640417249592" STUDY_ID="STD-Macke-2001" TOTAL_1="29" TOTAL_2="31" WEIGHT="69.30790090068962"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.4338081096971757E-32" CI_END="3.5389686519981765" CI_START="-10.998968651998169" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.7299999999999964" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-006.04" NO="4" P_CHI2="0.0" P_Q="1.0" P_Z="0.31454244848862556" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="23" TOTAL_2="21" UNITS="" WEIGHT="100.0" Z="1.0057363035022528">
<NAME>Respiratory rate (rpm)</NAME>
<GROUP_LABEL_1>Acetaminophen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acetamin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.538968651998176" CI_START="-10.998968651998169" EFFECT_SIZE="-3.729999999999997" ESTIMABLE="YES" MEAN_1="54.27" MEAN_2="58.0" ORDER="17128" SD_1="10.54" SD_2="13.69" SE="3.708725624212929" STUDY_ID="STD-Howard-1994" TOTAL_1="23" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" NO="7">
<NAME>DPNB versus EMLA</NAME>
<CONT_OUTCOME CHI2="27.347753615575616" CI_END="-0.2404970291213114" CI_START="-0.7139350316637557" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.4772160303925336" ESTIMABLE="YES" I2="96.34339253579328" I2_Q="96.34339253579328" ID="CMP-007.01" NO="1" P_CHI2="1.6996459906160055E-7" P_Q="1.6996459906160055E-7" P_Z="7.775740217987985E-5" Q="27.347753615575616" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="52" TOTAL_2="52" UNITS="" WEIGHT="200.0" Z="3.951208932919087">
<NAME>Pain score</NAME>
<GROUP_LABEL_1>DPNB</GROUP_LABEL_1>
<GROUP_LABEL_2>EMLA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DPNB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EMLA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.7057842402588426" CI_START="-3.2942157597411574" DF="0.0" EFFECT_SIZE="-2.5" ESTIMABLE="YES" I2="0.0" ID="CMP-007.01.01" NO="1" P_CHI2="1.0" P_Z="6.850855018707413E-10" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="21" WEIGHT="100.0" Z="6.169494751586224">
<NAME>neonatal infant pain scale (NIPS)</NAME>
<CONT_DATA CI_END="-1.7057842402588426" CI_START="-3.2942157597411574" EFFECT_SIZE="-2.5" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="4.8" ORDER="17129" SD_1="1.8" SD_2="0.7" SE="0.4052195683215763" STUDY_ID="STD-Butler-O_x0027_Hara-1998" TOTAL_1="23" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.032009607790080885" CI_START="-0.5279903922099192" DF="0.0" EFFECT_SIZE="-0.28" ESTIMABLE="YES" I2="0.0" ID="CMP-007.01.02" NO="2" P_CHI2="1.0" P_Z="0.026901210533315807" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="31" WEIGHT="100.0" Z="2.2129482952173207">
<NAME>behavioral distress score</NAME>
<CONT_DATA CI_END="-0.032009607790080885" CI_START="-0.5279903922099192" EFFECT_SIZE="-0.28" ESTIMABLE="YES" MEAN_1="1.22" MEAN_2="1.5" ORDER="17130" SD_1="0.48" SD_2="0.5" SE="0.1265280352935236" STUDY_ID="STD-Howard-1999" TOTAL_1="29" TOTAL_2="31" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="9.743844247015645" CI_START="-29.743844247015645" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-10.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.3208580234981735" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="15" UNITS="" WEIGHT="100.0" Z="0.9926962348461142">
<NAME>Cry time (%)</NAME>
<GROUP_LABEL_1>DPNB</GROUP_LABEL_1>
<GROUP_LABEL_2>EMLA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DPNB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EMLA</GRAPH_LABEL_2>
<CONT_DATA CI_END="9.743844247015648" CI_START="-29.743844247015648" EFFECT_SIZE="-10.0" ESTIMABLE="YES" MEAN_1="47.33" MEAN_2="57.33" ORDER="17131" SD_1="29.97" SD_2="23.66" SE="10.073575026251794" STUDY_ID="STD-Lander-1997" TOTAL_1="14" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="27.71721715299212" CI_END="-11.002270712083227" CI_START="-22.688805207663524" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-16.845537959873376" ESTIMABLE="YES" I2="92.78426838827109" I2_Q="92.21458096362444" ID="CMP-007.03" NO="3" P_CHI2="9.578256298103938E-7" P_Q="3.384709055077595E-4" P_Z="1.6009874474112903E-8" Q="12.84452378642349" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="66" TOTAL_2="67" UNITS="" WEIGHT="100.0" Z="5.6503744055246905">
<NAME>Heart rate (by unit)</NAME>
<GROUP_LABEL_1>DPNB</GROUP_LABEL_1>
<GROUP_LABEL_2>EMLA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DPNB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EMLA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.217910603278709E-32" CI_END="-0.27921006261615666" CI_START="-15.520789937383853" DF="0.0" EFFECT_SIZE="-7.900000000000005" ESTIMABLE="YES" I2="100.0" ID="CMP-007.03.01" NO="1" P_CHI2="0.0" P_Z="0.042176638514951396" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="31" WEIGHT="58.79109077352233" Z="2.0317730320725604">
<NAME>in bpm</NAME>
<CONT_DATA CI_END="-0.27921006261615755" CI_START="-15.520789937383853" EFFECT_SIZE="-7.900000000000006" ESTIMABLE="YES" MEAN_1="139.0" MEAN_2="146.9" ORDER="17132" SD_1="15.07" SD_2="15.03" SE="3.88822957844923" STUDY_ID="STD-Howard-1999" TOTAL_1="29" TOTAL_2="31" WEIGHT="58.79109077352233"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="14.87269336656863" CI_END="-20.505287041673018" CI_START="-38.710266185956016" DF="1.0" EFFECT_SIZE="-29.607776613814515" ESTIMABLE="YES" I2="93.27626829012803" ID="CMP-007.03.02" NO="2" P_CHI2="1.1501674939606854E-4" P_Z="1.8272639476791819E-10" STUDIES="2" TAU2="0.0" TOTAL_1="37" TOTAL_2="36" WEIGHT="41.208909226477665" Z="6.375198275753834">
<NAME>in bpm change-from-baseline</NAME>
<CONT_DATA CI_END="-29.47621110687744" CI_START="-50.52378889312256" EFFECT_SIZE="-40.0" ESTIMABLE="YES" MEAN_1="9.0" MEAN_2="49.0" ORDER="17133" SD_1="15.0" SD_2="20.0" SE="5.369378711105338" STUDY_ID="STD-Butler-O_x0027_Hara-1998" TOTAL_1="23" TOTAL_2="21" WEIGHT="30.829554156613494"/>
<CONT_DATA CI_END="19.397213493561214" CI_START="-16.877213493561218" EFFECT_SIZE="1.259999999999998" ESTIMABLE="YES" MEAN_1="21.86" MEAN_2="20.6" ORDER="17134" SD_1="26.05" SD_2="23.61" SE="9.253850395530346" STUDY_ID="STD-Lander-1997" TOTAL_1="14" TOTAL_2="15" WEIGHT="10.379355069864173"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="19.793182952948847" CI_END="-0.40028460093108315" CI_START="-1.138248108173278" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.7692663545521806" ESTIMABLE="YES" I2="89.89551097085153" I2_Q="84.67444350839607" ID="CMP-007.04" NO="4" P_CHI2="5.034646072854532E-5" P_Q="0.010636594668622212" P_Z="4.3849015981027895E-5" Q="6.525048539332637" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="66" TOTAL_2="67" UNITS="" WEIGHT="200.0" Z="4.086203002300668">
<NAME>Heart rate by wait time</NAME>
<GROUP_LABEL_1>DPNB</GROUP_LABEL_1>
<GROUP_LABEL_2>EMLA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DPNB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EMLA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="13.26813441361621" CI_END="-0.6238265874946368" CI_START="-1.4797023763652377" DF="1.0" EFFECT_SIZE="-1.0517644819299372" ESTIMABLE="YES" I2="92.4631453916101" ID="CMP-007.04.01" NO="1" P_CHI2="2.6996067418405545E-4" P_Z="1.456582091875053E-6" STUDIES="2" TAU2="0.0" TOTAL_1="52" TOTAL_2="52" WEIGHT="100.0" Z="4.817102041223345">
<NAME>wait time after anesthetic administration &lt;/= 5 min</NAME>
<CONT_DATA CI_END="-1.4690142182867976" CI_START="-3.005100597619593" EFFECT_SIZE="-2.2370574079531953" ESTIMABLE="YES" MEAN_1="9.0" MEAN_2="49.0" ORDER="17135" SD_1="15.0" SD_2="20.0" SE="0.3918659708671304" STUDY_ID="STD-Butler-O_x0027_Hara-1998" TOTAL_1="23" TOTAL_2="21" WEIGHT="31.04489575526414"/>
<CONT_DATA CI_END="-0.002778756032266849" CI_START="-1.0334674959563337" EFFECT_SIZE="-0.5181231259943003" ESTIMABLE="YES" MEAN_1="139.0" MEAN_2="146.9" ORDER="17136" SD_1="15.07" SD_2="15.03" SE="0.26293563250498686" STUDY_ID="STD-Howard-1999" TOTAL_1="29" TOTAL_2="31" WEIGHT="68.95510424473586"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7778262015073294" CI_START="-0.6791210910462424" DF="0.0" EFFECT_SIZE="0.049352555230543466" ESTIMABLE="YES" I2="0.0" ID="CMP-007.04.02" NO="2" P_CHI2="1.0" P_Z="0.8943646577830655" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="15" WEIGHT="100.0" Z="0.1327834318938924">
<NAME>wait time after anesthetic administration &gt; 5 min</NAME>
<CONT_DATA CI_END="0.7778262015073294" CI_START="-0.6791210910462424" EFFECT_SIZE="0.049352555230543466" ESTIMABLE="YES" MEAN_1="21.86" MEAN_2="20.6" ORDER="17137" SD_1="26.05" SD_2="23.61" SE="0.3716770573453865" STUDY_ID="STD-Lander-1997" TOTAL_1="14" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.672283046826955" CI_START="-7.472283046826952" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.8999999999999986" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.05" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.21382371697942404" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="29" TOTAL_2="31" UNITS="" WEIGHT="100.0" Z="1.2431197930999986">
<NAME>Respiratory rate (rpm)</NAME>
<GROUP_LABEL_1>DPNB</GROUP_LABEL_1>
<GROUP_LABEL_2>EMLA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DPNB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EMLA</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.672283046826955" CI_START="-7.472283046826952" EFFECT_SIZE="-2.8999999999999986" ESTIMABLE="YES" MEAN_1="53.4" MEAN_2="56.3" ORDER="17138" SD_1="9.15" SD_2="8.9" SE="2.3328403393595694" STUDY_ID="STD-Howard-1999" TOTAL_1="29" TOTAL_2="31" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" NO="8">
<NAME>DPNB versus sucrose</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-1.8113283137146774" CI_START="-4.648671686285322" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.2299999999999995" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="8.10459176513041E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="23" UNITS="" WEIGHT="100.0" Z="4.462402211353608">
<NAME>Pain score</NAME>
<GROUP_LABEL_1>DPNB</GROUP_LABEL_1>
<GROUP_LABEL_2>Sucrose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DPNB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sucrose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.8113283137146774" CI_START="-4.648671686285322" DF="0.0" EFFECT_SIZE="-3.2299999999999995" ESTIMABLE="YES" I2="0.0" ID="CMP-008.01.01" NO="1" P_CHI2="1.0" P_Z="8.10459176513041E-6" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="4.462402211353608">
<NAME>modified behavioral pain scale</NAME>
<CONT_DATA CI_END="-1.8113283137146774" CI_START="-4.648671686285322" EFFECT_SIZE="-3.2299999999999995" ESTIMABLE="YES" MEAN_1="4.4" MEAN_2="7.63" ORDER="17139" SD_1="2.8" SD_2="2.13" SE="0.7238253853007623" STUDY_ID="STD-Kass-2001" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.5642228172522093E-30" CI_END="-121.46012664494148" CI_START="-210.53987335505857" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-166.00000000000003" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-008.02" NO="2" P_CHI2="0.0" P_Q="1.0" P_Z="2.777186631470358E-13" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="23" UNITS="" WEIGHT="100.0" Z="7.304781018123336">
<NAME>Cry time (s)</NAME>
<GROUP_LABEL_1>DPNB</GROUP_LABEL_1>
<GROUP_LABEL_2>Sucrose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DPNB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sucrose</GRAPH_LABEL_2>
<CONT_DATA CI_END="-121.46012664494145" CI_START="-210.53987335505855" EFFECT_SIZE="-166.0" ESTIMABLE="YES" MEAN_1="90.0" MEAN_2="256.0" ORDER="17140" SD_1="87.0" SD_2="68.0" SE="22.724842755470707" STUDY_ID="STD-Kass-2001" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="17.1407109016709" CI_END="-19.762685763164914" CI_START="-33.362463078471016" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-26.562574420817967" ESTIMABLE="YES" I2="94.16593625703985" I2_Q="94.16593625703985" ID="CMP-008.03" NO="3" P_CHI2="3.471062980375805E-5" P_Q="3.471062980375805E-5" P_Z="1.9143175391352498E-14" Q="17.1407109016709" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="64" TOTAL_2="62" UNITS="" WEIGHT="99.99999999999999" Z="7.656256127499144">
<NAME>Heart rate (by unit)</NAME>
<GROUP_LABEL_1>DPNB</GROUP_LABEL_1>
<GROUP_LABEL_2>Sucrose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DPNB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sucrose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.2131243741933004E-30" CI_END="-36.435966714120696" CI_START="-61.724033285879315" DF="0.0" EFFECT_SIZE="-49.080000000000005" ESTIMABLE="YES" I2="100.0" ID="CMP-008.03.01" NO="1" P_CHI2="0.0" P_Z="2.7850149139604652E-14" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="28.922267742480944" Z="7.60793887411347">
<NAME>in bpm</NAME>
<CONT_DATA CI_END="-36.4359667141207" CI_START="-61.72403328587932" EFFECT_SIZE="-49.08000000000001" ESTIMABLE="YES" MEAN_1="133.03" MEAN_2="182.11" ORDER="17141" SD_1="22.19" SD_2="22.03" SE="6.451155932258873" STUDY_ID="STD-Kass-2001" TOTAL_1="24" TOTAL_2="23" WEIGHT="28.922267742480944"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-9.334430830891788" CI_START="-25.465569169108214" DF="0.0" EFFECT_SIZE="-17.400000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-008.03.02" NO="2" P_CHI2="1.0" P_Z="2.354990845558119E-5" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="39" WEIGHT="71.07773225751905" Z="4.228266178860092">
<NAME>in bpm change-from-baseline</NAME>
<CONT_DATA CI_END="-9.334430830891788" CI_START="-25.465569169108214" EFFECT_SIZE="-17.400000000000002" ESTIMABLE="YES" MEAN_1="9.7" MEAN_2="27.1" ORDER="17142" SD_1="17.3" SD_2="19.2" SE="4.11516192783561" STUDY_ID="STD-Herschel-1998" TOTAL_1="40" TOTAL_2="39" WEIGHT="71.07773225751905"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="23.016710802887523" CI_END="1.2748664415763058" CI_START="-0.7758079306144576" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.24952925548092408" ESTIMABLE="YES" I2="95.65533056150427" I2_Q="95.65533056150427" ID="CMP-008.04" NO="4" P_CHI2="1.6060183148924878E-6" P_Q="1.6060183148924878E-6" P_Z="0.633374265733547" Q="23.016710802887523" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="64" TOTAL_2="62" UNITS="" WEIGHT="100.0" Z="0.4769829481110906">
<NAME>Oxygen saturation (by unit)</NAME>
<GROUP_LABEL_1>DPNB</GROUP_LABEL_1>
<GROUP_LABEL_2>Sucrose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sucrose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DPNB</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.6430111685042075" CI_START="2.0569888314958096" DF="0.0" EFFECT_SIZE="3.8500000000000085" ESTIMABLE="YES" I2="0.0" ID="CMP-008.04.01" NO="1" P_CHI2="1.0" P_Z="2.5708812706720442E-5" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="32.70148141085834" Z="4.208485408807733">
<NAME>in %</NAME>
<CONT_DATA CI_END="5.6430111685042075" CI_START="2.0569888314958096" EFFECT_SIZE="3.8500000000000085" ESTIMABLE="YES" MEAN_1="98.2" MEAN_2="94.35" ORDER="17143" SD_1="2.24" SD_2="3.8" SE="0.9148184265870405" STUDY_ID="STD-Kass-2001" TOTAL_1="24" TOTAL_2="23" WEIGHT="32.70148141085834"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.25013255542321033" CI_START="-2.7498674445767897" DF="0.0" EFFECT_SIZE="-1.5" ESTIMABLE="YES" I2="0.0" ID="CMP-008.04.02" NO="2" P_CHI2="1.0" P_Z="0.018662425255306658" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="39" WEIGHT="67.29851858914165" Z="2.352206219600799">
<NAME>in % change-from-baseline</NAME>
<CONT_DATA CI_END="-0.25013255542321033" CI_START="-2.7498674445767897" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="0.7" ORDER="17144" SD_1="2.1" SD_2="3.4" SE="0.6376991895951071" STUDY_ID="STD-Herschel-1998" TOTAL_1="40" TOTAL_2="39" WEIGHT="67.29851858914165"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" NO="9">
<NAME>DPNB versus ring block</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="28.597055467410232" CI_START="-15.937055467410236" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="6.329999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.5774101604050967" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="0.5571716494036059">
<NAME>Cry time (%)</NAME>
<GROUP_LABEL_1>DPNB</GROUP_LABEL_1>
<GROUP_LABEL_2>RB</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DPNB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RB</GRAPH_LABEL_2>
<CONT_DATA CI_END="28.597055467410232" CI_START="-15.937055467410236" EFFECT_SIZE="6.329999999999998" ESTIMABLE="YES" MEAN_1="47.33" MEAN_2="41.0" ORDER="17145" SD_1="29.97" SD_2="27.91" SE="11.360951345560391" STUDY_ID="STD-Lander-1997" TOTAL_1="14" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="23.28202293075676" CI_START="-14.42202293075676" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="4.43" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.6451085014859868" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="0.46056810366737133">
<NAME>Heart rate (bpm) change-from-baseline</NAME>
<GROUP_LABEL_1>DPNB</GROUP_LABEL_1>
<GROUP_LABEL_2>RB</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DPNB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RB</GRAPH_LABEL_2>
<CONT_DATA CI_END="23.28202293075676" CI_START="-14.42202293075676" EFFECT_SIZE="4.43" ESTIMABLE="YES" MEAN_1="21.86" MEAN_2="17.43" ORDER="17146" SD_1="26.05" SD_2="22.99" SE="9.618555789524251" STUDY_ID="STD-Lander-1997" TOTAL_1="14" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" NO="10">
<NAME>DPNB versus local block</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="471.2087287468222" CI_START="141.33127125317773" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="306.27" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="2.732730024386977E-4" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="9" TOTAL_2="9" UNITS="" WEIGHT="100.0" Z="3.6394009709296213">
<NAME>Serum cortisol (nmol/dL) 30 min post</NAME>
<GROUP_LABEL_1>DPNB</GROUP_LABEL_1>
<GROUP_LABEL_2>Local</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DPNB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours local</GRAPH_LABEL_2>
<CONT_DATA CI_END="471.20872874682226" CI_START="141.3312712531777" EFFECT_SIZE="306.27" ESTIMABLE="YES" MEAN_1="721.27" MEAN_2="415.0" ORDER="17147" SD_1="159.47" SD_2="195.72" SE="84.15395897467398" STUDY_ID="STD-Masciello-1990" TOTAL_1="9" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" NO="11">
<NAME>Ring block versus EMLA</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="14.495640973423534" CI_START="-20.835640973423537" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.1700000000000017" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-011.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.7250598688746068" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="15" UNITS="" WEIGHT="100.0" Z="0.35170452294026794">
<NAME>Heart rate (bpm) change-from-baseline</NAME>
<GROUP_LABEL_1>Ring block</GROUP_LABEL_1>
<GROUP_LABEL_2>EMLA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ring block</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EMLA</GRAPH_LABEL_2>
<CONT_DATA CI_END="14.495640973423534" CI_START="-20.835640973423537" EFFECT_SIZE="-3.1700000000000017" ESTIMABLE="YES" MEAN_1="17.43" MEAN_2="20.6" ORDER="17148" SD_1="22.99" SD_2="23.62" SE="9.01324774984023" STUDY_ID="STD-Lander-1997" TOTAL_1="12" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.48733095699518" CI_START="-36.14733095699518" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-16.33" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-011.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.10629733790280142" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="15" UNITS="" WEIGHT="100.0" Z="1.615061681968905">
<NAME>Cry time (%)</NAME>
<GROUP_LABEL_1>Ring block</GROUP_LABEL_1>
<GROUP_LABEL_2>EMLA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ring block</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EMLA</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.48733095699518" CI_START="-36.14733095699518" EFFECT_SIZE="-16.33" ESTIMABLE="YES" MEAN_1="41.0" MEAN_2="57.33" ORDER="17149" SD_1="27.91" SD_2="23.66" SE="10.11106893458847" STUDY_ID="STD-Lander-1997" TOTAL_1="12" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" NO="12">
<NAME>Buffered lidocaine DPNB versus plain lidocaine DPNB</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.5013860771625138" CI_START="-0.30138607716251414" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.09999999999999987" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.6253381096208345" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="20" TOTAL_2="20" UNITS="" WEIGHT="99.99999999999999" Z="0.4882989460908724">
<NAME>Pain score</NAME>
<GROUP_LABEL_1>Buffered lidocaine</GROUP_LABEL_1>
<GROUP_LABEL_2>Plain lidocaine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours buffered</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours plain</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5013860771625138" CI_START="-0.30138607716251414" DF="0.0" EFFECT_SIZE="0.09999999999999987" ESTIMABLE="YES" I2="0.0" ID="CMP-012.01.01" NO="1" P_CHI2="1.0" P_Z="0.6253381096208345" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="99.99999999999999" Z="0.4882989460908724">
<NAME>behavioral distress score</NAME>
<CONT_DATA CI_END="0.5013860771625138" CI_START="-0.30138607716251414" EFFECT_SIZE="0.09999999999999987" ESTIMABLE="YES" MEAN_1="1.22" MEAN_2="1.12" ORDER="17150" SD_1="0.78" SD_2="0.48" SE="0.20479257799051215" STUDY_ID="STD-Stang-1997" TOTAL_1="20" TOTAL_2="20" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="29.706181189583983" CI_START="-11.706181189583983" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="9.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.39426745807191566" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="102" TOTAL_2="92" UNITS="" WEIGHT="100.0" Z="0.851903868673473">
<NAME>Cry time (%)</NAME>
<GROUP_LABEL_1>Buffered lidocaine</GROUP_LABEL_1>
<GROUP_LABEL_2>Plain lidocaine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours buffered</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours plain</GRAPH_LABEL_2>
<CONT_DATA CI_END="29.706181189583983" CI_START="-11.706181189583983" EFFECT_SIZE="9.0" ESTIMABLE="YES" MEAN_1="65.0" MEAN_2="56.0" ORDER="17151" SD_1="74.0" SD_2="73.0" SE="10.564572284445886" STUDY_ID="STD-Newton-1999" TOTAL_1="102" TOTAL_2="92" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.110816602950065" CI_START="-10.51081660295007" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.200000000000003" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.19209617907748305" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="102" TOTAL_2="92" UNITS="" WEIGHT="100.0" Z="1.3044030991520426">
<NAME>Heart rate (bpm)</NAME>
<GROUP_LABEL_1>Buffered lidocaine</GROUP_LABEL_1>
<GROUP_LABEL_2>Plain lidocaine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours bufffered</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours plain</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.110816602950065" CI_START="-10.51081660295007" EFFECT_SIZE="-4.200000000000003" ESTIMABLE="YES" MEAN_1="121.8" MEAN_2="126.0" ORDER="17152" SD_1="21.1" SD_2="23.5" SE="3.219863555008655" STUDY_ID="STD-Newton-1999" TOTAL_1="102" TOTAL_2="92" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.8661201198882174" CI_START="-0.8661201198882174" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.4731600988888722" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="102" TOTAL_2="92" UNITS="" WEIGHT="100.0" Z="0.7173468701641068">
<NAME>Oxygen saturation (%)</NAME>
<GROUP_LABEL_1>Buffered lidocaine</GROUP_LABEL_1>
<GROUP_LABEL_2>Plain lidocaine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours plain</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours buffered</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.8661201198882174" CI_START="-0.8661201198882174" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="95.3" MEAN_2="94.8" ORDER="17153" SD_1="4.9" SD_2="4.8" SE="0.69701286894249" STUDY_ID="STD-Newton-1999" TOTAL_1="102" TOTAL_2="92" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="177.21992428663933" CI_START="-105.6199242866393" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="35.80000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.05" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.6197825243567774" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" UNITS="" WEIGHT="100.0" Z="0.49615859293146986">
<NAME>Serum cortisol (nmol/dL) 30 min post</NAME>
<GROUP_LABEL_1>Buffered lidocaine</GROUP_LABEL_1>
<GROUP_LABEL_2>Plain lidocaine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours buffered</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours plain</GRAPH_LABEL_2>
<CONT_DATA CI_END="177.21992428663933" CI_START="-105.6199242866393" EFFECT_SIZE="35.80000000000001" ESTIMABLE="YES" MEAN_1="408.0" MEAN_2="372.2" ORDER="17154" SD_1="270.2" SD_2="176.4" SE="72.15434844830907" STUDY_ID="STD-Stang-1997" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" NO="13">
<NAME>EMLA versus 30% topical lidocaine</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="41.00197173586027" CI_START="-75.00197173586028" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-17.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-013.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.5656615202971254" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" UNITS="" WEIGHT="100.0" Z="0.5744526735904203">
<NAME>Cry time (s)</NAME>
<GROUP_LABEL_1>EMLA</GROUP_LABEL_1>
<GROUP_LABEL_2>Lidocaine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EMLA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lidocaine</GRAPH_LABEL_2>
<CONT_DATA CI_END="41.00197173586027" CI_START="-75.00197173586028" EFFECT_SIZE="-17.0" ESTIMABLE="YES" MEAN_1="155.0" MEAN_2="172.0" ORDER="17155" SD_1="104.91" SD_2="80.68" SE="29.593386507799337" STUDY_ID="STD-Woodman-1999" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-4.359803105493728" CI_START="-19.400196894506262" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-11.879999999999995" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-013.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.0019598834377207272" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" UNITS="" WEIGHT="100.0" Z="3.096245013657259">
<NAME>Heart rate (bpm)</NAME>
<GROUP_LABEL_1>EMLA</GROUP_LABEL_1>
<GROUP_LABEL_2>Lidocaine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EMLA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lidocaine</GRAPH_LABEL_2>
<CONT_DATA CI_END="-4.359803105493728" CI_START="-19.400196894506262" EFFECT_SIZE="-11.879999999999995" ESTIMABLE="YES" MEAN_1="137.37" MEAN_2="149.25" ORDER="17156" SD_1="14.12" SD_2="9.75" SE="3.8369056543000895" STUDY_ID="STD-Woodman-1999" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.0969465530270153" CI_START="-1.4369465530270187" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.1700000000000017" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-013.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.7925585283012506" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" UNITS="" WEIGHT="100.0" Z="0.2629896869569899">
<NAME>Oxygen saturation (%)</NAME>
<GROUP_LABEL_1>EMLA</GROUP_LABEL_1>
<GROUP_LABEL_2>Lidocaine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EMLA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lidocaine</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.0969465530270155" CI_START="-1.436946553027019" EFFECT_SIZE="-0.1700000000000017" ESTIMABLE="YES" MEAN_1="97.33" MEAN_2="97.5" ORDER="17157" SD_1="1.91" SD_2="2.17" SE="0.6464131805586888" STUDY_ID="STD-Woodman-1999" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" NO="14">
<NAME>EMLA versus sucrose</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="6.741047472210639" CI_START="-26.74104747221064" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-10.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-014.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.2416978959746522" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="1.1707534954389822">
<NAME>Cry time (%)</NAME>
<GROUP_LABEL_1>EMLA</GROUP_LABEL_1>
<GROUP_LABEL_2>Sucrose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EMLA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sucrose</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.741047472210639" CI_START="-26.74104747221064" EFFECT_SIZE="-10.0" ESTIMABLE="YES" MEAN_1="66.0" MEAN_2="76.0" ORDER="17158" SD_1="24.5" SD_2="18.66" SE="8.541507703336329" STUDY_ID="STD-Zahorodny-1998" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.3825316975839534" CI_START="-20.082531697583942" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-9.349999999999994" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-014.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.08773148718230742" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="21" UNITS="" WEIGHT="100.0" Z="1.7074874569972036">
<NAME>Heart rate (bpm)</NAME>
<GROUP_LABEL_1>EMLA</GROUP_LABEL_1>
<GROUP_LABEL_2>Sucrose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EMLA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sucrose</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.3825316975839552" CI_START="-20.082531697583946" EFFECT_SIZE="-9.349999999999994" ESTIMABLE="YES" MEAN_1="147.88" MEAN_2="157.23" ORDER="17159" SD_1="15.86" SD_2="19.12" SE="5.475882098977731" STUDY_ID="STD-Mohan-1998" TOTAL_1="20" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.9869327191482611" CI_START="-2.626932719148276" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8200000000000074" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-014.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.3737630294080033" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="21" UNITS="" WEIGHT="100.0" Z="0.8894467681566078">
<NAME>Oxygen saturation (%)</NAME>
<GROUP_LABEL_1>EMLA</GROUP_LABEL_1>
<GROUP_LABEL_2>Sucrose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sucrose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EMLA</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.9869327191482611" CI_START="-2.626932719148276" EFFECT_SIZE="-0.8200000000000074" ESTIMABLE="YES" MEAN_1="95.38" MEAN_2="96.2" ORDER="17160" SD_1="2.28" SD_2="3.52" SE="0.9219213890669028" STUDY_ID="STD-Mohan-1998" TOTAL_1="20" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-014.04" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="21" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Systolic blood pressure (mmHg)</NAME>
<GROUP_LABEL_1>EMLA</GROUP_LABEL_1>
<GROUP_LABEL_2>Sucrose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EMLA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sucrose</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="71.78" MEAN_2="83.5" ORDER="17161" SD_1="17.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Mohan-1998" TOTAL_1="20" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-014.05" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="21" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Diastolic blood pressure (mmHg)</NAME>
<GROUP_LABEL_1>EMLA</GROUP_LABEL_1>
<GROUP_LABEL_2>Sucrose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EMLA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sucrose</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="43.05" MEAN_2="51.95" ORDER="17162" SD_1="22.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Mohan-1998" TOTAL_1="20" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" NO="15">
<NAME>EMLA versus music</NAME>
<CONT_OUTCOME CHI2="7.186746314785102E-34" CI_END="4.438468389460044" CI_START="-3.6784683894600443" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.37999999999999995" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-015.01" NO="1" P_CHI2="0.0" P_Q="1.0" P_Z="0.8543946294140348" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="5" TOTAL_2="7" UNITS="" WEIGHT="100.0" Z="0.18351413455860627">
<NAME>Cry time (min)</NAME>
<GROUP_LABEL_1>EMLA</GROUP_LABEL_1>
<GROUP_LABEL_2>Music</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EMLA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours music</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.438468389460044" CI_START="-3.6784683894600443" EFFECT_SIZE="0.3799999999999999" ESTIMABLE="YES" MEAN_1="7.8" MEAN_2="7.42" ORDER="17163" SD_1="2.77" SD_2="4.39" SE="2.0706851868058416" STUDY_ID="STD-Joyce-2001" TOTAL_1="5" TOTAL_2="7" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="20.60659500245173" CI_START="-15.986595002451725" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.3100000000000023" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-015.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.804558952099296" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="5" TOTAL_2="7" UNITS="" WEIGHT="100.0" Z="0.247451331992693">
<NAME>Heart rate (bpm)</NAME>
<GROUP_LABEL_1>EMLA</GROUP_LABEL_1>
<GROUP_LABEL_2>Music</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EMLA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours music</GRAPH_LABEL_2>
<CONT_DATA CI_END="20.60659500245173" CI_START="-15.986595002451725" EFFECT_SIZE="2.3100000000000023" ESTIMABLE="YES" MEAN_1="144.02" MEAN_2="141.71" ORDER="17164" SD_1="16.03" SD_2="15.82" SE="9.335168986151242" STUDY_ID="STD-Joyce-2001" TOTAL_1="5" TOTAL_2="7" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.9385091704736377" CI_START="-3.558509170473614" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.19000000000001194" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-015.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.9208648769359252" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="5" TOTAL_2="7" UNITS="" WEIGHT="100.0" Z="0.09934433667547402">
<NAME>Oxygen saturation (%)</NAME>
<GROUP_LABEL_1>EMLA</GROUP_LABEL_1>
<GROUP_LABEL_2>Music</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours music</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EMLA</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.9385091704736377" CI_START="-3.558509170473614" EFFECT_SIZE="0.19000000000001194" ESTIMABLE="YES" MEAN_1="94.4" MEAN_2="94.21" ORDER="17165" SD_1="3.22" SD_2="3.33" SE="1.9125398221811154" STUDY_ID="STD-Joyce-2001" TOTAL_1="5" TOTAL_2="7" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="16.643209255805836" CI_START="-13.60320925580583" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.5200000000000031" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-015.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.8438341078070646" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="5" TOTAL_2="7" UNITS="" WEIGHT="100.0" Z="0.19699160450069078">
<NAME>Respiratory rate (rpm)</NAME>
<GROUP_LABEL_1>EMLA</GROUP_LABEL_1>
<GROUP_LABEL_2>Music</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EMLA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours music</GRAPH_LABEL_2>
<CONT_DATA CI_END="16.643209255805836" CI_START="-13.60320925580583" EFFECT_SIZE="1.5200000000000031" ESTIMABLE="YES" MEAN_1="48.13" MEAN_2="46.61" ORDER="17166" SD_1="12.95" SD_2="13.49" SE="7.716064874199616" STUDY_ID="STD-Joyce-2001" TOTAL_1="5" TOTAL_2="7" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-016" NO="16">
<NAME>Music versus no treatment</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.6466372901530306" CI_START="-5.806637290153031" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.58" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-016.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.4637578906519254" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="7" TOTAL_2="5" UNITS="" WEIGHT="100.0" Z="0.7326730171022469">
<NAME>Cry time (min)</NAME>
<GROUP_LABEL_1>Music</GROUP_LABEL_1>
<GROUP_LABEL_2>No music</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours music</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no music</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.6466372901530306" CI_START="-5.806637290153031" EFFECT_SIZE="-1.58" ESTIMABLE="YES" MEAN_1="7.42" MEAN_2="9.0" ORDER="17167" SD_1="4.39" SD_2="3.08" SE="2.1564872229756293" STUDY_ID="STD-Joyce-2001" TOTAL_1="7" TOTAL_2="5" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.7034775429267705E-33" CI_END="25.59011373351926" CI_START="-41.37011373351923" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-7.8899999999999855" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-016.02" NO="2" P_CHI2="0.0" P_Q="1.0" P_Z="0.6441605046551256" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="7" TOTAL_2="5" UNITS="" WEIGHT="100.0" Z="0.46188958499680394">
<NAME>Heart rate (bpm)</NAME>
<GROUP_LABEL_1>Music</GROUP_LABEL_1>
<GROUP_LABEL_2>No music</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours music</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no music</GRAPH_LABEL_2>
<CONT_DATA CI_END="25.59011373351926" CI_START="-41.37011373351923" EFFECT_SIZE="-7.889999999999986" ESTIMABLE="YES" MEAN_1="141.71" MEAN_2="149.6" ORDER="17168" SD_1="15.82" SD_2="35.78" SE="17.082004566209434" STUDY_ID="STD-Joyce-2001" TOTAL_1="7" TOTAL_2="5" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="5.63572692406327" CI_START="-0.6157269240632885" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.509999999999991" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-016.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.11551589650949615" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="7" TOTAL_2="5" UNITS="" WEIGHT="100.0" Z="1.5738769638905041">
<NAME>Oxygen saturation (%)</NAME>
<GROUP_LABEL_1>Music</GROUP_LABEL_1>
<GROUP_LABEL_2>No music</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours no music</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours music</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.63572692406327" CI_START="-0.6157269240632885" EFFECT_SIZE="2.509999999999991" ESTIMABLE="YES" MEAN_1="94.21" MEAN_2="91.7" ORDER="17169" SD_1="3.33" SD_2="2.19" SE="1.594787939328791" STUDY_ID="STD-Joyce-2001" TOTAL_1="7" TOTAL_2="5" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="9.745553629217873" CI_START="-21.40555362921787" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.829999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-016.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.4631783236952247" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="7" TOTAL_2="5" UNITS="" WEIGHT="100.0" Z="0.7336233627312997">
<NAME>Respiratory rate (rpm)</NAME>
<GROUP_LABEL_1>Music</GROUP_LABEL_1>
<GROUP_LABEL_2>No music</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours music</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no music</GRAPH_LABEL_2>
<CONT_DATA CI_END="9.745553629217873" CI_START="-21.40555362921787" EFFECT_SIZE="-5.829999999999998" ESTIMABLE="YES" MEAN_1="46.61" MEAN_2="52.44" ORDER="17170" SD_1="13.49" SD_2="13.63" SE="7.946857060678589" STUDY_ID="STD-Joyce-2001" TOTAL_1="7" TOTAL_2="5" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>